Ccr6 receptor modulators

Abstract

This invention relates to compounds of formula (I), their synthesis, and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, symptoms, or conditions. Formula (I)

Description

Technical Field

[0001] This invention relates to novel (I) compounds or their pharmaceutically acceptable salts, and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, symptoms, or conditions improved by modulating the receptor. Furthermore, this invention relates to related forms, such as pharmaceutical compositions containing one or more (I) compounds, and methods for preparing such compounds. Prior Technology

[0002] Chemokine receptors comprise a family of G protein-coupled receptors (GPCRs) that recognize and bind to peptide chemokine ligands. The primary function of chemokine receptors and their ligands is to induce leukocyte migration to and from lymphoid organs and tissues under homeostatic conditions and in cases of infection or inflammation. Furthermore, chemokine signaling events can induce the activation of integrin molecules on the surface of immune cells, allowing for strong adhesion to activated endothelium and promoting migration from the bloodstream to inflamed tissues (Montresor A, Frontiers in Imm., 2012; Meissner A, Blood, 2003). Chemokines receptor 6 (CCR6, also known as BN-1, CC CKR-6, CD196, CKRL3, CMKBR6, DCR2, DRY6, GPR29, GPRCY4, STRL22) is a GPCR that is mainly expressed on effector CD4+ T helper cells, but it is also present on B cells, CD8+ cytotoxic T cells, regulatory T cells (Treg), immature dendritic cells (DCs), and type 3 innate lymphocytes (ILC3) (Cua DJ, Nat Rev Immunol. 2010 July; 10(7):479-89. doi: 10.1038 / nri2800). CCR6 binds to the chemokine CCL20 (chemokine (CC motif) ligand 20) (Greaves DR, J Exp Med. Sep 15, 1997; 186(6):837-44. doi: 10.1084 / jem.186.6.837.). CCL20 is also known as macrophage inflammatory protein 3a (MIP-3a), liver and activation-regulated chemokine (LARC), or Exodus-1 (Schutyser E, Cytokine Growth Factor Rev. Oct 2003; 14(5):409-26. doi: 10.1016 / s1359-6101(03)00049-2). The interaction between CCR6 and CCL20 determines the humoral response in the intestinal mucosa and is necessary for lymphocyte homeostasis in the small intestinal mucosa (Cook DN, Immunity. May 2000; 12(5):495-503. doi: 10.1016 / s1074-7613(00)80201-0).Under steady-state conditions, CCR6 and CCL20 regulate the production of IgA in the intestine. CCL20, manifested in Peyer's patches, guides CCR6+IgA+ B cells to the mucosa, and secretory IgA can be released into the intestinal lumen (Lin YL, Front Immunol. 2017; 8:805. doi: 10.3389 / fimmu.2017.00805; Reboldi A, Science. May 13, 2016; 352(6287):aaf4822. doi: 10.1126 / science.aaf4822). In inflammatory conditions, CCL20 expression in endothelial and epithelial cells (Harper EG, J Invest Dermatol. Sep 2009; 129(9):2175-83. doi: 10.1038 / jid.2009.65; PLoS One. 2015; 10(11):e0141710. doi: 10.1371 / journal.pone.0141710) and histiofibroblasts (Hattori T, Mediators Inflamm. 2015; 2015:436067. doi: 10.1155 / 2015 / 436067) is highly upregulated by pro-inflammatory cytokines including IL-17A, TNFα, and IL-1β. Interleukin (IL)-17A expression is restricted in cells expressing the transcription factor RORgt (Cell. Sep 22, 2006; 126(6):1121-33. doi: 10.1016 / j.cell.2006.07.035). IL-17A expression has been shown to be separate from CCR6 expression on human T cells (Singh SP, J Immunol. Jan 1, 2008; 180(1):214-21. doi: 10.4049 / jimmunol.180.1.214;Nat Immunol. Jun 2007; 8(6):639-46. doi: 10.1038 / ni1467). It also describes CCR6 as a target gene of RORgt (PLoS One. 2017; 12(8):e0181868. doi: 10.1371 / journal.pone.0181868;Skepner J, J Immunol. March 15, 2014; 192(6):2564-75. doi: 10.4049 / jimmunol.1302190), thus elucidating the co-expression of IL-17A and CCR6 in RORgt+ cell types.

[0003] Some disclosures in the prior art can be considered related to the regulation of CCR6. For example, Tawaraishia et al. (Bioorganic & Medicinal Chemistry Letters, Vol. 28, No. 18, 2018, pp. 3067-3072, ISSN 0960-894X, https: / / doi.org / 10.1016 / j.bmcl.2018.07.042) disclosed a series of benzylsulfonyl-aminocyclohexane derivatives as selective CCR6 inhibitors. CN103588697 teaches sulfonamide derivatives as CCR6 antagonists and their use in the treatment of CCR6-mediated diseases, such as autoimmune diseases, inflammation, psoriasis, multiple sclerosis, or cancer. WO2014 / 075580 describes the use of aurintricarboxylic acid for targeting chemokine receptors. WO2015 / 084842 teaches certain sulfonamides that can be used to treat CCR6-related diseases. WO2017 / 087607, WO2010 / 131145, WO2013 / 061004, WO2013 / 061005, WO2019 / 036374, and WO2020 / 058869 provide certain cyclobutenediones for the treatment of chemokine / CCR6-related diseases. WO2019 / 136370 teaches a method for treating a type of psoriasis. WO2019 / 147862 proposes azacyclobutane derivatives that can be used as chemokine modulators.

[0004] In addition, WO1999 / 43664 discloses certain pyrrolidones with anti-inflammatory and analgesic properties. WO2019 / 105915 provides certain heterocyclic compounds that can be used as MAGL inhibitors. WO2015 / 057626, US2015 / 0105366, WO2014 / 062658, WO2015 / 057205 and Tanis VM et al. (Bioorg Med Chem Lett. 15 June 2019; 29(12):1463-1470. doi: 10.1016 / j.bmcl.2019.04.021) are about RORγt receptor modulators that can be used to treat rheumatoid arthritis or psoriasis. WO03 / 022808 proposes certain nitrogen-containing heterocyclic butane derivatives for use as insecticides. WO2008 / 103426 and WO2007 / 022351 disclose certain quaternary ammonium compounds suitable as muscarinic receptor antagonists. WO2006 / 136830 teaches certain heteroaryl-alkylamines as protein kinase inhibitors. WO91 / 13359 proposes heterocyclic choline activators. US28141 teaches certain pyrrolidines that can be used to treat depression. GB 1304650 discloses antispasmodic pyrrolidines. US3479370, US3489769, US3499002, US 3542807, and US3651085 relate to certain pyrrolidines with analgesic / sedative activities.

[0005] The CCR6 modulator of this invention can be used alone or in combination to treat or prevent the following diseases or conditions: rheumatoid arthritis (RA) causing chronic inflammation of the joints and chemokine-mediated infiltration of inflammatory cells into the inflamed synovium. RA is characterized by increased release of CCL20 and subsequent recruitment of CCR6+ T cells to the inflamed joints. CCL20 is highly expressed in the synovial fluid of RA (Hirota, J Exp Med. 26 Nov 2007; 204(12):2803-12. doi: 10.1084 / jem.20071397; Matsui T, Clin Exp Immunol. 2001 Jul; 125(1):155-61. doi: 10.1046 / j.1365-2249.2001.01542.x). CCR6+ Th cells have been found in inflamed synovium in RA patients, and an increased proportion of peripheral blood CCR6+ Th cells has been found in patients with early RA (van Hamburg JP, Arthritis Rheum. Jan 2011; 63(1):73-83. doi: 10.1002 / art.30093; Leipe J Arthritis Rheum. Oct 2010; 62(10):2876-85. doi: 10.1002 / art.27622; Nistala K, Arthritis Rheum. Mar 2008; 58(3):875-87. doi: 10.1002 / art.23291). It is known that CCL20 production is upregulated in synovial explants or fibroblast-like synovial cells from RA patients after stimulation with TNF-α, IL-1β, and IL-17 (Matsui T, Clin Exp Immunol. July 2001; 125(1):155-61. doi: 10.1046 / j.1365-2249.2001.01542.x; J Immunol. November 15, 2001; 167(10):6015-20. doi: 10.4049 / jimmunol.167.10.6015; Chevrel G, Ann Rheum Dis. August 2002; 61(8):730-3. doi: 10.1136 / ard.61.8.730). CCR6+ B cells in the synovium of RA have been reported to contribute to the pathogenesis of RA through antigen presentation, autoantibody production, and / or the production of inflammatory cytokines.Furthermore, rituximab is an effective treatment for RA (Cohen SB, Arthritis Rheum. Sep 2006; 54(9):2793-806. doi: 10.1002 / art.22025), confirming the role of CCR6+ B cells in the pathogenesis of RA. Additionally, mice lacking CCR6 exhibit impaired IgG1-dependent memory B cell responses (J Immunol. Jan 15, 2015; 194(2):505-13. doi: 10.4049 / jimmunol.1401553). Preclinical rodent models showed that mice lacking CCR6 exhibited mild joint inflammation in a collagen-induced arthritis (CIA) model. Compared to WT mice, mice lacking CCR6 showed reduced production of collagen-specific antibodies and decreased inflammation in arthritis (J Cell Mol Med. 2018 Nov; 22(11):5278-5285. doi: 10.1111 / jcmm.13783). Furthermore, depletion of CCR6+ cells reduced the severity of SKG arthritis (Hirota K, J Exp Med. 2007 Nov 26; 204(12):2803-12. doi: 10.1084 / jem.20071397).

[0006] Increased CCR6+ Th17 levels in peripheral blood have been observed in patients with ankylosing spondylitis (Shen H, Arthritis Rheum. June 2009; 60(6):1647-56. doi: 10.1002 / art.24568). Interleukin-23 receptor-positive circulating γ / δ T cells secreting interleukin-17 have also been reported in patients with active ankylosing spondylitis (Kenna TJ, Arthritis Rheum. May 2012; 64(5):1420-9. doi: 10.1002 / art.33507). Secuginumab, an IL-17A inhibitor, has shown efficacy in ankylosing spondylitis (AS) (Baeten D, N Engl J Med. 24 Dec 2015; 373(26):2534-48. doi: 10.1056 / NEJMoa1505066). CD32B expression on memory B cells is increased in AS and correlated with disease activity. Furthermore, CCR6+ cytotoxic T cells and CD32B+ memory B cells are highly enriched in the synovial cavity of AS patients (Sucur A, Clin Exp Rheumatol. 20 Nov 20 2019; PMID: 31820725).

[0007] Psoriasis is a common autoimmune skin disease. The role of Th17-related cytokines has been clinically confirmed and their role in psoriatic inflammation has been demonstrated (Paul C, J Eur Acad Dermatol Venereol. 2015 Jun; 29(6):1082-90. doi: 10.1111 / jdv.12751). IL-17R blocking antibodies (brodalumab, AMG 827) have been shown to reduce the clinical manifestations of psoriasis and also reduce CCL20 expression in skin sections from psoriasis patients (Papp KA, N Engl J Med. 2012 Mar 29; 366(13):1181-9. doi: 10.1056 / NEJMoa1109017). Furthermore, the IL-23 neutralizing antibody (guselkumab) was shown to effectively reduce psoriatic inflammation (Reich K, Lancet. Sep 7, 2019; 394(10201):831-839. doi: 10.1016 / S0140-6736(19)31773-8). Mice lacking CCR6 did not show psoriatic skin lesions after intradermal IL-23 injection (Hedrick MN, J Clin Invest. Aug 2009; 119(8):2317-29. doi: 10.1172 / jci37378). Small molecule CCR6 antagonists have also been shown to be effective in mouse psoriasis models injected with Aldara and IL-36a (Campbell JJ, J Immunol. March 15, 2019; 202(6):1687-1692. doi: 10.4049 / jimmunol.1801519;Campbell JJ, J Immunol. November 1, 2017; 199(9):3129-3136. doi: 10.4049 / jimmunol.1700826). In addition, mice lacking CCR6 have been shown to be protected against imiquimod-induced ear swelling (Yu S, J Invest Dermatol. Feb 2019; 139(2): 485-488. doi: 10.1016 / j.jid.2018.07.036).

[0008] It also showed the efficacy of anti-CCR6 neutralizing antibodies in Aldara-induced ear swelling in mice (Robert R, JCI Insight. 3 Aug 2017; 2(15): e94821. Published online 3 Aug 2017. doi: 10.1172 / jci.insight.94821). It also showed that engineered disulfide-linked CCL20 dimers that bind to CCR6 but inhibit T cell migration reduced skin swelling in an IL-23-dependent mouse model of psoriasis (Getschman AE, Proc Natl Acad Sci US A. 21 Nov 2017; 114(47):12460-12465. doi: 10.1073 / pnas.1704958114). Overall, these data suggest that the pathogenic Th17 response in psoriatic skin lesions is driven by a positive feedback loop consisting of CCL20 production in the epidermis and dermis, effective recruitment of CCR6+ T cells to inflamed psoriatic skin, activation of IL-23, and expression of IL-17A and IL-22. Therefore, inhibition of CCR6 has been identified as a potential therapeutic pathway for psoriasis (Hedrick MN, Expert Opin Ther Targets. Sep 2010; 14(9):911-22. doi: 10.1517 / 14728222.2010.504716; Mabuchi T, J Dermatol Sci. Jan 2012; 65(1):4-11. doi: 10.1016 / j.jdermsci.2011.11.007). CCR6 was upregulated in the synovium of patients with psoriatic arthritis (PsA) (Dolcino M, PLoS One. 18 June 2015; 10(6):e0128262. doi: 10.1371 / journal.pone.0128262). CCR6 was also observed in CD4+ T cells of IL-17A and GM-CSF in synovial fluid separation from PsA patients (Al-Mossawi et al., Nat Commun. 15 November 2017; 8(1):1510. doi: 10.1038 / s41467-017-01771-2). CCL20 was highly upregulated in synovial fluid collected from PsA patients (Melis L, Ann Rheum Dis. March 2010;69(3):618-23. doi: 10.1136 / ard.2009.107649).

[0009] Other inflammatory skin conditions, including rosacea, have been shown to have highly elevated levels of CCL20 in inflamed skin (Buhl T, JID, 2015).

[0010] CCR6 and CCL20 are highly elevated in active Crohn's disease (CD) and ulcerative colitis (UC) (Skovdahl et al., PLoS One. 2015 Nov 4; 10(11):e0141710. doi: 10.1371 / journal.pone.0141710). Increased production of CCL20 in intestinal epithelial cells has been shown to play an important role in lymphocyte recruitment of colonic epithelial cells in irritable bowel syndrome (IBD) (Kwon JH, Gut. 2002 Dec; 51(6):818-26. doi: 10.1136 / gut.51.6.818). CCL20 and CCR6 levels are also correlated with the histological severity of rectal resection from UC patients. Pathological examination revealed that CCL20 levels in chronic UC were higher than those in acute UC (Uchida K, Gastroenterol Res Pract. 2015; 2015:856532. doi: 10.1155 / 2015 / 856532). Compared to healthy controls, CCL20 levels in the PBMCs of UC patients were significantly upregulated. UC patients treated with sulfasalazine and GC showed reduced CCL20 levels in their PBMCs, accompanied by disease improvement. TNFα or IL-1β-induced CCL20 secretion was strongly reduced by treatment of human intestinal epithelial cell lines with sulfasalazine and / or GC (Lee HJ, 2 Inflamm Bowel Dis. Dec 2005; 11(12):1070-9. doi: 10.1097 / 01.mib.0000187576.26043.ac). CCR6 deficiency resulted in reduced intestinal lesions in mice treated with sodium polydextrose sulfate (DSS) to induce colitis (Varona R, Eur J Immunol. Oct 2003; 33(10):2937-46. doi: 10.1002 / eji.200324347).

[0011] Th17 cells exhibiting CCR6 expression are shown to be important effectors mediating dry eye disease (DED) (an inflammatory state of the ocular surface that may lead to corneal perforation). In a mouse model of DED, antibody-mediated neutralization of CCL20 and reduction of Th17 recruitment to the ocular surface resulted in improved clinical readings (Dohlman TH, Invest Ophthalmol Vis Sci. 2013 JOIN 12; 54(6):4081-91. doi: 10.1167 / iovs.12-11216). Therefore, inhibition of the CCR6 / CCL20 axis is proposed as a therapeutic mechanism for DED.

[0012] CCR6 expression has been described on T cells isolated from the cerebrospinal fluid of patients with multiple sclerosis (MS) (van Langelaar J, Brain, May 1, 2018; 141(5):1334-1349. doi: 10.1093 / brain / awy069). CCR6 expression has also been observed on T cells infiltrating the inflamed CNS in experimental autoimmune encephalomyelitis (EAE) (Mony JT, Front Cell Neurosci. 2014; 8:187. doi: 10.3389 / fncel.2014.00187). Furthermore, CCL20 gene polymorphism has been shown to be associated with MS patient populations (El Sharkav et al., Gene. 2019 Feb 15; 685:164-169. doi: 10.1016 / j.gene.2018.11.006). Preclinical data showed that CCR6 is crucial for the development of EAE (Reboldi A, Nat Immunol. 2009 May; 10(5):514-23. doi: 10.1038 / ni.1716). This finding was confirmed in subsequent studies, showing that mice lacking CCR6 were resistant to disease induction and had reduced peak severity. In the same study, vaccination with hCCL20 induced an anti-mouse CCL20 response in host mice, which was sufficient to reduce clinical scores (Abraham M, Clin Immunol. Oct 2017; 183:316-324. doi: 10.1016 / j.clim.2017.09.018). However, conflicting data exist regarding the role of CCR6 in EAE development (J Neuroimmunol. Aug 2009; 213(1-2):91-9. doi: 10.1016 / j.jneuroim.2009.05.011). Injection of anti-CCL20 at the first clinical presentation significantly reduced the severity and pathological histology of EAE (Kohler RE, J Immunol. 15 June 2003; 170(12):6298-306. doi: 10.4049 / jimmunol.170.12.6298). Anti-CCR6 neutralizing antibody reduced the severity of EAE in mice (Robert R, JCI Insight. 3 August 2017; 2(15): e94821. Published online 3 August 2017. doi: 10.1172 / jci.insight.94821).IL-6 and IL-17 increase the expression of CCL20 in mouse astrocytes (Meares GP, Glia. May 2012; 60(5):771-81. doi: 10.1002 / glia.22307).

[0013] CCR6 and CCL20 are proposed to influence the dynamics of germinal center (GC) formation and B cell response, and CCR6 is considered a marker memory B cell precursor in both mouse and human germinal centers (Suan D, Immunity. Dec 19, 2017; 47(6):1142-1153.e4. doi: 10.1016 / j.immuni.2017.11.022). Increased expression of CCR6 on primitive, pre-GC, GC / plasma cell, and memory B cells in peripheral B cells of patients with systemic lupus erythematosus (SLE) (Lee AYS, Clin Rheumatol. Jun 2017; 36(6):1453-1456. doi: 10.1007 / s10067-017-3652-3). CD4+CCR6+ cells can also affect disease severity in SLE patients and are shown to increase in anti-DNA+ SLE patients, which is associated with disease severity and erythrocyte sedimentation rate (Zhong W, Peer J. 2018; 6:e4294. doi: 10.7717 / peerj.4294).

[0014] Increased CCR6 expression in the salivary glands of patients with primary Sjögren's syndrome (pSS) was confirmed [Scand J Immunol. 2020 Mar;91(3):e12852. doi: 10.1111 / sji.12852]. A trend of increased CCL20 mRNA expression was also observed. Compared with healthy controls (HC), the number of circulating CCR6+ Th cells (CCR9- and CCR9+) was significantly reduced in pSS patients [Scand J Immunol. 2020 Mar;91(3):e12852. doi: 10.1111 / sji.12852].

[0015] In an animal model of autoimmune hepatitis (AIH), administration of anti-TNF-α suppressed hepatic CCL20 expression. Mice receiving anti-CCL20 showed reduced AIH. Furthermore, TNF-α stimulation enhanced CCL20 expression in hepatocytes. These findings suggest that TNF-α is necessary in inducing AIH via upregulation of hepatic CCL20 expression, which recruits CCR6+ T cells that drive pathology (Clin Immunol. Jan 2013; 146(1):15-25. doi: 10.1016 / j.clim.2012.10.008).

[0016] The CCR6 modulator of this invention can be used alone or in combination for the treatment or prevention of autoimmune diseases or conditions, including posterior uveitis, allergic conjunctivitis, gastrointestinal allergic diseases, type I diabetes, and endometriosis (Medicina (Kaunas). 16 Nov 2018; 54(5). doi: 10.3390 / medicina54050088). The CCR6 modulator can also be used alone or in combination for the treatment of ocular surface diseases with recorded elevated levels of IL-17A, including meibomian gland dysfunction; GVHD, graft-versus-host disease; autoimmune keratitis, filamentous keratitis, dry eye syndrome with rheumatoid arthritis; dry eye syndrome without systemic disease; and Stevens-Johnson syndrome. (J Korean Med Sci. July 2011;26(7):938-44. doi: 10.3346 / jkms.2011.26.7.938).

[0017] The CCR6 modulators of this invention can be used alone or in combination for the treatment or prevention of malignant diseases. They have been shown to modulate tumor growth and metastasis in experimental disease models as a single agent or in combination with immunotherapies for the prevention / treatment of cancer (especially such as blocking PD1 and / or PDL1), using siRNA, shRNA, CCR6 gene knockout animals, CCL20 ligand therapy, or antibodies to alter the CCR6 / CCL20 axis.

[0018] The therapeutic potential of using small interfering RNA (siRNA) or small hairpin RNA (shRNA) to mediate CCR6 or CCL20 silencing to treat malignant diseases has been described in mouse models of tumors. Specifically, in a mouse model of cutaneous T-cell lymphoma (My-La cells), Abe et al. reported that administration of CCR6-targeting siRNA prolonged animal survival compared to control animals (Oncotarget. Jan 31, 2017; 8(5):7572-7585. doi: 10.18632 / oncotarget.13810.). Using another method, Ito and colleagues demonstrated that mice injected with T-lymphoma cells (My-La) containing siRNA constructs that silence CCR6 had significantly longer survival than mice injected with control cells (Blood. March 6, 2014; 123(10):1499-511. doi: 10.1182 / blood-2013-09-527739.). Zhu and colleagues demonstrated that when CCR6 in cancer cells was silenced by shRNA, the mean volume and weight of tumor nodules in mice subcutaneously injected with a group of colorectal cancer cell lines decreased (PMID Biochim Biophys Acta Mol Basis Dis. February 2018; 1864(2):387-397. doi: 10.1016 / j.bbadis.2017.10.033.). In a glioblastoma xenograft model using patient-derived glioblastoma cell lines, mice injected with cells containing shRNA constructs that silence CCR6 expression survived longer than mice injected with control cells. Furthermore, histological and immunohistochemical studies showed that tumors formed from glioma cells with CCR6-targeting shRNAs were significantly smaller and exhibited significantly lower tumor angiogenesis compared to control tumors. Overall, these data further support the concept that enhanced CCR6 signaling has a carcinogenic potential in lymphoma, colorectal tumors, and glioblastoma (Oncogene. 2018 June; 37(23):3070-3087. doi: 10.1038 / s41388-018-0182-7.). Specifically, the literature reports that the CCR6 / CCL20 axis is associated with tumorigenesis in CCR6 knockout animals. In the CMT93 mouse model of colorectal cancer (CRC), T regulatory cell infiltration was completely prevented in tumors of mice lacking CCR6 compared to wild-type animals.The reported data further indicate that the homing and migration of tumor-infiltrating T regulatory cells to tumor masses depend on the in vivo chemokine receptor CCR6 (PLoS One. April 29, 2011; 6(4):e19495. doi: 10.1371 / journal.pone.0019495.). According to Nandi et al., in a mouse model of spontaneous intestinal tumor formation [APCMIN / + mice, for xenografting mutations in the colonic adenomatous polyposis (APC) gene], mice lacking CCR6 showed a lower incidence of spontaneous intestinal tumor formation (PLoS One. 2014; 9(5):e97566. doi: 10.1371 / journal.pone.0097566.).

[0019] The potential role of the CCR6 / CCL20 axis in tumorigenesis was also demonstrated by administration of recombinant CCL20 chemokines. Specifically, in a mouse model of colorectal cancer (CMT93 cells), Liu et al. showed that tumor size was significantly increased in mice treated with recombinant mouse CCL20 compared to the PBS control, indicating the key role of CCL20 in the growth and development of colorectal cancer (PLoS One. April 29, 2011; 6(4):e19495. doi: 10.1371 / journal.pone.0019495.).

[0020] Specifically, using a neutralizing CCL20 antibody, the potential role of the CCR6 / CCL20 axis in tumor promotion has been demonstrated in the literature using a mouse model. Ikeda et al. used a specific cutaneous T-cell lymphoma (CTCL) mouse model in which animals died from CTCL cell metastasis to multiple organs. However, administration of a neutralizing CCL20 antibody significantly prolonged the survival of xenograft mice (Oncotarget. 22 Mar 2016; 7(12):13563-74. doi: 10.18632 / oncotarget.6916.). Lee et al. described how administering anti-CCL20 antibodies prevented the development of bone metastasis in a mouse model of metastatic breast cancer (MDA-MB-231 cells injected into the left ventricle of nude mice). The bone is one of the main sites of breast cancer metastasis in human diseases (Sci Rep. Aug 29, 2017; 7(1):9610. doi: 10.1038 / s41598-017-09040-4.). In a humanized mouse model of nasopharyngeal carcinoma, Mrizak et al. observed that, compared to sham-treated animals, T regulatory cells were significantly reduced in recruitment to the tumor when mice were injected with anti-CCL20 monoclonal antibodies (J Natl Cancer Inst. Jan 2015; 107(1):363. doi: 10.1093 / jnci / dju363.). In addition, in a mouse model of liver cancer (Hepa1-6 cells), blocking CCL20 activity in immune-competent mice with anti-CCL20 antibodies reduced tumor incidence and limited tumor growth and distant metastasis. Furthermore, the authors reported that tumor angiogenesis was significantly inhibited upon CCL20 neutralization in this mouse model (He et al., PMID 28560063 - Am J Cancer Res. 2017; 7(5):1151-1163.). Using the same mouse model, administration of anti-CCL20 neutralizing antibodies significantly reduced T regulatory cell infiltration into tumors, especially CCR6-positive T regulatory cells, and significantly reduced tumor growth. The antitumor efficacy was further enhanced when mice were co-treated with anti-PDL-1 antibodies. Overall, these data sets suggest that CCL20 blockade can eliminate anti-PD-L1 resistance in a mouse hepatocellular carcinoma model by inhibiting the recruitment of T regulatory cells to the tumor (Hepatology. July 2019; 70(1):198-214. doi: 10.1002 / hep.30593.).

[0021] Specifically, the potential role of the CCR6 / CCL20 axis in tumor metastasis has been described in the literature. Dellacasagrande et al. reported that in a mouse plasmacytoma model, tumor cells from the primary tumor (subcutaneously injected with mouse plasmacytoma (MOPC315)) disseminated to the liver overexpressed functional CCR6. The same authors found that CCR6 was overexpressed in small liver metastases of colon cancer, thyroid cancer, and ovarian cancer compared to normal liver (Scand J Immunol. 2003 Jun; 57(6):534-44. doi: 10.1046 / j.1365-3083.2003.01263.x.).

[0022] Furthermore, the CCR6 modulators of this invention can be used alone or in combination to treat or prevent cancers in which CCR6 and / or CCL20 expression is associated with disease progression and resistance to standard treatment care. Specifically, the literature describes the association between CCR6 expression and disease progression for many cancer indications. For example, in renal cell carcinoma, CCR6 expression is associated with lower overall survival (Cancers (Basel). Dec 30, 2019; 12(1). doi: 10.3390 / cancers12010089.). In colorectal cancer, tumor manifestation of CCR6 is positively correlated with metastasis, and upregulated CCR6 predicts poor survival, shorter disease-free survival (PLoS One. 2014; 9(6):e101137. doi: 10.1371 / journal.pone.0101137.) and poor 5-year survival (Biochim Biophys Acta Mol Basis Dis. 2018 Feb; 1864(2):387-397. doi: 10.1016 / j.bbadis.2017.10.033.). In ovarian cancer, high CCR6 mRNA expression is also associated with poor prognosis (Cancer Lett. 2020 Mar 1; 472:59-69. doi: 10.1016 / j.canlet.2019.12.024.). CCR6 expression is associated with the aggressiveness of rectal cancer; in fact, high levels of CCR6 protein expression are more common in radiotherapy-unresponsive patients than in responders (Cancer Res Treat. Oct 2018; 50(4):1203-1213. doi: 10.4143 / crt.2017.538.). CCR6 expression in prostate cancer is associated with clinicopathological features of more advanced and aggressive disease (J Cancer Res Clin Oncol. Nov 2008; 134(11):1181-9. doi: 10.1007 / s00432-008-0403-5.). In non-small cell lung cancer (NSCLC), high CCR6 expression is associated with shorter disease-free survival and a 5-fold increased risk of disease recurrence that is not disease stage-dependent (PLoS One. 2011; 6(9):e24856. doi: 10.1371 / journal.pone.0024856.). Patients with hepatocellular carcinoma exhibiting increased infiltration of CCR6-positive immune cells in tumor tissue show poor prognosis (Am J Cancer Res. 2017; 7(5):1151-1163.).

[0023] Similar to CCR6, the expression of its ligand CCL20 has been reported to be associated with adverse disease outcomes in several indications. Specifically, in breast cancer, elevated CCL20 expression is associated with lower overall progression-free survival, lower percentage of metastasis-free survival (Sci Rep. 29 Aug 2017; 7(1):9610. doi: 10.1038 / s41598-017-09040-4.), higher histological grade, higher Ki67 levels, and axillary lymph node metastasis. In addition, CCL20 expression in breast tumors is positively correlated with FOXP3 (a marker of T regulatory cells). Patients with axillary lymph node metastasis and elevated CCL20 expression and FOXP3-positive T regulatory cells have the worst overall survival. (Medicine (Baltimore). Dec 2019; 98(50):e18403. doi: 10.1097 / MD.0000000000018403.). In NSCLC, higher CCL20 performance is associated with lower overall survival (Biomed Pharmacother. Feb 2015; 69:242-8. doi: 10.1016 / j.biopha.2014.12.008.)(Cancer Lett. Jul 10 2015; 363(1):60-70. doi: 10.1016 / j.canlet.2015.04.005.). Similar to NSCLC, hepatocellular carcinoma patients with high CCL20 performance have poorer overall survival and poorer recurrence-free survival. The same author described CCL20 as significantly associated with tumor size, tumor number, vascular invasion, tumor differentiation and tumor recurrence (J Gastrointest Surg. April 2012; 16(4):828-36. doi: 10.1007 / s11605-011-1775-4.).

[0024] Besides CCR6 or CCL20 alone, the literature reports a correlation between CCR6 / CCL20 co-expression and disease progression. In fact, compared to low-grade tissues, overexpression of both CCL20 and CCR6 was detected in high-grade glioma tissues, and this overexpression increased with increasing World Health Organization (WHO) tumor grade. In particular, glioma patients with CCL20 / CCR6 co-expression had the shortest overall survival (Med Oncol. Dec 2012; 29(5):3491-7. doi: 10.1007 / s12032-012-0314-9.).

[0025] Furthermore, CCR6 and / or CCL20 expression is associated with enhanced chemotherapeutic resistance and metastasis. In fact, CCL20 expression can increase chemotherapeutic resistance in breast cancer cells (PLoS Biol. 2018 July; 16(7):e2005869. doi: 10.1371 / journal.pbio.2005869.). Rubie et al. described the detection of significant upregulation of CCL20 / CCR6 in human samples of colorectal liver metastases (CRLM) and hepatocellular carcinoma (HCC) (RT-PCR). Furthermore, compared to primary HCC, CCL20 was significantly overexpressed in colorectal liver metastases, indicating that CCL20 / CCR6 ligand-receptor is involved in the occurrence and progression of liver malignancies (World J Gastroenterol. 2006 Nov 7; 12(41):6627-33. doi: 10.3748 / wjg.v12.i41.6627.).

[0026] The CCR6 modulators of this invention can be used alone or in combination to treat or prevent diseases or conditions in which CCR6 and / or CCL20 are expressed or overexpressed in patient samples or cancer cell lines. Specifically, the expression of the chemokine receptor CCR6 in several cancer types or cancer cell lines is described in the literature. Lu et al. described higher CCR6 expression in laryngeal cancer tissue compared to its normal controls. The authors also reported that CCR6 is expressed in commonly used laryngeal cancer cells such as TU212, M4E, M2E, and Hep-2 (Biomed Pharmacother. Jan 2017; 85:486-492. doi: 10.1016 / j.biopha.2016.11.055.). Based on gene expression data from malignant melanoma, the CCR6 gene, reported in Biological Networks, is described and characterized as a useful factor involved in immune response and tumor progression (PLoS One. 2018; 13(1):e0190447. doi: 10.1371 / journal.pone.0190447.). Whole-exome sequencing of 21 types of MALT lymphomas of the salivary gland and thyroid gland showed CCR6 expression (Haematologica. Aug 2018; 103(8):1329-1336. doi: 10.3324 / haematol.2018.191601.). CCR6 transcripts were detected in samples from adult T-cell leukemia / lymphoma (ATLL), and CCR6 was also found at the protein level using flow cytometry analysis (Leuk Lymphoma. Oct 2006; 47(10):2163-73. doi: 10.1080 / 10428190600775599.). In patient-derived prostate cancer samples, CCR6 (mRNA) gene expression in tumor tissues was significantly higher than in adjacent normal tissues (Cancer Res Treat. Apr 2015; 47(2):306-12. doi: 10.4143 / crt.2014.015.). In common cancer cell lines, CCR6 expression was actually detected in salivary gland adenoid cystic cancer cells SACC-83 by Mays and colleagues. In other CC chemokine receptors, CCR6 expression was detected using RT-PCR gene analysis (Anticancer Res. 2016 Aug; 36(8):4013-8.).According to Möller et al., CCR6 has also been observed in multiple myeloma (MM) cell lines including U266 1970, U-266 1984, U-1958, Karpas 707, LP-1,28 L-363, HL407E, and HL407L.3 (Leukemia. January 2003; 17(1):203-10. doi: 10.1038 / sj.leu.2402717.).

[0027] Similar to CCR6, the ligand CCL20 has been reported to be expressed in multiple tumor samples and tumor cell lines in the literature. For example, Zhang et al. demonstrated that, using RT-PCR, CCL20 expression in tumor samples from NSCLC patients was higher than in samples from adjacent tissues, which was also verified at the protein level using immunohistochemistry (Biomed Pharmacother. 2015 Feb; 69:242-8. doi: 10.1016 / j.biopha.2014.12.008.). Gene expression analysis of cholangiocarcinoma samples and corresponding normal tissues showed that CCL20 is one of the most significantly overexpressed genes in malignant tissues compared to healthy tissues (EXCLI J. 2020; 19:154-166. doi: 10.17179 / excli2019-1893.). CCL20 expression has also been reported in human samples of multiple myeloma (MM) (Cancer Res. 2008 Aug 15; 68(16):6840-50. doi: 10.1158 / 0008-5472.CAN-08-0402.). Furthermore, according to Rubies et al., CCL20 mRNA and protein were significantly upregulated (8-fold) in pancreatic cancer compared to matched normal pancreas with weak CCL20 expression (J Transl Med. 2010 May 10; 8:45. doi: 10.1186 / 1479-5876-8-45.). CCL20 is also expressed in oral squamous cell carcinoma (IHC staining) and Lee et al. reported that it is enriched in human CCR6+ regulatory T cells with excellent inhibitory activity (J Immunol. July 15, 2017; 199(2):467-476. doi: 10.4049 / jimmunol.1601815.).

[0028] Besides CCR6 or CCL20 alone, co-expression of CCR6 and CCL20 in samples from cancer patients and cancer cell lines has been reported in the literature. The expression of the two genes in adult T-cell leukemia / lymphoma patient samples (microarray and IHC protein staining) has been described (Int J Oncol. 2014 Sep 45(3):1200-8. doi: 10.3892 / ijo.2014.2524.) and in CTCL. In the latter, CCL20 and CCR6 were detected at both the mRNA and protein levels (Clin Cancer Res. 2011 Dec 15; 17(24):7529-38. doi: 10.1158 / 1078-0432.CCR-11-1192.). Transcriptome analysis (nanostrings) of hepatocellular carcinoma samples showed the expression of CCR6 and CCL20. Furthermore, the chemotactic gradient between non-tumor and tumor tissues was reported, and the recruitment process of T regulatory cells, tumor-associated macrophages, and natural killer cells involved in the CCR6 / CCL20 axis was proposed (Proc Natl Acad Sci US A. July 18, 2017; 114(29):E5900-E5909. doi: 10.1073 / pnas.1706559114.). Similarly, Guo et al. reported the upregulation of CCR6 and CCL20 in hepatocellular carcinoma lesions and the expression of CCR6 and CCL20 in hepatocellular carcinoma cell lines (L02, Li- / , Huh-7, SNU-387, Hep3B) compared to healthy tissues (Oncol Rep. Sep 2019; 42(3):1075-1089. doi: 10.3892 / or.2019.7221.). According to Nandi et al. (IHC protein staining), both CCL20 and CCR6 are expressed in human colorectal cancer. CCR6 and CCL20 were found to be highly expressed (protein and mRNA) in NSCLC samples (Oncol Lett. Dec 2017; 14(6):8183-8189. doi: 10.3892 / ol.2017.7253). Using in situ hybridization, the mRNA components of both CCL20 and CCR6 were strongly expressed in all pancreatic cancer samples analyzed. In contrast, CCL20 and CCR6 were low in healthy pancreas (Int J Cancer. May 17, 1999; 81(4):650-7. doi: 10.1002 / (sici)1097-0215(19990517)81:4<650::aid-ijc23>3.0.co;2-#.). Jin and colleagues used publicly available datasets to examine the expression of CCR6 and CCL20 in glioblastoma.The authors used the GEO dataset GSE2223 to compare the mRNA levels of CCL20 and CCR6 between normal brain and glioblastoma tissues. Again, the expression levels of CCR6 and CCL20 were significantly higher in glioblastoma tissues than in normal brain tissue (Oncogene. 2018, 6; 37(23):3070-3087. doi: 10.1038 / s41388-018-0182-7.). Additionally, Wallace and colleagues observed higher expression levels of CCL20 and its receptor CCR6 in endometrial adenocarcinoma explants and cell lines than in non-malignant endometrium (mRNA, RT-PCR) (Mol Cell Endocrinol. 2011, 1 Jan; 331(1):129-35. doi: 10.1016 / j.mce.2010.08.018.). The CCL20 / CCR6 axis may play a role in breast cancer, cholangiocarcinoma, and thyroid cancer, as evidenced by reports in patient-derived breast cancer cells (Mol Carcinog. 2016 Jul; 55(7):1175-86. doi: 10.1002 / mc.22360.), HuCCT1 and TFK-1 cholangiocarcinoma cell lines (Win et al., PMID 32194362) (EXCLI J. 2020; 19:154-166. doi: 10.17179 / excli2019-1893.), and thyroid cancer cell lines such as TPC-1, BCPAP, FTC-133, and SW1736 (Tumour Biol. 2016 Apr; 37(4):5569-75. doi: The expression of the CCR6 / CCL20 gene and / or protein in (10.1007 / s13277-015-4418-7.). Furthermore, the CCR6 regulator of this invention can be used alone or in combination to treat or prevent cancers in which CCR6 / CCL20 axis activity has been reported and / or evidence has been presented, or in which CCR6+ regulatory T cells have been identified within the tumor microenvironment. Summary of the Invention

[0029] 1) One state of the present invention relates to the compound of formula (I), wherein Formula (I) [A] indicates the presence of one to three cyclic nitrogen atoms (especially one or two cyclic nitrogen atoms; particularly relative to...). [A] The attachment point with the rest of the molecule, in A 6-membered heteroaryl group (one or two cyclic nitrogen atoms at the [A]-position and / or para-position), wherein the 6-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted or trisubstituted (especially relative to the [A]-position). [A] The attachment point with the rest of the molecule, in [A] mono- or di-substituted at the position between and / or at the para position), wherein the substituent (etc.) is independently selected if present. ● Halogens (especially fluorine); ● Cyano; ● Hydroxyl-C1-6 alkyl groups further substituted with one to three fluorine atoms, as appropriate (wherein the hydroxyl group is separated from any fluorine atom by at least two carbon atoms; such hydroxy-C1-6 alkyl groups particularly represent 3-hydroxy-propyl, 4-hydroxy-butyl, 3-hydroxy-butyl, 3-hydroxy-3-methyl-butyl, 3-hydroxy-4-methyl-pentyl, 3-hydroxy-3-trifluoromethyl-butyl or 2,2-difluoro-3-hydroxy-propyl-1-yl); ● C1-5 alkyl groups (especially methyl, ethyl, propyl, isopropyl, butyl, or isobutyl), which are unsubstituted or monosubstituted with the following groups: Ø C1-3 alkoxy groups (especially methoxy groups); Ø C3-6 cycloalkyl group fused with the pyridine ring (especially at positions 2 and 3 adjacent to the nitrogen atom of the pyridine ring), wherein the C3-6 cycloalkyl group is unsubstituted or monosubstituted with a hydroxyl group (especially at the junction of the C3-6 cycloalkyl group and the C1-5 alkyl group); Ø -O- [R, O1 , ],in [R, O1 , ] indicates an independently unsubstituted or C3-6 cycloalkyl (especially cyclopentyl) or pyrrolidyl (especially pyrrolid-2-yl) monosubstituted C1-3 alkyl (especially methyl) or C1-4 alkyl-carbonyl (especially acetyl); Ø Phenyl- [L, 1 , ]-, wherein the phenyl group is unsubstituted or monosubstituted with fluorine, C1-4 alkoxy-carbonyl (especially methoxy-carbonyl) or hydroxy-C1-4 alkyl (especially hydroxy-methyl); wherein - [L, 1 , ]- indicates a single bond (i.e., the phenyl group is directly attached to the alkyl group), an oxygen group (i.e., the phenyl group is attached to the alkyl group via an oxygen group), or a group -CH2-O- (where the phenyl group is attached to the methylene group); Ø Contains one or two independent C4-6 heterocyclic groups selected from nitrogen and oxygen cyclic heteroatoms (especially aziridine, imidazolidinyl, pyrrolidyl, acezolidinyl, piperidinyl or tetrahydropiperanyl; especially aziridine-3-yl, tetrahydropiperanyl-4-yl, imidazolidin-1-yl, pyrrolidin-1-yl, acezolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl), wherein the C4-6 heterocyclic group is unsubstituted, monosubstituted or disubstituted with a side oxygen, hydroxyl, C1-3 alkyl (especially methyl), C1-4 alkyl-carbonyl (especially acetyl) or C1-4 alkoxy-carbonyl (especially tert-butoxy-carbonyl); [In detail, this type of C4-6 heterocyclic group represents 1-(tert-butoxy-carbonyl)-3-hydroxy-azacyclobutane-3-yl, tetrahydropiperan-4-yl, 4-hydroxy-tetrahydropiperan-4-yl, 2-sideoxy-imidazolidine-1-yl, 2-sideoxy-3-methyl-imidazolidine-1-yl, 2-sideoxy-pyrrolidine-1-yl, 2-sideoxy-azolidine-3-yl, 2-sideoxy-azolidine-3-yl, N-acetylated-2-methyl-pyrrolidine-2-yl, N-(tert-butoxy-carbonyl)-3-hydroxy-pyrrolidine-3-yl, N-acetylated-piperidine-4-yl, or N-(tert-butoxy-carbonyl)-piperidine-4-yl] Ø A 5-membered heteroaryl group (especially pyrazolyl; especially pyrazol-4-yl) containing one or two cyclic nitrogen atoms, wherein the 5-membered heteroaryl group is unsubstituted or monosubstituted with a C1-3 alkyl group (especially methyl); Ø -N [R, N1 , R, N2 , ],in [R, N1 , ] represents hydrogen and [R, N2 , ] indicates a C1-3 alkyl-carbonyl group (especially acetyl) or a hydroxy-C1-3 alkyl-carbonyl group (especially hydroxymethyl-carbonyl). [In detail, this type of -N [R, N1 , R, N2 , ] represents acetyl-amino or hydroxymethyl-carbonyl-amino; Ø Indole group (especially indole-2-yl); Ø Pyrrolopyridyl (especially 1H-pyrrolo[2,3-b]pyridin-2-yl)); Ø N-(C1-3 alkyl)-amino-carbonyl-oxy; or Ø 1-Hydroxy-1-C3-5 cycloalkyl-1-(pyridinyl)-methyl (especially 1-hydroxy-1-cyclopropyl-1-(pyridin-2-yl)-methyl); In detail, these C1-5 alkyl groups represent methyl, ethyl, isopropyl, cyclopentyl-oxy-methyl, 2-(1-hydroxy-cyclopropyl)-ethyl, 2-(1-hydroxy-cyclobutyl)-ethyl, 2-(1-hydroxy-cyclopentyl)-ethyl, 3-methoxy-propyl, 4-fluoro-phenoxy-methyl, 2-(2-(methoxy-carbonyl)-phenyl)-ethyl, benzyl-oxy-methyl, N-(isopropyl)-amino-carbonyl-oxy-methyl, 2-(1-(tert-) (butoxy-carbonyl)-3-hydroxyazacyclobutane-3-yl)-ethyl, 3-methyl-3-(2-sideoxy-imidazolidine-1-yl)-butyl, 3-methyl-3-(2-sideoxy-3-methyl-imidazolidine-1-yl)-butyl, 3-methyl-3-(2-sideoxy-pyrrolidine-1-yl)-butyl, 2-(N-(tert-butoxy-carbonyl)-3-hydroxy-pyrrolidine-3-yl)-ethyl, 3-methyl-3-(2-sideoxy-imidazolidine-3-yl) )-Butyl, 2-(1-methyl-1H-pyrazol-4-yl)-ethyl, 2-(2-hydroxymethyl-phenyl)-ethyl, 2-(tetrahydropiperan-4-yl)-ethyl, 2-(4-hydroxy-tetrahydropiperan-4-yl)-ethyl, 2-(indol-2-yl)-ethyl, 2-(8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl)-ethyl, 2-(7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl)-ethyl, 2-(N -acetylated-piperidin-4-yl)-ethyl, 2-(N-(tert-butoxy-carbonyl)-piperidin-4-yl)-ethyl, N-acetylated-2-methyl-pyrrolidin-2-yl-oxy-methyl, acetylated-amino-isopropyl, N-(hydroxymethyl-carbonyl)-amino-methyl, 3-hydroxy-3-cyclopropyl-3-(pyridin-2-yl)-propyl, 2-(indol-2-yl)-ethyl or 2-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl] ● Hydroxy and [R, A1 The substituents are C3-5 alkyl groups (especially n-propyl, n-butyl, or n-pentyl), wherein the substituents are all located at the 3-position relative to the attachment point between the C3-5 alkyl group and the rest of the molecule; wherein Ø [R, A1 , ]express ▪ Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl); ▪ Unsubstituted or monosubstituted phenyl groups with fluorine (especially 3-fluorophenyl) or C1-3 alkoxy groups (especially 2-methoxyphenyl or 4-methoxyphenyl); ▪ Contains one or two 5- or 6-membered heteroaryl groups (especially thiazolyl, pyrazolyl, pyridinyl, pyridyl or pyrimidinyl; especially thiazolyl-4-yl, thiazolyl-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyridyl-2-yl or pyrimidin-4-yl) independently selected from nitrogen or sulfur ring heteroatoms, wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted or disubstituted, and wherein the substituent(e) is, if present, independently selected from C1-3 alkyl (especially methyl), C3-5 cycloalkyl (especially cyclopropyl) or C1-3 alkoxy (especially methoxy); or ▪ Indazole group (especially indazole-3-yl); In detail, these C3-5 alkyl groups represent 3-hydroxy-3-(tetrahydropiperan-4-yl)-propyl, 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(3-fluoro-phenyl)-butyl, 3-hydroxy-3-(2-methoxy-phenyl)-butyl, 3-hydroxy-3-(4-methoxy-phenyl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-butyl, 3-Hydroxy-3-(1-methyl-pyrazole-3-yl)-butyl, 3-hydroxy-3-(1-cyclopropyl-1H-pyrazole-3-yl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazole-3-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazolyl-4-yl)-butyl, 3-hydroxy-3-(2-methyl-thiazolyl-5-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl 3-Hydroxy-3-(5-methyl-pyridin-3-yl)-butyl, 3-Hydroxy-3-(pyridin-2-yl)-butyl, 3-Hydroxy-3-(6-methyl-pyridin-2-yl)-butyl, 3-Hydroxy-3-(pyrimidin-2-yl)-butyl, 3-Hydroxy-3-(6-methoxy-pyrimidin-4-yl)-butyl, 3-Hydroxy-3-(6-methyl-pyrimidin-4-yl)-pentyl, 3-Hydroxy-3-(2-methyl-pyrimidin-4-yl)-butyl 3-hydroxy-3-(5-methyl-pyridine-2-yl)-butyl, 3-hydroxy-3-(1H-indazol-3-yl)-butyl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazolyl-4-yl)-propyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl or 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pentyl ● Unsubstituted (especially isopropenyl) or C3-5 alkenyl groups monosubstituted with hydroxyl groups (especially 4-hydroxy-but-1-en-2-yl); ● Unsubstituted, mono- or disubstituted C4-6 cycloalkenyl groups (especially cyclopentenyl; especially cyclopent-1-en-1-yl); wherein, if applicable, one ring carbon atom of the C4-6 cycloalkenyl group is substituted with an oxygen atom; [In detail, this type of C4-6 cycloalkenyl group represents cyclopent-1-en-1-yl, 3-sideoxy-cyclopent-1-en-1-yl, 3-hydroxy-cyclopent-1-en-1-yl, 3-hydroxy-3-methyl-cyclopent-1-en-1-yl, or 2,3-dihydro-furan-3-yl] ● Unsubstituted, C3-6 cycloalkyl groups mono- or disubstituted with C1-3 alkyl (especially methyl, ethyl, isopropyl), hydroxyl, or hydroxy-C1-3 alkyl (especially 1-hydroxy-1-methyl-ethyl), wherein, where applicable, one ring carbon atom of the C3-6 cycloalkyl group is substituted with an oxygen atom; [In detail, this type of C3-6 cycloalkyl group represents cyclopropyl, cyclopentyl, 3-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 3-hydroxy-3-ethyl-cyclopentyl, 3-hydroxy-3-isopropyl-cyclopentyl, 2-(2-hydroxy-isopropyl)-cyclopropyl, 4-hydroxy-cyclohexyl, 4-hydroxy-4-methyl-cyclohexyl, oxetane-3-yl, tetrahydrofuran-3-yl, tetrahydrofuran-2-yl, tetrahydropiperan-4-yl, 5-methyl-tetrahydrofuran-2-yl, or 5,5-dimethyl-tetrahydrofuran-2-yl] ● -O- [R, O2 , ],in Ø [R, O2 , ]express ▪ C1-4 alkyl groups (especially methyl, ethyl, isopropyl, dibutyl, or isobutyl); ▪ C2-5 alkyl groups monosubstituted with hydroxyl or C1-3 alkoxy (especially methoxy); [In detail, these C2-5 alkyl groups represent 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 3-hydroxy-3-methyl-butyl, or 2-methoxy-ethyl.] ▪ - [L, 2 , ]- [CY, 2 , ],in v - [L, 2 , ] - Independently represents a one-key (i.e., the key) [CY, 2, ] directly attached to the rest of the molecule), -CH2- or -CH2-CH2-; and v [CY, 2 , ] represent independently o Unsubstituted or monosubstituted phenyl groups with hydroxy-C1-3 alkyl groups (especially 2-hydroxy-ethyl); o benzyl-oxy; o Contains one to three 5- to 6-membered heteroaryl groups (especially pyridinyl, acediazolyl, or triazolyl); especially pyridin-2-yl, 1,2,4-acediazol-5-yl, or 1,2,4-triazol-1-yl), wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, or disubstituted; wherein the substituent(e) present is independently selected from C1-3 alkyl (especially methyl) or C1-3 cycloalkyl (especially cyclopropyl); o C3-6 cycloalkyl, wherein, depending on the case, one carbon ring atom is replaced by a heteroatom selected from oxygen and nitrogen (especially oxobutyryl, cyclopentyl, or cyclohexyl); wherein the C3-6 cycloalkyl is unsubstituted, monosubstituted, or disubstituted, wherein the substituents are selected from C1-3 alkyl (especially methyl), hydroxyl, fluorine, oxy, C1-3 alkyl-carbonyl (especially acetyl), and C1-3 alkoxy (especially methoxy); o Benzo[a]azolone group (especially 3H-benzo[a]azol-2-one-6-yl); o alkyl (especially alkyl-6-yl); [To elaborate, this type of -] [L, 2 , ]- [CY, 2 , ] represents phenyl, 4-(2-hydroxy-ethyl)-phenyl, 2-(2-hydroxy-ethyl)-phenyl, benzyl, 2-(benzyl-oxy)-ethyl, 2-(pyridin-2-yl)-ethyl, 3-cyclopropyl-1,2,4-diazol-5-yl-methyl, 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethyl, oxetane-3-yl-methyl, 2,2 -Dimethyl-cyclopentyl, 3,3-difluoro-cyclopentyl, 3-methoxy-cyclopentyl, cyclohexyl, 4-hydroxy-cyclohexyl, 4-methyl-4-hydroxy-cyclohexyl, 4-side-oxy-cyclohexyl, tetrahydrofuran-3-yl, tetrahydropiperan-4-yl, tetrahydropiperan-4-yl-methyl, N-acetylopidin-4-yl-methyl, 3H-benzopyrazole-2-one-6-yl or alkyl-6-yl] [To elaborate, this type of -O-] [R, O2, ] represents methoxy, ethoxy, isopropoxy, isobutoxy, dibutoxy, phenoxy, 4-(2-hydroxy-ethyl)-phenoxy, 2-(2-hydroxy-ethyl)-phenoxy, benzyl-oxy, 2-(benzyl-oxy)-ethoxy, 2-methoxy-ethoxy, 3-hydroxy-propoxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, 2,2-dimethyl-cyclopentyl-oxy, 3,3-difluoro-cyclopentyl-oxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4-hydroxy-cyclo Hexyl-oxy, 4-side-oxy-cyclohexyl-oxy, tetrahydrofuran-3-yl-oxy, tetrahydropiperan-4-yl-oxy, tetrahydropiperan-4-yl-methoxy, 3-methoxy-cyclopentyl-oxy, oxacyclobutane-3-yl-methoxy, 2-(pyridin-2-yl)-ethyl-oxy, (3-cyclopropyl-1,2,4-diazol-5-yl)-methoxy, 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethoxy, N-acetylopidin-4-yl-methyl-oxy, 3H-benzopyrazole-2-one-6-yl or alkyl-6-yl-oxy ● -C≡C- [R, T1 , ],in Ø [R, T1 , ]express ▪ C1-4 alkyl groups (especially methyl, ethyl, isopropyl, or isobutyl), wherein the C1-4 alkyl group is independently monosubstituted with the following groups: v Hydroxyl group; [In detail, the C1-4 alkyl group represents hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl-propyl, 1-hydroxy-1-methyl-ethyl, or 1-hydroxy-1-trifluoromethyl-ethyl]; v C1-3 alkoxy groups (especially methoxy groups); v -S(=O)2- [R, SOT , ],in [R, SOT , ] indicates C1-3 alkyl, C1-3 alkyl-amino or C3-5 cycloalkyl (especially such -S(=O)2- [R, SOT , ] represents methyl-sulfonyl, methyl-amino-sulfonyl, or cyclopropyl-sulfonyl); v -N [R, NT1 , R, NT2 , ],in [R,NT1 , ] represents hydrogen and [R, NT2 , ] represents C1-3 alkyl-carbonyl, C1-3 alkoxy-C1-3 alkyl-carbonyl or C3-5 cycloalkyl-carbonyl (especially such -N) [R, NT1 , R, NT2 , ] represents acetyl-amino, isopropyl-carbonyl-amino, methoxy-methyl-carbonyl-amino, or cyclopropyl-carbonyl-amino. v Contains one or two independent C4-6 heterocyclic groups selected from nitrogen and oxygen cyclic heteroatoms (especially azolidinyl, imidazodinyl, or pyrrolidinyl; especially azolidin-3-yl, imidazodin-3-yl, or pyrrolidin-1-yl); wherein the C4-6 heterocyclic group is monosubstituted with a side oxygen group; or disubstituted with a side oxygen group and a C1-3 alkyl group (especially methyl); (especially such C4-6 heterocyclic groups represent azolidin-2-one-3-yl, imidazodin-2-one-3-yl, 1-methyl-imidazodin-2-one-3-yl, or pyrrolidin-2-one-1-yl); or v N-(C1-3 alkyl-carbonyl)-piperidinyl-C1-3 alkyl (especially N-acetylopidin-4-yl-methyl); ▪ C3-6 cycloalkyl groups (especially cyclopropyl groups), which are monosubstituted with the following groups (especially at the attachment points between the C3-6 cycloalkyl group and the rest of the molecule): v Hydroxyl group; v. Depending on the case, an amino-sulfonyl group disubstituted with a methyl group; v. Phenyl groups monosubstituted with halogens (especially 4-fluoro-phenyl); v. Pyridyl (especially pyridin-2-yl); v. Pyrimidinyl groups monosubstituted with C1-3 alkyl groups (especially 6-methyl-pyrimidin-4-yl); v. Azolacillinone group (especially azolacil-2-one-3-yl); [In detail, these C3-6 cycloalkyl groups represent 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 1-(amino-sulfopropyl)-cyclopropyl, 1-(dimethyl-amino-sulfopropyl)-cyclopropyl, 1-(6-methyl-pyrimidin-4-yl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl, 1-(4-fluoro-phenyl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl, or 1-(azolidin-2-one-3-yl)-cyclopropyl]; ▪ A C3-6 cycloalkyl group (particularly cyclopentyl or cyclohexyl) fused to a pyridine ring (particularly at the 2 and 3 positions of the pyridine ring), wherein the C3-6 cycloalkyl group is monosubstituted with a hydroxyl group (particularly at the 1 position of the C3-6 cycloalkyl ring); wherein one of the ring carbon atoms in the C3-6 cycloalkyl group is substituted with an oxygen atom; [In detail, such C3-6 cycloalkyl groups represent 8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl, 7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl, or 4-hydroxy-3,4-dihydro-2H-piperano[3,2-b]pyridin-4-yl); ▪ Contains a C4-6 heterocyclic group independently selected from nitrogen and oxygen cyclic heteroatoms (especially aziridine, pyrrolidinyl, piperidinyl, tetrahydropiperanyl; especially aziridine-3-yl, piperidin-4-yl, pyrrolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-1-yl or tetrahydropiperanyl-4-yl); wherein the C4-6 heterocyclic group is monosubstituted, disubstituted or trisubstituted (especially monosubstituted or disubstituted), wherein the substituent is independently selected from C1-3 alkyl (especially methyl), hydroxyl, syloxy, C1-3 alkyl-carbonyl (especially acetyl), C1-3 alkoxy-carbonyl (especially tert-butoxy-carbonyl), C1-3 alkyl-sulfonyl (especially methyl-sulfonyl) and C1-3 alkyl-amino-sulfonyl (especially methyl-amino-sulfonyl); In detail, these C4-6 heterocyclic groups represent N-(isopropyl-carbonyl)-3-hydroxy-azacyclobutane-3-yl, N-(tert-butoxy-carbonyl)-3-hydroxy-azacyclobutane-3-yl, N-methyl-3-hydroxy-pyrrolidin-2-one-3-yl, N-acetylated-2-methyl-pyrrolidin-2-yl, 3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, 2-sideoxy-pyrrolidin-1-yl, N-acetylated-piperidin-4-yl, N-acetylated-4-methyl-piperidin-4-yl, N-(methyl-amino-sulfonylurea)-4-methyl-piperidin-4-yl, N-acetylated-4-hydroxy-piperidin-4-yl, N-(methyl-sulfonylurea)-piperidin-4-yl, N-(terbutoxy-carbonyl)-piperidin-4-yl, 3-hydroxy-2-sideoxy-1-methyl-pyrrolidin-2-yl or 4-hydroxy-tetrahydropiperan-4-yl); ▪ A pyrazol group substituted with a methyl group at N (especially 1H-pyrazol-4-yl); ▪ Indole (especially indole-2-yl); ▪ 3-Hydroxy-1-methyl-1,3-dihydro-indole-2-one-3-yl; or ▪ 4-Hydroxy-3,4-dihydro-2H-piperano[3,2-b]pyridin-4-yl; [To elaborate, this type of -C≡C-] [R, T1, ] represents 3-hydroxy-3-trifluoromethyl-but-1-yn-1-yl, 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-methyl-3-(pyrrolidin-2-one-1-yl)-but-1-yn-1-yl, 3-methyl-3-(cyclopropyl-sulfonylurea)-but-1 -yn-1-yl, 3-methyl-3-(acetylamino)-but-1-yn-1-yl, 3-methyl-3-(1-methyl-imidazol-2-one-3-yl)-but-1-yn-1-yl, 3-methyl-3-(imidazol-2-one-3-yl)-but-1-yn-1-yl, 3-methyl-3-(1-methyl-imidazol-2-one-3-yl)-but-1-yn-1-yl, 3-methyl-3-(2- 3-methyl-3-(methyl-sulfonylurea)-but-1-yn-1-yl, 3-methyl-3-(cyclopropyl-carbonyl-amino)-but-1-yn-1-yl, 3-methyl-3-(isopropyl-carbonyl-amino)-but-1-yn-1-yl, 3-methyl-3-(methoxy-methyl-carbonyl-amino)-but-1-yn-1-yl, 3- Hydroxy-4-methyl-pent-1-yn-1-yl, 3-methoxy-prop-1-yn-1-yl, 3-(N-acetylopyridine-4-yl)-prop-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl)-ethynyl, (7-hydroxy-6,7-Dihydro-5H-cyclopentano[b]pyridin-7-yl)-ethynyl, (1-methyl-pyrazol-4-yl)-ethynyl, (tetrahydropiperan-4-yl)-ethynyl, (4-hydroxy-tetrahydropiperan-4-yl)-ethynyl, indole-2-yl-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azacyclobutane-3-yl)-ethynyl, (1-(tert-butoxy-carbonyl)-3-hydroxy-azacyclobutane-3-yl) -Ethynyl, (1-(6-methyl-pyrimidin-4-yl)-cyclopropyl)-ethynyl, (N-acetylo-4-methyl-piperidin-4-yl)-ethynyl, (N-acetylo-4-hydroxy-piperidin-4-yl)-ethynyl, (1-(4-fluoro-phenyl)-cyclopropyl)-ethynyl, (N-acetylo-piperidin-4-yl)-ethynyl, (N-(methyl-sulfonylo)-piperidin-4-yl)-ethynyl, (1-(dimethyl- (1-(amino-sulphyl)-cyclopropyl)-ethynyl, (N-(methyl-amino-sulphyl)-4-methyl-piperidin-4-yl)-ethynyl, (1-(pyridin-2-yl)-cyclopropyl)-ethynyl, (3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl)-ethynyl, (1-(azolinidin-2-one-3-yl)-cyclopropyl)-ethynyl, (3 -hydroxy-1-methyl-1,3-dihydro-indol-2-one-3-yl)-ethynyl, (4-hydroxy-3,4-dihydro-2H-piperano[3,2-b]pyridin-4-yl)-ethynyl, (N-(tert-butoxy-carbonyl)-piperidin-4-yl)-ethynyl, (N-acetylated-2-methyl-pyrrolidin-2-yl)-ethynyl or (3-hydroxy-2-sideoxy-1-methyl-pyrrolidin-3-yl)-ethynyl], · -C≡CC(OH)( [R, T2 , ])( [R, T3 , ]),in Ø [R, T2 , ] indicates hydrogen or a C1-3 alkyl group (especially methyl or ethyl; particularly methyl); Ø [R, T3 , ]express ▪ Unsubstituted or monosubstituted phenyl groups, wherein the substituent, if present, is selected from C1-3 alkoxy groups (especially methoxy groups) or halogens (especially fluorine groups); [In detail, such unsubstituted or monosubstituted phenyl groups are 2-fluorophenyl, 4-methoxyphenyl, or 2-methoxyphenyl.] ▪ Contains one or two 5- to 6-membered heteroaryl groups (especially thienyl, thiazolyl, pyrrolyl, pyrazole, isozolyl, pyridyl, pyridyl or pyrimidinyl; especially thien-2-yl, thiazolyl-4-yl, thiazolyl-5-yl, pyrrol-2-yl, pyrazole-3-yl, pyrazole-4-yl, isozolyl-5-yl, pyridin-2-yl, pyrimidin-2-yl, pyridin-2-yl or pyrimidin-4-yl) independently selected from nitrogen, oxygen or sulfur ring heteroatoms, wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted or disubstituted, and wherein the substituent(e) is, if present, independently selected from C1-3 alkyl (especially methyl), C1-3 cycloalkyl (especially cyclopropyl), C1-3 fluoroalkyl (especially C1-fluoroalkyl; especially difluoromethyl or trifluoromethyl) and C1-3 alkoxy (especially methoxy); In detail, these 5- to 6-membered heteroaryl groups include 5-methyl-thiophene-2-yl, 2-methyl-thiazolyl-5-yl, 1-methyl-1H-pyrrole-2-yl, 1-cyclopropyl-1H-pyrazole-3-yl, 1-methyl-1H-pyrazole-3-yl, 1,3-dimethyl-pyrazole-4-yl, 1,5-dimethyl-1H-pyrazole-3-yl, 2-methyl-thiazolyl-4-yl, 3-methyl-isoazol-5-yl, 1-methyl-1H-imidazol-2-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methyl-pyridin-2-yl, pyrimidin-2-yl, 2-methoxy-pyrimidin-4-yl, 6 -Methoxy-pyrimidin-4-yl, pyrimidin-4-yl, 2-methyl-pyrimidin-4-yl, 6-methyl-pyrimidin-4-yl, 2,6-dimethyl-pyrimidin-4-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2-methyl-6-methoxy-pyrimidin-4-yl, 2-methoxy-6-methyl-pyrimidin-4-yl, 5-methyl-pyridine-2-yl, 1-cyclopropyl-1H-pyrazole-3-yl, 6-cyclopropyl-pyrimidin-4-yl, 6-difluoromethyl-pyrimidin-4-yl, 2-trifluoromethyl-pyrimidin-4-yl, 6-trifluoromethyl-pyrimidin-4-yl or 1,5-dimethyl-1H-pyrazole-3-yl] ▪ Contains a C4-7 heterocyclic group selected from nitrogen and oxygen ring heteroatoms; wherein the C4-7 heterocyclic group is unsubstituted, monosubstituted, or disubstituted, wherein the substituent(s), if present, is independently selected from C1-3 alkyl (especially methyl) or C1-3 alkyl-carbonyl (especially acetyl); or [In detail, this type of C4-7 heterocyclic group represents N-acetylopidin-4-yl, N-acetylopidin-4-yl, or tetrahydropiperan-4-yl] ▪ Indazole group (especially indazole-3-yl); [To elaborate, this type of -C≡CC(OH)( [R, T2 , ])( [R, T3, ]) represents 3-hydroxy-3-(5-methyl-thiophen-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazo-5-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-1H-pyrrolo-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(3-methyl-isoazololo-5-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-1H-pyrrolo-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-1H-imidazo-2-yl)-but-1-yn-1-yl 3-hydroxy-3-(5-methyl-pyridine-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(tetrahydropiperan-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(N-acetylopyridine-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(N-acetylopyridine-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazolyl-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(1,3-dimethyl-pyrazole) 3-hydroxy-3-phenyl-1-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-1H-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-cyclopropyl-1H-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1,5-dimethyl-1H-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl 3-Hydroxy-3-(1-methylpyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(3-fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methylpyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxypyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-6-methylpyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxypyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-Dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-4-yl)-but-1-yn-1-yl 3-Pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(1H-indazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-cyclopropyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-difluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(indazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl] , ▪ -N [R, N3 , R, N4 , ],in Ø [R, N3 , ] indicates C1-3 alkyl (especially methyl); and [R, N4 , ] indicates hydroxy-C1-3 alkyl (especially 2-hydroxy-ethyl) or 2-(benzylmethyl-oxy)-C1-3 alkyl (especially 2-(benzylmethyl-oxy)-ethyl); or Ø [R, N3 , ]and [R, N4 Together with the nitrogen atom attached to it, it forms a 4 to 6-membered (especially 5 to 6-membered) heterocycle, wherein the members required for the integrity of the heterocycle are each independently selected from -CH2-, -O-, -(C=O)-, -CH [R, X , ]- and -C( [R, Y, ])2-; wherein the heterocycle does not contain more than one member of the group consisting of -O- and -(C=O)- independently selected; wherein the heterocycle does not contain more than two members of the group consisting of -CH [R, X , ]- members of a group; and wherein the heterocycle does not contain more than two choices -C( [R, Y , ])2- The members of the group; among which [R, X , ] independently represent fluorine, methyl, isopropyl, isobutyl, tributyl, hydroxy, trifluoromethyl, hydroxy-methyl, 1-hydroxy-ethyl, 1-hydroxy-1-methyl-ethyl, cyclopropyl, 2-methoxy-ethyl, 2-methyl-thiazolyl-5-yl, 4-methyl-thiazolyl-2-yl, phenyl, benzyl, tetrahydropiperan-4-yl, N-acetylopyridine-4-yl, 1,2,4-diazolyl, 3-methyl-1,2,4-diazolyl Azol-5-yl, 2-methyl-2H-[1,2,3]triazol-4-yl, 1-methyl-1H-pyrazole-4-yl, 1-difluoromethyl-1H-pyrazole-4-yl, 1,3-dimethyl-1H-pyrazole-4-yl, pyridin-2-yl, 6-methyl-pyridin-3-yl, 6-isopropyl-pyridin-2-yl, 6-trifluoromethyl-pyridin-3-yl, 2-isopropyl-pyrimidin-4-yl or 1-methoxy-methyl; and wherein [R, Y , ] independently represent fluorine, hydroxyl, cyclopropyl, methyl, hydroxy-methyl or trifluoromethyl [such -N [R, N3 , R, N4 , ] particularly pyrrolidyl; 2-pyrrolidone; acezolidinone (especially 1,3-acezolidin-2-one-3-yl); piperidinyl; or morpholino, as appropriate, independently selected by one or two independent groups. [R, X , ]and [R, Y Substituents of the group consisting of , ]; [In detail, this type of -N] [R, N3 , R, N4, ] represents pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4-difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-(hydroxy-methyl)-pyrrolidin-1-yl, 2-(hydroxy-methyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-hydroxy-3-cyclopropyl-pyrrolidin-1-yl, 3-hydroxy-3-trifluoromethyl-pyrrolidin-1-yl, 3-trifluoromethyl-pyrrolidin-1-yl, 3 -(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-(hydroxy-methyl)-3-methyl-pyrrolidin-1-yl, 1,3-azolidin-2-one-3-yl, 5-(tert-butyl)-1,3-azolidin-2-one-3-yl, 5-phenyl-1,3-azolidin-2-one-3-yl, 5-benzyl-1,3-azolidin-2-one-3-yl, 5-isopropyl-1,3-azolidin-2-one-3-yl, 5-(tetrahydropiperan-4-yl)-1,3-azolidin-2-one-3-yl, 5,5-dimethyl-1,3-azolidin-2-one-3-yl, morpholin-4-yl, piperidin-1-yl 4-Hydroxy-piperidin-1-yl, 3-Hydroxy-piperidin-1-yl, 3-(tetrahydropiperan-4-yl)-pyrrolidin-2-one-1-yl, N-methyl-N-(2-(benzyl-oxy)-ethyl)-amino, N-methyl-N-(2-hydroxy-ethyl)-amino, pyrrolidin-2-one-1-yl, 4-phenyl-pyrrolidin-2-one-1-yl, 4-(N-acetylated-piperidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(6- Isopropyl-pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-(6-trifluoromethyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-methyl-pyrrolidin-2-one-1-yl, 4-isopropyl-pyrrolidin-2-one-1-yl, 3-isopropyl-pyrrolidin-2-one-1-yl, 3,3-dimethyl-pyrrolidin-2-one-1-yl, 4,4-dimethyl-pyrrolidin-2-one-1-yl, 3-(piperidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(1-methyl-1H-pyrazole-4-yl)-pyrrolidin-2-one-1-yl, 4-(1,3-Dimethyl-1H-pyrazol-4-yl)-pyrrolidin-2-one-1-yl, 4-(6-isopropyl-pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-isobutyl-pyrrolidin-2-one-1-yl, 4-cyclopropyl-pyrrolidin-2-one-1-yl, 4-trifluoromethyl-pyrrolidin-2-one-1-yl, 3-(2-methoxy-ethyl)-pyrrolidin-2-one-1-yl, 4-(2-methoxy-ethyl)-pyrrolidin-2-one-1-yl, 2,2,6,6-tetrafluoro-morpholine Lino-4-yl, 2,6-dimethyl-morpholin-4-yl, 2-(methoxy-methyl)-morpholin-4-yl, 3-(3-methyl-1,2,4-diazol-5-yl)-pyrrolidin-1-yl, 4-(2-methyl-thiazolyl-5-yl)-pyrrolidin-2-one-1-yl, 4-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrrolidin-2-one-1-yl, 3-(4-methyl-thiazolyl-2-yl)-pyrrolidin-1-yl or 3-(phenyl)-pyrrolidin-1-yl], · -(C=O)-N( [R, N5 , ])( [R, N6 , ]),in Ø [R, N5 , ] represents hydrogen; and [R, N6 , ] indicates C3-6 cycloalkyl (especially cyclopentyl) or tetrahydropiperanyl (especially tetrahydropiperan-4-yl); or Ø [R, N5 , ]and [R, N6 , ] together with the nitrogen attached to it, form a pyrrolidin group; In detail, this type of -(C=O)-N( [R, N5 , ])( [R, N6 , ]) represents N-cyclopentyl-amino-carbonyl, N-(tetrahydropiperan-4-yl)-amino-carbonyl or pyrrolidinyl-carbonyl. • A piperidin-4-yl or pyrrolidin-3-yl monosubstituted at a nitrogen ring atom, wherein the substituent is independently selected from C1-4 alkoxy-carbonyl (especially tert-butoxy-carbonyl), pyridinyl (especially pyridin-2-yl), phenyl, and (4-methylphenyl)-sulfonyl; [In detail, these piperidine-4-yl or pyrrolidine-3-yl groups are N-(tert-butoxy-carbonyl)-piperidine-4-yl, N-(tert-butoxy-carbonyl)-pyrrolidine-3-yl, N-(pyridin-2-yl)-piperidine-4-yl, N-(phenyl)-piperidine-4-yl, or N-((4-methylphenyl)-sulfonylurea)-piperidine-4-yl] • Contains one to three (especially two or three; especially three) 5- or 6-membered heteroaryl groups independently selected from nitrogen, oxygen, and sulfur cyclic heteroatoms (especially pyrazolyl, triazolyl, acezolyl, thiazolyl, acediazolyl, pyrimidinyl, or pyridinyl; especially pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, acezol-2-yl, thiazol-2-yl, 1,2,4-acediazol-5-yl, 1,2,4-acediazol-3-yl, pyrimidin-2-yl, or pyridin-2-yl); wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially monosubstituted; especially relative to the 5- or 6-membered heteroaryl group and...). [A] is attached at position 3 by monosubstitution, wherein the substituent (or the substituent) is independently selected if present. Ø C1-4 alkyl groups (especially methyl, ethyl, propyl, isopropyl, or tert-butyl), their ▪ Not replaced; or ▪ Replaced by the following basic units: v Hydroxyl group; v C1-4 alkoxy groups (especially methoxy and tert-butoxy groups); or v -N( [R, N7 , ])( [R, N8 , ]),in [R, N7 , ] indicates hydrogen or C1-3 alkyl (especially methyl); and [R, N8 , ] independently represent C3-5 cycloalkyl-carbonyl (especially cyclopropyl-carbonyl), C1-3 alkyl (especially methyl), C1-3 alkyl-carbonyl (including deuterated C1-3 alkyl-carbonyl) (especially acetyl, ethyl-carbonyl, isopropyl-carbonyl or acetyl-2,2,2-d3), C1-3 alkoxy-C1-3 alkyl-carbonyl (especially methoxy-methyl-carbonyl), tetrahydropiperanyl-carbonyl (especially tetrahydropiperanyl-4-yl-carbonyl) or hydroxy-C1-3 alkyl-carbonyl (especially hydroxy-methyl-carbonyl); ▪ Disubstituted, where one substituent is hydroxyl and the other is trifluoromethyl; or both substituents are hydroxyl; or ▪ Disubstituted or trisubstituted, wherein two of the substituents are fluorine and, if present, the third substituent is a hydroxyl group (wherein the hydroxyl group is at least two carbon atoms away from either of the fluorine substituents); In detail, these C1-4 alkyl groups represent methyl, isopropyl, hydroxy-methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, tert-butoxy-methyl; 1,2-dihydroxy-ethyl, N-acetylglucosinolate-2-amino-ethyl, N-(acetylglucosinolate-2,2,2-d3)-2-amino-ethyl, 2-(methylmethoxylamino)-2-methyl-propyl, 2-(ethylmethoxylamino)-2-methyl-propyl, 2-(cyclopropylmethoxylamino)-2-methyl-propyl, 2-(tetrahydropiperan-4-ylmethoxylamino)-2- Methyl-propyl, 2-(methoxy-methyl-methamido)-2-methyl-propyl, 2-(ethyl-methamido)-2-methyl-propyl, 2-(isopropyl-methamido)-2-methyl-propyl, 2-(methyl-d3-methamido)-2-methyl-propyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetylglucosinolate-2-amine 2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl, 1,1-difluoro-2-hydroxy-ethyl, 1,1-difluoro-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl; such C1-4 alkyl groups are especially 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. Ø - [L, 3 , ]- [CY, 3 , ],in ▪ - [L, 3 , ] - Independently represents a one-key (i.e., the key) [CY, 3 , ] directly attached to the rest of the molecule), -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)- or -O-CH2-, where - [L, 3 When , ]- is -O-CH2-, then [CY, 3 , ] is attached to the oxygen atom of -O-CH2-; and ▪ [CY,3 , ] independently represents a C3-6 cycloalkyl or C4-6 heterocyclic group, the C4-6 heterocyclic group containing one or two cyclic heteroatoms independently selected from nitrogen and oxygen (especially [CY, 3 ] represents cyclopropyl, cyclobutyl, oxetane, azirone, pyrrolidyl, tetrahydropiperanyl, tetrahydrofuranyl, morpholinyl, imidazolyl, piperidinyl, or piperidine); where the [CY, 3 , ] Independently unsubstituted, monosubstituted, disubstituted, or trisubstituted, wherein the substituent system is selected from Ø Halogens (especially fluorine); Ø Side oxygen group; Ø Hydroxyl group; Ø C1-3 alkyl groups monosubstituted with C1-3 alkoxy groups, as appropriate (especially if such C1-3 alkyl groups represent methyl, ethyl, isopropyl, or methoxy-methyl); Ø C1-3 alkoxy groups (especially methoxy groups); Ø -(C=O)- [R, CO , ],in [R, CO , ]express o C1-3 alkyl groups monosubstituted with hydroxyl or C1-3 alkoxy groups (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy-methyl, methoxy-methyl, benzyl-oxy, or 2-methoxy-ethyl), depending on the case. o C1-3 fluoroalkyl groups (especially 2,2,2-trifluoroethyl); o C1-3 alkoxy group, wherein the C1-3 alkoxy group is monosubstituted with a C1-3 alkoxy group as appropriate (especially methoxy, ethoxy or 2-methoxy-ethoxy); o C3-6 cycloalkyl-(CH2) [, n , ]-, where one or two carbon ring atoms are replaced by one or two oxygen ring atoms, depending on the situation; where [n] represents the integer 0, 1, or 2 (especially for such C3-5 cycloalkyl-(CH2) groups). [, n , ]- indicates cyclopropyl, cyclopentyl, oxetane-3-yl, oxetane-3-yl-methyl, 1,4-dialkyl-2-yl, or tetrahydropiperan-4-yl); or o-phenyl; [This type -(C=O)-] [R, COIn particular, it represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tributyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetane-3-yl-carbonyl, oxetane-3-yl-methyl-carbonyl, phenyl-carbonyl or tetrahydropiperan-4-yl-carbonyl, methoxy-methyl-carbonyl or 1,4-dimethyl-2-yl-carbonyl. Ø -N( [R, N9 , ])( [R, N10 , ]),in [R, N9 , ] indicates hydrogen or C1-3 alkyl (especially methyl); and [R, N10 , ] represents C1-3 alkyl (especially methyl), C1-3 alkyl-carbonyl (especially acetyl), C1-3 alkyl-sulfonyl (especially methyl-sulfonyl), C1-3 alkoxy-carbonyl (especially ethoxy-carbonyl), C1-3 alkoxy-C1-3 alkyl-carbonyl (especially methoxy-methyl-carbonyl) or tetrahydropiperanyl-carbonyl (especially tetrahydropiperan-4-yl-carbonyl); Ø -S(=O)2 - [R, SO , ],in [R, SO , ]express o C1-3 alkyl groups monosubstituted with hydroxyl, C1-3 alkoxy, or amino groups, as appropriate (especially if such C1-3 alkyl groups are methyl, n-propyl, isopropyl, 2-hydroxy-ethyl, 2-methoxy-ethyl, or methyl-amino); or o C3-5 cycloalkyl, wherein, depending on the case, one carbon ring atom is substituted by an oxygen ring atom (especially cyclopropyl, cyclopentyl, or tetrahydropiperanyl); [This type of -S(=O)2-] [R, SO , ] especially represents methyl-sulfonyl, n-propyl-sulfonyl, isopropyl-sulfonyl, 2-hydroxyethyl-sulfonyl, cyclopropyl-sulfonyl, cyclopentyl-sulfonyl, 2-methoxy-ethyl-sulfonyl, methyl-amino-sulfonyl, or tetrahydropiperan-4-yl-sulfonyl] Ø Contains a 5-membered heteroaryl group selected from nitrogen, oxygen, and sulfur (especially oxygen); wherein the 5-membered heteroaryl group is unsubstituted (especially furanyl; especially furan-2-yl); and Ø Phenyl-(CH2) [, p , ]-,in [p] represents the integer 0, 1, or 2 (especially for this type of phenyl-(CH2)). [, p , ]- indicates phenyl or benzyl); [To elaborate, this type of -] [L, 3 , ]- [CY, 3, ] represents 1-hydroxy-cyclopropyl, 1-(methyl-amino)-cyclopropyl, 1-(acetyl-amino)-cyclopropyl-1-yl-methyl, 1-(N-acetyl-N-methyl-amino)-cyclopropyl-1-yl-methyl, 1-(N-(methoxy-methyl-carbonyl)-amino)-cyclopropyl-1-yl-methyl, 1-(N-(ethoxy-carbonyl)-N-methyl-amino)-cyclopropyl-1-yl, 1-(N-methylacetylamino)-cyclopropyl-1-yl (including 1-(N-methylacetyl-d3-acetylamino)-cyclopropyl-1-yl), 1-(1-(methoxy-methyl)-cyclopropyl)-methyl, 1-(tetrahydropiperan-4-yl-carbonyl-amino)-cyclopropyl-methyl, cyclobutyl-oxy -Methyl, 1-hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1-methoxy-cyclobutyl, 1-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 1-hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1-hydroxy-cyclohexyl)-methyl, (1-hydroxy-cyclobutyl)-methyl, 1-hydroxy-1-cyclohexyl-methyl, 1-methoxy-cyclopentyl, oxacyclobutane-3-yl, tetrahydrofuran-2-yl-methyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropiperan-3-yl, tetrahydropiperan-4-yl, 4-hydroxy-tetrahydropiperan-4-yl, 4-hydroxy-tetrahydropiperan-4-yl-methyl, 4-methyl-tetrahydropiperan-4-yl-methyl, 4-methyl-tetrahydropiperan-4-yl-methyl, 4-methyl-tetrahydropiperan-4-yl-methyl 4-Hydropiperan-4-yl, 2,6-dimethyl-tetrahydropiperan-4-yl, 4-methoxy-tetrahydropiperan-4-yl, 4-fluoro-tetrahydropiperan-4-yl, tetrahydropiperan-4-yl-methyl, 2-(tetrahydropiperan-4-yl)-ethyl, 1-(tetrahydropiperan-4-yl)-1-methyl-ethyl, tetrahydropiperan-4-yl-oxy-methyl, (4-methyl-tetrahydropiperan-4-yl)-oxy-methyl, N-acetylgyn-3-fluoro-azacyclobutane-3-yl (including N-acetylgyn-d3-3-fluoro-azacyclobutane-3-yl), N-acetylgyn-3-methyl-azacyclobutane-3-yl (including N-acetylgyn-d3-3-methyl-azacyclobutane-3-yl), 2-side oxygen 3-yl-azacyclobutane, 2-sideoxy-azacyclobutane-4-yl, N-acetylated-azacyclobutane-3-yl, 5-sideoxy-pyrrolidin-2-yl, N-phenyl-5-sideoxy-pyrrolidin-2-yl, N-phenyl-5-sideoxy-pyrrolidin-3-yl, N-benzyl-5-sideoxy-pyrrolidin-3-yl, N-benzyl-2-sideoxy-pyrrolidin-3-yl, 5-sideoxy-pyrrolidin-3-yl, N-(furan-2-yl-methyl)-5-sideoxy-pyrrolidin-3-yl, 3-methyl-5-sideoxy-pyrrolidin-3-yl, 1-methyl-5-sideoxy-pyrrolidin-3-yl, 1-isopropyl-5-sideoxy-pyrrolidin-3-yl, 1,3-Dimethyl-2-sideoxy-pyrrolidin-3-yl, 2-sideoxy-pyrrolidin-1-yl-methyl, 2-sideoxy-pyrrolidin-1-yl-methyl, 1-ethyl-5-sideoxy-pyrrolidin-3-yl, 1-isobutyl-5-sideoxy-pyrrolidin-3-yl, N-acetylgyn-pyrrolidin-3-yl, N-acetylgyn-pyrrolidin-3-yl-methyl, 2,5-disideoxy-3,3-dimethyl-pyrrolidin-1-yl-methyl, 2-sideoxy-imidazolidine-1-yl-methyl, 2-sideoxy-imidazolidine-3-yl-methyl, piperidin-4-yl, 1-methyl-2,6-disideoxy-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 2-sideoxy-piperidin-4-yl 6-Side-oxy-piperidin-2-yl, 6-Side-oxy-piperidin-3-yl, 1-methyl-6-side-oxy-piperidin-3-yl, 3-methyl-6-side-oxy-piperidin-3-yl, N-acetylopidin-4-yl, N-acetylopidin-4-yl-methyl, N-acetylopidin-2-methyl-piperidin-4-yl, N-acetylopidin-4-fluoro-piperidin 4-yl, N-acetyl-3-methyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin-4-yl, N-acetyl-4-methoxy-piperidin-4-yl, N-acetyl-piperidin-3-yl, N-acetyl-piperidin-3-yl-methyl, N-acetyl-3-methyl-piperidin-3-yl, N-acetylated-3-hydroxy-piperidin-3-yl, N-(isopropyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(tert-butyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethoxy-carbonyl)-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl, N-(cyclopropyl-sulfonylurea)-piperidin-4-yl, N- (Methyl-sulfonylurea)-piperidin-4-yl, N-(n-propyl-sulfonylurea)-piperidin-4-yl, N-(isopropyl-sulfonylurea)-piperidin-4-yl, N-(2-hydroxy-ethyl-sulfonylurea)-piperidin-4-yl, N-(cyclopentyl-sulfonylurea)-piperidin-4-yl, N-(methoxy-carbonyl)-piperidin-4-yl, N-(cyclopropyl-carbonyl) -piperidin-4-yl, N-(cyclopentyl-carbonyl)-piperidin-4-yl, N-(methyl-amino-sulfonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-sulfonyl)-piperidin-4-yl, N-(ethyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-piperidin-4-yl, N-(ethoxy-carbonyl)-piperidin-4-yl, N-acetylated-4-ethyl-piperidin-4-yl, N-(n-propyl-carbonyl)-piperidin-4-yl, N-(2-methoxy-ethyl-carbonyl)-piperidin-4-yl, N-(oxetane-3-yl-carbonyl)-piperidin-4-yl, N-(oxetane-3-yl-methyl-carbonyl)-piperidin-4-yl, N-(2,2,2-Trifluoro-ethyl-carbonyl)-piperidin-4-yl, N-(tetrahydropiperan-4-yl-carbonyl)-piperidin-4-yl, N-(phenyl-carbonyl)-piperidin-4-yl, N-(tetrahydropiperan-4-yl-sulfonylurea)-piperidin-4-yl, N-(benzylmethyl-oxy-carbonyl)-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-4-isopropyl-piperidin-4-yl, N-(1,4-dialkyl-2-yl-carbonyl)-piperidin-4-yl, morpholin-4-yl, morpholin-4-yl-methyl, 1-methyl-1-(morpholin-4-yl)-ethyl, (2,6- (dimethylmorpholino-4-yl)-methyl, 2,4-dioxy-imidazolidine-1-yl-methyl, 2,5-dioxy-imidazolidine-1-yl-methyl, 2,5-dioxy-3-methyl-imidazolidine-1-yl-methyl, 2,4-dioxy-3-methyl-imidazolidine-1-yl-methyl, 2-dioxy-3-methyl-imidazolidine-1-yl-methyl, 2-dioxy-3-methyl-imidazolidine-1-yl-methyl, 2,5-dioxy-pyrrolidine-1-yl-methyl, N-acetylgyrrolidine-3-yl or 4-acetylgyrrolidine-1-yl]; , Ø A phenyl or 6-membered heteroaryl group containing one or two cyclic nitrogen atoms (especially pyridinyl or pyrimidinyl; especially pyridin-3-yl or pyrimidin-4-yl); wherein the phenyl or 6-membered heteroaryl group is independently unsubstituted or monosubstituted with a C1-3 alkyl (especially methyl) or C1-3 alkoxy (especially methoxy); [In detail, such phenyl or 6-membered heteroaryl groups are 3-methoxy-phenyl, pyridin-3-yl, or 6-methyl-pyrimidin-4-yl] Ø Pyrazolyl-C1-3 alkyl (especially 2-(pyrazol-1-yl)-ethyl); Ø C1-3 alkyl-sulfonyl-C1-3 alkyl (especially methyl-sulfonyl-methyl); Ø 3-Hydroxymethyl-bicyclo[1.1.1]pent-1-yl; Ø 7-oxa-bicyclo[2.2.1]hept-2-yl; and Ø 6-oxa-spiro[2.5]octyl-1-yl; • 5-Side-oxy-4-oxa-6-azaspiro[2.4]hept-6-yl, 5-azaspiro[2.4]hept-6-one-5-yl, 2,2-dimethyl-6-side-oxy-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-cyclopropyl-6-side-oxy-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-side-oxy-1-oxa-3-azaspiro[4.4]non-3-yl, 8,8-difluoro-2-side-oxy-1-oxa-3-azaspiro[4.5]dec-3-yl or 8-side-oxy-7-oxa-9-azabispiro[3.1.4.1]undecane-9-yl; • 7-aza-bicyclo[2.2.1]hept-7-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl or 8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl; • 5-Sideoxy-6-azaspiro[3.4]oct-6-yl, 3-Sideoxy-2-azaspiro[4.4]non-2-yl, 1-oxa-3-azaspiro[4.5]dec-2-one-3-yl, 1-Sideoxy-2-azaspiro[4.5]dec-2-yl, 1-Sideoxy-8-oxa-2-azaspiro[4.5]dec-2-yl, 3-Sideoxy-8-oxa-2-azaspiro[4.5]dec-2-yl or 4-Sideoxy-hexahydro-5H-furano[2,3-c]pyrrole-5-yl; • 3-(7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl)propyl); • 6-Acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl; • 6-Acetyl-5,6,7,8-Tetrahydro-1,6-N-Dinidin-2-yl; · 2-(6,7-dihydro-5H-[1]pyridine-7-ol)-ethyl; · 2-(8-hydroxy-5,6,7,8-tetrahydro-quinoline-8-yl)-ethyl; · 7,8-Dihydro-5H-[1,6]pyridin-6-yl; · 2,3-Dihydro-isoindol-1-one-2-yl; · 7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl; and • 6-Acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl; [B] represents a phenyl group, which is unsubstituted, monosubstituted, disubstituted, or trisubstituted, wherein the first substituent (especially at the para position relative to the attachment site of B to the rest of the molecule) is selected if present. • Halogens (especially bromine); • C1-5 alkyl groups (especially methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tributyl, 1-ethyl-propyl, 2,2-dimethyl-propyl, 1,1-dimethyl-propyl; especially methyl, ethyl or isopropyl; particularly isopropyl); • C2-4 alkenyl (especially propyl-1-en-2-yl); • C1-3 alkoxy groups (especially methoxy, ethoxy, or isopropoxy groups); • C1-3 alkoxy-C1-4 alkyl (especially 3-methoxy-propyl); • C1-4 fluoroalkyl groups (especially trifluoromethyl, 1-methyl-1-fluoro-ethyl, 1,1-difluoro-ethyl, 2,2,2-trifluoro-ethyl, 1,1-dimethyl-1-trifluoromethyl-methyl, 1,1,2,2,2-pentafluoro-ethyl or 1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl); • C3-5 cycloalkyl groups (especially cyclopropyl or cyclobutyl), which are independently unsubstituted or monosubstituted with a C1-3 alkyl group (especially methyl) or a C1-3 fluoroalkyl group (especially trifluoromethyl) (particularly at the attachment point between the C3-5 cycloalkyl group and the rest of the molecule); · -SF5; • Bicyclo[1.1.1]pentyl-1-yl; • C3-5 cycloalkoxy groups (especially cyclopropoxy or cyclobutoxy groups); and • C1-3 fluoroalkoxy groups (especially trifluoromethoxy groups); and The remaining substituent of [B], if present, is independently selected from halogens (especially fluorine or chlorine; particularly the remaining substituent relative to...). [B] The attachment sites with the rest of the molecule, at the meta position and C1-3 alkyl groups (especially methyl groups); or [B] indicates benzothiophene (especially 1-benzothiophene; especially 1-benzothiophene-5-yl) or naphthyl (especially naphthyl-2-yl); [To elaborate, this type of] [B] represents phenyl, 4-bromo-phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 4-(1-ethyl-propyl)-phenyl, 4-(1,1-dimethyl-propyl)-phenyl, 4-(2,2-dimethyl-propyl)-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 3-methyl-4-isopropyl-phenyl, 4-(prop-1-en-2-yl)-phenyl, 4-cyclopropyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl, 4-isopropoxy-phenyl, 4-trifluoromethyl-phenyl, 4-(1-methyl-1-fluoro-ethyl)-phenyl, 4-( 1,1-Difluoro-ethyl)-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-(1,1-dimethyl-1-trifluoromethyl-methyl)-phenyl, 4-(1,1,2,2,2-pentafluoro-ethyl)-phenyl, 4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-(pentafluoro-16-thioalkyl)-phenyl, 4-(bicyclo[1.1.1]pent-1-yl)-phenyl, 4-cyclopropoxy-phenyl, 4-cyclobutoxy-phenyl, 4-(trifluoromethoxy)-phenyl, 4-(3-methoxy-propyl)-phenyl, 4-(1-trifluoromethyl-cyclopropyl)-phenyl, naphthio-2-yl or 1-benzothiophene-5-yl] [R, 1 , ] indicates a C1-3 alkyl group (especially methyl or ethyl), a cyano group, or a halogen (especially fluorine); [R, 2 , ] represents C1-4 alkyl (especially methyl, ethyl, n-propyl, isopropyl, tributyl or isobutyl), C3-5 cycloalkyl (especially cyclopropyl or cyclobutyl), C3-5 cycloalkyl-C1-3 alkyl (especially cyclopropyl-methyl), hydroxy-C1-3 alkyl (especially 2-hydroxy-ethyl), C1-3 alkoxy-C1-3 alkyl (especially 2-methoxy-ethyl), or C1-3 fluoroalkyl (especially 2,2-difluoro-ethyl, 3,3,3-trifluoro-propyl or 2-fluoroethyl).

[0030] The definitions provided herein are intended to apply uniformly to compounds of formula (I) as defined in any of Examples 1) through 53), and, with necessary modifications, are provided throughout the specification and claims unless expressly stated otherwise. It should be fully understood that the definition or preferred definition of a term is independently (and in combination with) defined and substitutes for any other definition or preferred definition of any or all other terms as defined herein. Groups defined herein are not substituted unless expressly defined otherwise in the individual examples or claims.

[0031] The term "halogen" used alone or in combination means fluorine, chlorine, bromine or iodine; especially fluorine or chlorine; especially fluorine.

[0032] The term "cyano" used alone or in combination refers to the group -CN.

[0033] The term "oxygen group" used alone or in combination refers to the group -O-.

[0034] The term "side radical" used alone or in combination refers to the =O group.

[0035] The term "amine" used alone or in combination refers to the group -NH2.

[0036] The term "amino-carbonyl" used alone or in combination refers to the group -C(=O)-NH2.

[0037] The term "amino-carbonyl-oxy" used alone or in combination refers to the group -OC(=O)-NH2, where substitution of the amino group may be further defined. For example, N-(C1-3 alkyl)-amino-carbonyl-oxy means that the amino group of the amino-carbonyl-oxy is substituted with a C1-3 alkyl group, which is defined below. One example of N-(C1-3 alkyl)-amino-carbonyl-oxy is N-(isopropyl)-amino-carbonyl-oxy.

[0038] The term "alkyl," used alone or in combination, refers to a saturated straight-chain or branched hydrocarbon chain containing one to six carbon atoms. The term "(Cx-y)alkyl" (where x and y are integers) refers to an alkyl group containing x to y carbon atoms as previously defined. When a Cx-y alkyl group is used in combination with another substituent, the term means that the substituent is linked to the remainder of the molecule via the Cx-y alkyl group. For example, C1-6 alkyl groups contain one to six carbon atoms. Examples of C1-6 alkyl groups are C1-4 alkyl groups, methyl, ethyl, n-propyl, isopropyl, n-butyl, dibutyl, tributyl, and isobutyl, as well as n-pentyl and isopentyl. (The last sentence appears to be incomplete and possibly refers to a different context.) [R, 1 A preferred example of one of the C1-3 alkyl groups is methyl. (If used as a substituent) [R, 2 One of the C1-4 alkyl groups is preferably ethyl or methyl; most preferably methyl. For example, when used... A particularly preferred example of one of the C1-5 alkyl groups of the [B] substituent is isopropyl.

[0039] The term "amino-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by an amino group. The term "amino-Cx-y alkyl" (where x and y are each integers) used alone or in combination refers to an amino-alkyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, an amino-C1-4 alkyl group is an amino-alkyl group containing one to four carbon atoms. Examples of such amino-C1-4 alkyl groups are amino-methyl, 1-amino-ethyl, 2-amino-ethyl, and 2-amino-2,2-dimethyl-ethyl.

[0040] The term "hydroxyalkyl" as used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by a hydroxyl group. The term "hydroxy-Cx-y alkyl" (where x and y are integers) as used alone or in combination refers to a hydroxyalkyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, hydroxy-C1-6 alkyl is a hydroxyalkyl group as previously defined that contains one to six carbon atoms.

[0041] The term "hydroxy-alkyl" refers to an alkyl group as defined herein, in which one hydrogen atom is replaced by a hydroxyl group.

[0042] The term "oxetane-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by an oxetane; such oxetanes are particularly oxetane-3-yl. The term "oxetane-Cx-y alkyl" (where x and y are each integers) used alone or in combination refers to an oxetane-alkyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, an oxetane-C1-3 alkyl group is an oxetane as previously defined containing one to three carbon atoms.

[0043] The term "pyridyl-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by a pyridinyl group; such pyridinyl groups are particularly pyridin-2-yl. The term "pyridyl-Cx-y alkyl" (where x and y are each integers) used alone or in combination refers to a pyridyl-alkyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, pyridyl-C1-3 alkyl is a pyridyl-alkyl group as previously defined containing one to three carbon atoms.

[0044] The term "pyrazolyl-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by a pyrazolyl group; such pyrazolyl groups are particularly pyrazol-1-yl. The term "pyrazolyl-Cx-y alkyl" (where x and y are each integers) used alone or in combination refers to a pyrazolyl-alkyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, pyrazolyl-C1-3 alkyl is a pyrazolyl-alkyl group as previously defined containing one to three carbon atoms.

[0045] The term "benzyl-oxy-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by the group C6H5-CH2-O-. The term "benzyl-oxy-Cx-y alkyl" (where x and y are each integers) used alone or in combination refers to a benzyl-oxy-alkyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, benzyl-oxy-C1-3 alkyl is a benzyl-oxy-alkyl group as previously defined containing one to three carbon atoms.

[0046] The term "alkyl-carbonyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by a -C (=O)- group. The term "Cx-y alkyl-carbonyl" (where x and y are each integers) used alone or in combination refers to an alkyl-carbonyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, a C1-3 alkyl-carbonyl group is an alkyl-carbonyl group as previously defined containing one to three carbon atoms.

[0047] The term "amino-carbonyl-oxy" used alone or in combination refers to the group H2N-C(=O)-O-, where substitution of the amino group can be further defined.

[0048] The term "(hydroxy-alkyl)-carbonyl" used alone or in combination refers to a hydroxy-alkyl group as previously defined, wherein one hydrogen atom of the alkyl group has been replaced by a -C (=O)- group. The term "(hydroxy-Cx-y alkyl)-carbonyl" (where x and y are integers) used alone or in combination refers to a (hydroxy-alkyl)-carbonyl group as previously defined, wherein the alkyl group contains x to y carbon atoms. For example, a (hydroxy-C1-3 alkyl)-carbonyl group is a (hydroxy-alkyl)-carbonyl group as previously defined, containing one to three carbon atoms.

[0049] The term "alkyl-sulfonyl-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by an alkyl-sulfonyl group, wherein the alkyl portion of the alkyl-sulfonyl group is as previously defined. The term "Cx1-y1alkyl-sulfonyl-Cx2-y2alkyl" (x1, x2, y1, and y2 are each integers) used alone or in combination refers to an alkyl-sulfonyl-alkyl group as previously defined, wherein the alkyl groups independently contain x1 to y1 and x2 to y2 carbon atoms. For example, C1-3alkyl-sulfonyl-C1-3alkyl is an alkyl-sulfonyl-alkyl group as previously defined, wherein each of the two alkyl portions independently contains one to three carbon atoms.

[0050] The term "fluoroalkyl" as used alone or in combination refers to an alkyl group as previously defined, wherein one or more (and possibly all) hydrogen atoms have been replaced by fluorine. The term "Cx-y fluoroalkyl" (where x and y are each integers) refers to a fluoroalkyl group as previously defined containing x to y carbon atoms. For example, C1-3 fluoroalkyl groups contain one to three carbon atoms, wherein one to seven hydrogen atoms have been replaced by fluorine. Examples of C1-3 fluoroalkyl groups are trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, and 2,2,2-trifluoroethyl.

[0051] The term "alkenyl," used alone or in combination, refers to a straight-chain or branched alkyl group of a hydrocarbon chain as previously defined, wherein the chain contains a double bond. The term "Cx-y alkenyl," used alone or in combination (where x and y are integers), refers to an alkenyl group as previously defined, containing x to y carbon atoms. For example, the term "C3-5 alkenyl," used alone or in combination, refers to an alkenyl group as previously defined, containing 3 to 5 carbon atoms. Examples of C3-5 alkenyl groups are -CH=CH2, -CH=CH2-CH3, -CH2-CH=CH2, and -C(CH3)=CH2.

[0052] The term "alkylene" used alone or in combination refers to a saturated, branched, or straight-chain divalent aliphatic hydrocarbon group, which is considered to be derived from an alkane by removing two hydrogen atoms. The term "Cx-y alkylene" used alone or in combination (where x and y are each integers) refers to an alkylene group as previously defined, containing x to y carbon atoms. For example, a C1-2 alkylene group is an alkylene group as defined above, containing one or two carbon atoms. Examples of C1-2 alkylene groups are -CH2-, -(CH2)2-, and -CH(CH3)-.

[0053] The term "hydroxy-enylalkyl" used alone or in combination refers to an enylalkyl group as previously defined, wherein one hydrogen atom has been replaced by a hydroxyl group. The term "hydroxy-Cx-y enylalkyl" (where x and y are integers) used alone or in combination refers to a hydroxy-enylalkyl group as previously defined, containing x to y carbon atoms. For example, a hydroxy-C1-2 enylalkyl group is a hydroxy-enylalkyl group as defined above, containing one or two carbon atoms. Examples of hydroxy-C1-2 enylalkyl groups are -CH(OH)-, -CH(OH)-CH2-, and -C(OH)(CH3)-; preferably -CH(OH)-.

[0054] The term oxy-C1-2-alkyl, used alone or in combination, refers to the group -O-C1-2-alkyl, wherein the C1-2-alkyl group is as defined above. Preferably, the oxy-C1-2-alkyl group is -O-CH2-.

[0055] The term "amino-alkoxy" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by -O-. The term "Cx-y alkoxy" used alone or in combination (where x and y are integers) refers to an alkoxy group as previously defined, wherein the alkoxy group contains x to y carbon atoms. For example, a C1-3 alkoxy group is an alkoxy group as previously defined containing one to three carbon atoms. Examples of C1-3 alkoxy groups are methoxy, ethoxy, n-propoxy, or isopropoxy; particularly methoxy.

[0056] The term "alkoxy-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by an alkoxy group as previously defined. The term "Cx1-y1alkoxy-Cx2-y2 alkyl" (x1, x2, y1, and y2 are each integers) used alone or in combination refers to an alkoxy-alkyl group as previously defined, wherein the two hydrocarbon portions of the group independently contain carbon atoms x1 to y1 and x2 to y2. For example, C1-3alkoxy-C1-3 alkyl is an alkoxy-alkyl group as previously defined, which independently contains one to three carbon atoms in the two hydrocarbon portions of the group. Examples of C1-3alkoxy-C1-3 alkyl are methoxy-methyl or ethoxy-ethyl.

[0057] The term "fluoroalkoxy" used alone or in combination refers to an alkoxy group as previously defined, containing one to three carbon atoms, wherein one or more (and possibly all) hydrogen atoms have been replaced by fluorine. The term "Cx-y fluoroalkoxy" (where x and y are each integers) refers to a fluoroalkoxy group as previously defined, containing x to y carbon atoms. For example, C1-3 fluoroalkoxy groups contain one to three carbon atoms, wherein one to seven hydrogen atoms have been replaced by fluorine. Examples of C1-3 fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, and 2,2,2-trifluoroethoxy.

[0058] The term "C1-4 alkoxy-carbonyl" refers to an alkoxy group, as previously defined, attached to a carbonyl group (i.e., C1-4 alkoxy-C(=O)-).

[0059] The term "cycloalkyl" used alone or in combination refers to a saturated monocyclic hydrocarbon ring containing three to seven carbon atoms (preferably three to six carbon atoms). The term "Cx-y cycloalkyl" (where x and y are integers) refers to a saturated monocyclic hydrocarbon ring containing x to y carbon atoms. For example, C3-6 cycloalkyl contains three to six carbon atoms. Examples of C3-6 cycloalkyl are cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0060] Similarly, the term "Cx-y heterocyclic group" refers to a cycloalkyl group as defined above containing x to y ring atoms, wherein one or more ring carbon atoms in the group are replaced by heteroatoms as defined above.

[0061] The term "cycloalkenyl," used alone or in combination, refers to an unsaturated monocyclic hydrocarbon ring containing one carbon-carbon double bond, which has four to six carbon atoms (preferably five). The term "Cx-y cycloalkenyl" (where x and y are each integers) refers to a cycloalkenyl ring as previously defined, containing x to y carbon atoms. For example, C4-6 cycloalkenyl contains four to six carbon atoms. Examples of C4-6 cycloalkenyl are cyclobutenyl, cyclopentenyl, and cyclohexenyl; particularly cyclopentenyl; especially cyclopent-1-en-1-yl.

[0062] The term "cycloalkoxy" used alone or in combination refers to a cycloalkyl group as previously defined, wherein one hydrogen atom has been replaced by -O-. The term "Cx-y cycloalkoxy" (where x and y are each integers) used alone or in combination refers to a cycloalkoxy group as previously defined, wherein the cycloalkoxy group contains x to y carbon atoms. For example, a C3-5 cycloalkoxy group is a cycloalkoxy group as previously defined containing three to five carbon atoms. Examples of C3-5 cycloalkoxy groups are cyclopropoxy, cyclobutoxy, or cyclopentoxy.

[0063] The term "cycloalkyl-sulfonyl" used alone or in combination refers to a cycloalkyl group as previously defined, in which one hydrogen atom is replaced by a sulfonyl group (i.e., -S(=O)2-). The term "Cx-y cycloalkyl-sulfonyl" (where x and y are each integers) refers to a cycloalkyl group containing x to y carbon atoms. For example, C3-5 cycloalkyl-sulfonyl groups contain three to five carbon atoms. Examples of C3-5 cycloalkyl-sulfonyl groups are cyclopropyl-sulfonyl, cyclobutyl-sulfonyl, and cyclopentyl-sulfonyl.

[0064] The term "cycloalkyl-alkyl" used alone or in combination refers to an alkyl group as previously defined, wherein one hydrogen atom has been replaced by a cycloalkyl group as previously defined. The term "Cx1-y1cycloalkyl-Cx2-y2alkyl" (where x1, x2, y1, and y2 are each integers) used alone or in combination refers to a cycloalkyl-alkyl group as previously defined, wherein the two hydrocarbon portions of the group independently contain x1 to y1 and x2 to y2 carbon atoms respectively. For example, C3-5 cycloalkyl-C1-3 alkyl is a cycloalkyl-alkyl group as previously defined, containing three to five carbon atoms in the cycloalkyl portion and an alkyl portion containing one to three carbon atoms. Examples of C3-5 cycloalkyl-C1-3 alkyl are cyclopropyl-methyl or cyclopropyl-ethyl.

[0065] The term "C3-6 cycloalkyl fused to a pyridine ring," used alone or in combination, refers to a C3-6 cycloalkyl group fused to a pyridine ring as previously defined. Examples of C3-6 cycloalkyl groups fused to a pyridine ring include the following groups: Preferably, the last two groups from left to right. It should be understood that when a substituent is referred to as "C3-6 cycloalkyl fused with a pyridine ring", the attachment point of the substituent to the rest of the molecule is in the C3-6 cycloalkyl portion of the substituent and not in the fused pyridine ring.

[0066] The term "hydroxy-aziridine" as used alone or in combination refers to an aziridine substituted with a hydroxyl group. Preferably, the term hydroxy-aziridine refers to 3-hydroxy-aziridine-3-yl.

[0067] The term "heteroaryl," used alone or in combination, refers to a 5- to 10-member monocyclic or bicyclic aromatic ring containing one to at most four heteroatoms (particularly one to at most three heteroatoms) independently selected from oxygen, nitrogen, and sulfur. Examples of such heteroaryl groups include furanyl, acezolyl, isoacezolyl, acediazolyl, thiophene, thiazolyl, isothiazolyl, thiadiazolyl, pyrroleyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridyl, pyridyl, indoleyl, isoindoleyl, benzofuranyl, isobenzofuranyl, benzothiophene, indoleyl, benzimidazolyl, benzoacezolyl, and others. Benzo[azolyl], benzo[thiazolyl], benzo[azolyl], benzo[triazol], benzo[azodiazol], benzo[thiazodiazol], quinolinyl, isoquinolinyl, acetylinyl, octolinyl, quinazolinyl, quinolinyl, teryl, pyrrolopyridyl, pyrazolopyridyl, pyrazolopyrimidinyl, pyrrolopyridyl, imidazopyridyl, imidazopyridyl, and imidazothiazolyl. The heteroaryl / heteroaryl groups mentioned above are either unsubstituted or, as explicitly defined, substituted.

[0068] The term "5 to 6 member heteroaryl" used alone or in combination means a 5 to 6 member monocyclic aromatic ring containing one to a maximum of four cyclic heteroatoms (preferably one to a maximum of three cyclic heteroatoms) independently selected from oxygen, nitrogen and sulfur. Examples of 5-membered groups are 5-membered heteroaryl groups, such as furanyl, acezolyl, isoacezolyl, acedizolyl, thiophene, thiazolyl, isothiazolyl, thiadizolyl, pyrrole, imidazolyl, pyrazolyl, triazolyl, tetrazolyl; particularly pyrazolyl, triazolyl, acezolyl, thiazolyl, acedizolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, acezo-2-yl, thiazolyl-2-yl, 1,2,4-acedizolyl-5-yl or 1,2,4-acedizolyl-3-yl; preferably 1,2,4-acedizolyl-5-yl or 1,2,4-acedizolyl-3-yl. Examples of 6-membered heteroaryl groups are groups such as pyridyl, pyrimidinyl, pyridyl, pyridyl. The heteroaryl groups mentioned above are either unsubstituted or substituted as defined above.

[0069] In the case of a monosubstituted 5-membered heteroaryl group, it should be understood that, relative to the 5-membered heteroaryl group and... The substitution at position 3, the attachment point of [A], means that the substituents at position 3 and the attachment point of A are in a relative 1,3-arrangement. This is in contrast to the 5-membered heteroaryl group. The preferred examples of such 5-membered heteroaryl compounds with a single substitution at position 3 of [A] are selected from the group consisting of the following: One asterisk (*) indicates the connection point with the substituent, and two asterisks (**) indicate the connection point with the substituent. The attachment point of [A]. Especially preferred are the last two (from left to right) 5-member mixed aryl groups.

[0070] Other embodiments of the present invention are presented below:

[0071] 2) One embodiment relates to the compound according to Example 1), wherein [A] represents pyridyl, pyrimidinyl, pyridyl or taryl (especially taryl or pyridyl; especially pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, pyridin-2-yl or taryl-4-yl), wherein [A] Independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially relative to) [A] The attachment point with the rest of the molecule, in [A] is mono- or di-substituted at the mid-position and / or para-position; especially relative to the position of [A] [A] The attachment point with the rest of the molecule, in [A] (monosubstituted between), wherein the substituent (etc.) is defined as in Example 1 if present. [ ]

[0072] 3) Another embodiment relates to the compound according to Example 1), wherein [A] represents pyridin-3-yl, pyridin-4-yl, or pyridin-4-yl (specifically, pyridin-3-yl or pyridin-4-yl), where [A] Independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially relative to) [A] The attachment point with the rest of the molecule, in [A] is mono- or di-substituted at the mid-position and / or para-position; especially relative to the position of [A] [A] The attachment point with the rest of the molecule, in [A] is monosubstituted between positions), where the substituent (etc.) is defined as 1 in the examples if it is present.

[0073] In one sub-implementation, [A] independently for Ø Not replaced; Ø Monosubstituted (especially relative to) [A] The attachment point with the rest of the molecule, in [A] between positions), where the substituents are as defined in Example 1); or Ø Disubstituted, wherein the first substituent (especially relative to) [A] The attachment point with the rest of the molecule, in [A] The substituents between the two groups are selected from those defined in Example 1) (especially excluding halogens (especially fluorine) or cyano); and the second substituent group (especially relative to) [A] The attachment point with the rest of the molecule, in [A] is selected from halogens (especially fluorine) and cyano groups.

[0074] 4) Another embodiment relates to the compound according to Example 1), wherein [A] represents pyridin-3-yl, pyridin-4-yl, or pyridin-4-yl (especially pyridin-3-yl or pyridin-4-yl; especially pyridin-3-yl), wherein [A] via monosubstituted (especially relative to) [A] The attachment point with the rest of the molecule, in [A] between positions), where the substituents are as defined in Example 1).

[0075] 5) Another embodiment relates to a compound according to any one of Examples 1) to 4), wherein [A] of the substituent / At least one of the substituents in [A] is -O- as defined in Example 1) [R, O2 , ].

[0076] 6) Another embodiment relates to the compound according to Example 5), wherein [A] of the substituent / At least one of the substituents in [A] is Ø -O- [R, O2 , ],in Ø [R,O2 , ]express ▪ C1-4 alkyl groups (especially isopropyl, dibutyl, or isobutyl); ▪ C2-5 alkyl groups monosubstituted with hydroxyl or C1-3 alkoxy (especially methoxy); [In detail, these C2-5 alkyl groups represent 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, 3-hydroxy-3-methyl-butyl, or 2-methoxy-ethyl.] ▪ - [L, 2 , ]- [CY, 2 , ],in v - [L, 2 , ] - Independently represents a one-key (i.e., the key) [CY, 2 , ] directly attached to the rest of the molecule); and v [CY, 2 , ] represent independently o C3-6 cycloalkyl (especially oxetyl, cyclopentyl, or cyclohexyl), wherein, whereby, one carbon atom is substituted with an oxygen atom; wherein the C3-6 cycloalkyl is unsubstituted, monosubstituted, or disubstituted, wherein the substituents are selected from C1-3 alkyl (especially methyl), hydroxyl, fluorine, oxy, C1-3 alkyl-carbonyl (especially acetyl), and C1-3 alkoxy (especially methoxy); o alkyl (especially alkyl-6-yl); [To elaborate, this type of -] [L, 2 , ]- [CY, 2 ] represents 2-(benzyl-oxy)-ethyl, 2,2-dimethyl-cyclopentyl, 3,3-difluoro-cyclopentyl, 3-methoxy-cyclopentyl, cyclohexyl, 4-hydroxy-cyclohexyl, 4-methyl-4-hydroxy-cyclohexyl, 4-side-oxy-cyclohexyl, tetrahydrofuran-3-yl, tetrahydropiperan-4-yl, tetrahydropiperan-4-yl-methyl or alkyl-6-yl] [To elaborate, this type of -O-] [R, O2, ] represents isopropoxy, isobutoxy, dibutoxy, 2-(benzyl-oxy)-ethoxy, 2-methoxy-ethoxy, 3-hydroxy-propoxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, 2,2-dimethyl-cyclopentyl-oxy, 3,3-difluoro-cyclopentyl-oxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4-hydroxy-cyclohexyl-oxy, 4-side-oxy-cyclohexyl-oxy, tetrahydrofuran-3-yl-oxy, tetrahydropiperan-4-yl-oxy, tetrahydropiperan-4-yl-methoxy, 3-methoxy-cyclopentyl-oxy, or alkyl-6-yl-oxy]

[0077] 7) Another embodiment relates to a compound according to any one of Examples 1) to 4), wherein [A] of the substituent / At least one of the substituents in [A] is ˙ C3-5 alkyl as defined in Example 1).

[0078] 8) Another embodiment relates to the compound according to Example 7), wherein [A] of the substituent / At least one of the substituents in [A] is ˙ Hydroxy and [R, A1 The substituents are C3-5 alkyl groups (especially n-propyl, n-butyl, or n-pentyl), wherein the substituents are all located at the 3-position relative to the attachment point between the C3-5 alkyl group and the rest of the molecule; wherein Ø [R, A1 , ]express ▪ Unsubstituted or monosubstituted phenyl groups with fluorine (especially 3-fluorophenyl) or C1-3 alkoxy groups (especially 2-methoxyphenyl or 4-methoxyphenyl); ▪ A 6-membered heteroaryl group (especially pyridin-2-yl, pyridin-3-yl, pyrimidin-2-yl, pyridin-2-yl, or pyrimidin-4-yl) containing one or two cyclic nitrogen heteroatoms, wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, or disubstituted, and wherein the substituent(e.g.), if present, is independently selected from C1-3 alkyl (especially methyl), C3-5 cycloalkyl (especially cyclopropyl), or C1-3 alkoxy (especially methoxy); or In detail, this type of C3-5 alkyl group represents 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(3-fluoro-phenyl)-butyl, 3-hydroxy-3-(2-methoxy-phenyl)-butyl, 3-hydroxy-3-(4-methoxy-phenyl)-butyl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl, 3-hydroxy-3-(5-methyl-pyridin-3-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)-butyl, 3-hydroxy-3- (6-Methylpyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3-hydroxy-3-(6-methoxypyrimidin-4-yl)-butyl, 3-hydroxy-3-(6-methylpyrimidin-4-yl)-pentyl, 3-hydroxy-3-(2-methylpyrimidin-4-yl)-butyl, 3-hydroxy-3-(5-methylpyridin-2-yl)-butyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl or 3-hydroxy-3-(6-methoxypyridin-2-yl)-pentyl

[0079] 9) Another embodiment relates to a compound according to any one of Examples 1) to 4), wherein [A] of the substituent / At least one of the substituents in [A] is ˙ -N [R, N3 , R, N4 , ],in [R, N3 , ] [, 及 , ] [R, N4 Together with the nitrogen attached thereto, they form a heterocycle as defined in Example 1).

[0080] 10) Another embodiment relates to the compound according to Example 9), wherein [A] of the substituent / At least one of the substituents in [A] is ˙ -N [R, N3 , R, N4 , ],in Ø [R, N3 , ]and [R, N4Together with the nitrogen atom attached to it, it forms a 4- to 6-membered (especially 5- to 6-membered) heterocycle, wherein the members required for the integrity of the heterocycle are each independently selected from -CH2-, -O-, -(C=O)-, -CH [R, X , ]- and -C( [R, Y , ])2-; wherein the heterocycle does not contain more than one member of the group consisting of -O- and -(C=O)- independently selected; wherein the heterocycle does not contain more than two members of the group consisting of -CH [R, X , ]- members of a group; and wherein the heterocycle does not contain more than two choices -C( [R, Y , ])2- The members of the group; among which [R, X , ] independently represent fluorine, methyl, isopropyl, hydroxyl, trifluoromethyl, cyclopropyl, phenyl, 3-methyl-1,2,4-diazol-5-yl; and wherein [R, Y , ] independently represent fluorine, hydroxyl, cyclopropyl, methyl or trifluoromethyl [such -N [R, N3 , R, N4 , ] particularly pyrrolidyl; 2-pyrrolidone; acezolidinone (especially 1,3-acezolidin-2-one-3-yl); piperidinyl; or morpholino, as appropriate, independently selected by one or two independent groups. [R, X , ]and [R, Y Substituent substitution of the group consisting of , ] [In detail, this type of -N] [R, N3 , R, N4, ] represents pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4-difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-hydroxy-3-trifluoromethyl-pyrrolidin-1-yl, 3-trifluoromethyl-pyrrolidin-1-yl, 3-trifluoromethyl-pyrrolidin-1-yl 4-yl morpholino-4-yl, 3-(tetrahydropiperan-4-yl)-pyrrolidin-2-one-1-yl, pyrrolidin-2-one-1-yl, 4-phenyl-pyrrolidin-2-one-1-yl, 4-(pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-one-1-yl, 4-(6-isopropyl-pyridin-2-yl)- Pyrrolidin-2-one-1-yl, 4-(6-trifluoromethyl-pyridin-3-yl)-pyrrolidin-2-one-1-yl, 4-methyl-pyrrolidin-2-one-1-yl, 4-isopropyl-pyrrolidin-2-one-1-yl, 3-isopropyl-pyrrolidin-2-one-1-yl, 3,3-dimethyl-pyrrolidin-2-one-1-yl, 4,4-dimethyl-pyrrolidin-2-one-1-yl, 3-(piperidin-4-yl)-pyrrolidin-2-one-1-yl, 4- (6-Isopropyl-pyridin-2-yl)-pyrrolidin-2-one-1-yl, 4-isobutyl-pyrrolidin-2-one-1-yl, 4-cyclopropyl-pyrrolidin-2-one-1-yl, 4-trifluoromethyl-pyrrolidin-2-one-1-yl, 2,2,6,6-tetrafluoro-morpholin-4-yl, 2,6-dimethyl-morpholin-4-yl, 3-(3-methyl-1,2,4-diazol-5-yl)-pyrrolidin-1-yl or 3-(phenyl)-pyrrolidin-1-yl]

[0081] 11) Another embodiment relates to a compound according to any one of Examples 1) to 4), wherein [A] of the substituent / At least one of the substituents in [A] is Ø As defined in Example 1), a 5- or 6-membered heteroaryl group, wherein the substituents of the 5- or 6-membered heteroaryl group, if present, are independently selected. Ø C1-4 alkyl as defined in Example 1).

[0082] 12) Another embodiment relates to the compound according to Example 11), wherein [A] of the substituent / At least one of the substituents in [A] is Ø Contains one to three (especially two or three; especially three) 5- or 6-membered heteroaryl groups independently selected from nitrogen, oxygen, and sulfur cyclic heteroatoms (especially pyrazolyl, acezolyl, thiazolyl, acediazolyl, pyrimidinyl, or pyridinyl; especially pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, acezol-2-yl, thiazol-2-yl, 1,2,4-acediazol-5-yl, 1,2,4-acediazol-3-yl, pyrimidin-2-yl, or pyridin-2-yl; especially 1,2,4-acediazol-5-yl or 1,2,4-acediazol-3-yl; especially 1,2,4-acediazol-3-yl); wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially monosubstituted; especially relative to the 5- or 6-membered heteroaryl group and...). [A] is attached at position 3 by monosubstitution, wherein the substituent (or the substituent) is independently selected if present. Ø C1-4 alkyl groups (especially methyl, ethyl, propyl, isopropyl, or tert-butyl), their ▪ Not replaced; ▪ Replaced by the following basic units: v. hydroxyl group; or v C1-4 alkoxy groups (especially methoxy and tert-butoxy groups); or [In detail, such C1-4 alkyl groups represent methyl, isopropyl, hydroxy-methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, or tert-butoxy-methyl; especially such C1-4 alkyl groups represent 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1,1-dimethyl-ethyl] ▪ Disubstituted, where one substituent is a hydroxyl group and the other substituent is a trifluoromethyl group; or both substituents are hydroxyl groups; ▪ It is di- or tri-substituted, wherein two of the substituents are fluorine, and if present, one of the substituents is a hydroxyl group (wherein the hydroxyl group is separated from any of the fluorine substituents by at least two carbon atoms); In detail, these C1-4 alkyl groups represent methyl, isopropyl, hydroxy-methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, tert-butoxy-methyl; 1,2-dihydroxy-ethyl, N-acetylglucosinolate-2-amino-ethyl, N-(acetylglucosinolate-2,2,2-d3)-2-amino-ethyl, 2-(methylmethoxylamino)-2-methyl-propyl, 2-(ethylmethoxylamino)-2-methyl-propyl, 2-(cyclopropylmethoxylamino)-2-methyl-propyl, 2-(tetrahydropiperan-4-ylmethoxylamino)-2- Methyl-propyl, 2-(methoxy-methyl-methamido)-2-methyl-propyl, 2-(ethyl-methamido)-2-methyl-propyl, 2-(isopropyl-methamido)-2-methyl-propyl, 2-(methyl-d3-methamido)-2-methyl-propyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetylglucosinolate-2-amine 2,2,2-trifluoro-1-hydroxy-1-methyl-ethyl, 1,1-difluoro-2-hydroxy-ethyl, 1,1-difluoro-ethyl or N-methyl-N-(acetyl-2,2,2-d3)-2-amino-ethyl; especially such C1-4 alkyl groups are 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl.

[0083] 13) Another embodiment relates to the compound according to Example 11), wherein [A] of the substituent / At least one of the substituents in [A] is Ø 1,2,4-Azil-5-yl or 1,2,4-Azil-3-yl (especially 1,2,4-Azil-3-yl), wherein the acediazole group is monosubstituted, wherein the substituent is independently selected from... Ø C1-4 alkyl groups (especially methyl, ethyl, propyl, isopropyl, or tert-butyl), their ▪ Replaced by the following basic units: v. hydroxyl group; or v C1-4 alkoxy groups (especially methoxy and tert-butoxy groups). [In detail, such C1-4 alkyl groups represent hydroxy-methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, or terbutoxy-methyl; especially such C1-4 alkyl groups represent 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1,1-dimethyl-ethyl]

[0084] 14) Another embodiment relates to the compound according to Example 11), wherein [A] of the substituent / At least one of the substituents in [A] is Ø 1,2,4-Diazol-3-yl, which is monosubstituted (especially relative to the diazolyl group and) [A] is attached at position 3), where the substituent is... Ø C1-4 alkyl groups (especially methyl, ethyl, propyl, isopropyl, or tert-butyl), their ▪ Replaced by the following basic units: v Hydroxyl group; [In detail, such C1-4 alkyl groups represent hydroxy-methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, or 2-hydroxy-1,1-dimethyl-ethyl.]

[0085] 15) Another embodiment relates to the compound according to Example 11), wherein [A] represents a pyridin-3-yl group, wherein the pyridin-3-yl group is monosubstituted at the meta position relative to the attachment site between the pyridin-3-yl group and the rest of the molecule, wherein the substituent is... Ø 1,2,4-Diazol-3-yl, which is monosubstituted (especially relative to the diazolyl group and) [A] is the attachment point at position 3), where the substituent is hydroxy-methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl. [In detail, this type of 1,2,4-diazol-3-yl represents 5-(hydroxy-methyl)-1,2,4-diazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-diazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-diazol-3-yl, or 5-(2-hydroxy-1,1-dimethyl-ethyl)-1,2,4-diazol-3-yl]

[0086] 16) Another embodiment relates to a compound according to any one of Examples 1) to 4), wherein [A] of the substituent / At least one of the substituents in [A] is Ø As defined in Example 1), a 5- or 6-membered heteroaryl group, wherein the substituents of the 5- or 6-membered heteroaryl group, if present, are independently selected. Ø As defined in Example 1) - [L, 3 , ]- [CY, 3 , ].

[0087] 17) Another embodiment relates to the compound according to Example 16), wherein [A] of the substituent / At least one of the substituents in [A] is • Contains one to three (especially two or three; especially three) 5- or 6-membered heteroaryl groups independently selected from nitrogen, oxygen, and sulfur cyclic heteroatoms (especially pyrazolyl, acezolyl, thiazolyl, acediazolyl, pyrimidinyl, or pyridinyl; especially pyrazol-1-yl, 1H-1,2,3-triazol-1-yl, acezol-2-yl, thiazol-2-yl, 1,2,4-acediazol-5-yl, 1,2,4-acediazol-3-yl, pyrimidin-2-yl, or pyridin-2-yl; especially 1,2,4-acediazol-5-yl or 1,2,4-acediazol-3-yl; especially 1,2,4-acediazol-3-yl); wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially monosubstituted; especially relative to the 5- or 6-membered heteroaryl group and...). [A] is attached at position 3 by monosubstitution, wherein the substituent (or the substituent) is independently selected if present. Ø - [L, 3 , ]- [CY, 3 , ],in ▪ - [L, 3, ] - Independently represents a one-key (i.e., the key) [CY, 3 , ] directly attached to the rest of the molecule), -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)- or -O-CH2-, where - [L, 3 When , ]- is -O-CH2-, then [CY, 3 , ] is attached to the oxygen atom of -O-CH2-; and ▪ [CY, 3 , ] independently represents piperidinyl; wherein the piperidinyl is independently unsubstituted, monosubstituted, disubstituted or trisubstituted as defined in Example 1).

[0088] 18) Another embodiment relates to the compound according to Example 16), wherein [A] of the substituent / At least one of the substituents in [A] is Ø 1,2,4-Azil-5-yl or 1,2,4-Azil-3-yl (especially 1,2,4-Azil-3-yl), wherein the acediazole group is monosubstituted, wherein the substituent is independently selected from... · - [L, 3 , ]- [CY, 3 , ],in ▪ - [L, 3 , ] - Independently represents a one-key (i.e., the key) [CY, 3 , ] directly attached to the rest of the molecule), -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)- or -O-CH2-, where - [L, 3 When , ]- is -O-CH2-, then [CY, 3 , ] is attached to the oxygen atom of -O-CH2-; and ▪ [CY, 3 , ] independently represents a piperidinyl group (especially piperidin-2-yl, piperidin-3-yl, or piperidin-4-yl; especially piperidin-4-yl), wherein the piperidinyl group is independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially unsubstituted, monosubstituted, or disubstituted): Ø Halogens (especially fluorine); Ø Side oxygen group; Ø Hydroxyl group; Ø C1-3 alkyl groups monosubstituted with C1-3 alkoxy groups, as appropriate (especially if such C1-3 alkyl groups represent methyl, ethyl, propyl, isopropyl, or methoxy-methyl); Ø C1-3 alkoxy groups (especially methoxy groups); Ø -(C=O)- [R, CO , ],in [R, CO , ]express o C1-3 alkyl groups monosubstituted with hydroxyl or C1-3 alkoxy groups (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy-methyl, methoxy-methyl, benzyl-oxy, or 2-methoxy-ethyl; especially the -(C=O)- [R, CO , ] is acetyl); o C1-3 fluoroalkyl groups (especially 2,2,2-trifluoroethyl); o C1-3 alkoxy groups (especially methoxy groups); o C3-6 cycloalkyl-(CH2) [, n , ]-, where one or two carbon ring atoms are replaced by one or two oxygen ring atoms, depending on the situation; where [n] represents the integer 0 or 1 (especially for this type of C3-6 cycloalkyl-(CH2)). [, n , ]- indicates cyclopropyl, cyclopentyl, oxetane-3-yl, oxetane-3-yl-methyl, 1,4-dialkyl-2-yl, or tetrahydropiperan-4-yl); or o-phenyl; [This type -(C=O)-] [R, CO In particular, it represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tributyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetane-3-yl-carbonyl, oxetane-3-yl-methyl-carbonyl, phenyl-carbonyl or tetrahydropiperan-4-yl-carbonyl, methoxy-methyl-carbonyl or 1,4-dimethyl-2-yl-carbonyl. Ø -S(=O)2 - [R, SO , ],in [R, SO , ]express o C1-3 alkyl groups monosubstituted with hydroxyl, C1-3 alkoxy, or amino groups (especially methyl, n-propyl, isopropyl, 2-hydroxy-ethyl, 2-methoxy-ethyl, or methyl-amino); or o C3-5 cycloalkyl, wherein, depending on the case, one carbon ring atom is substituted by an oxygen ring atom (especially cyclopropyl, cyclopentyl, or tetrahydropiperan-4-yl); [This type of -S(=O)2-] [R, SO , ] especially represents methyl-sulfonyl, n-propyl-sulfonyl, isopropyl-sulfonyl, 2-hydroxyethyl-sulfonyl, cyclopropyl-sulfonyl, cyclopentyl-sulfonyl, 2-methoxy-ethyl-sulfonyl, methyl-amino-sulfonyl, or tetrahydropiperan-4-yl-sulfonyl] [To elaborate, this type of -] [L, 3 , ]- [CY, 3Piperidin-4-yl, 1-methyl-2,6-di-side-oxy-piperidin-4-yl, 4-methyl-piperidin-4-yl, 4-fluoro-piperidin-4-yl, 2-side-oxy-piperidin-4-yl, 6-side-oxy-piperidin-2-yl, 6-side-oxy-piperidin-3-yl, 1-methyl-6-side-oxy-piperidin-3-yl, 3-methyl-6-side-oxy-piperidin-3-yl, N-acetyl-piperidin-4-yl, N-acetyl-piperidin-4-yl-methyl, N-acetyl-2-methyl-piperidin-4-yl, N-acetyl-4-fluoro-piperidin-4-yl, N-acetyl-3-methyl-piperidin-4-yl, N-acetyl-4-methyl-piperidin-4-yl, N-acetyl-4-hydroxy-piperidin- 4-yl, N-acetylated-4-methoxy-piperidin-4-yl, N-acetylated-piperidin-3-yl, N-acetylated-piperidin-3-yl-methyl, N-acetylated-3-methyl-piperidin-3-yl, N-acetylated-3-hydroxy-piperidin-3-yl, N-(isopropyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(tertiary butyl-carbonyl) N-(2-methoxy-ethoxy-carbonyl)-piperidin-4-yl, N-(hydroxymethyl-carbonyl)-piperidin-4-yl, N-(cyclopropyl-sulfonylurea)-piperidin-4-yl, N-(methyl-sulfonylurea)-piperidin-4-yl, N-(n-propyl-sulfonylurea)-piperidin-4-yl, N-(isopropyl-sulfonylurea)-piperidin-4-yl Pyridine-4-yl, N-(2-hydroxy-ethyl-sulfonylurea)-piperidin-4-yl, N-(cyclopentyl-sulfonylurea)-piperidin-4-yl, N-(methoxy-carbonyl)-piperidin-4-yl, N-(cyclopropyl-carbonyl)-piperidin-4-yl, N-(cyclopentyl-carbonyl)-piperidin-4-yl, N-(methyl-amino-sulfonylurea)-piperidin-4-yl, N-(2-methoxy-ethyl-sulfonylurea)-piperidin-4-yl, N-(ethyl-carbonyl)-4-hydroxy-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-piperidin-4-yl, N-(ethoxy-carbonyl)-piperidin-4-yl, N-acetylsalicylic acid-4-ethyl-piperidin-4-yl, N-(n-propyl-carbonyl)-piperidin-4-yl - , N-(2-methoxy-ethyl-carbonyl)-piperidin-4-yl, N-(oxetane-3-yl-carbonyl)-piperidin-4-yl, N-(oxetane-3-yl-methyl-carbonyl)-piperidin-4-yl, N-(2,2,2-trifluoro-ethyl-carbonyl)-piperidin-4-yl, N-(tetrahydropiperan-4-yl-carbonyl)-piperidin-4-yl, N-(phenyl-carbonyl)-piperidin-4-yl, N-(tetrahydropiperan-4-yl-sulfonyluyl)-piperidin-4-yl, N-(benzyl-oxy-carbonyl)-piperidin-4-yl, N-(methoxy-methyl-carbonyl)-4-isopropyl-piperidin-4-yl, N-(1,4-dialkyl-2-yl-carbonyl)-piperidin-4-yl).

[0089] 19) Another embodiment relates to the compound according to Example 16), wherein [A] of the substituent / At least one of the substituents in [A] is Ø 1,2,4-Diazol-3-yl, wherein the diazolyl group is monosubstituted, wherein the substituent is independently selected from... · - [L, 3 , ]- [CY, 3 , ],in ▪ - [L, 3 , ]- indicates a one-click (i.e., the key) [CY, 3 , ] directly attached to the rest of the molecule); and ▪ [CY, 3 , ] independently represents unsubstituted or monosubstituted or disubstituted piperidin-4-yl, wherein A substituent is attached to the nitrogen atom of the piperidine ring, wherein the substituent is -(C=O)-. [R, CO , ],in [R, CO , ]express o As appropriate, a monosubstituted C1-3 alkyl group, wherein the substituent represents a C1-3 alkoxy or hydroxyl group (especially such C1-3 alkyl groups are methyl, ethyl, n-propyl, isopropyl, tert-butyl, hydroxy-methyl, methoxy-methyl, or 2-methoxy-ethyl; the -(C=O)- [R, CO (especially acetylated) o C1-3 fluoroalkyl groups (especially 2,2,2-trifluoroethyl); o C1-3 alkoxy groups (especially methoxy groups); o C3-6 cycloalkyl-(CH2) [, n , ]-, where one or two carbon ring atoms are replaced by one or two oxygen ring atoms, depending on the situation; where [n] represents the integer 0 or 1 (especially for this type of C3-6 cycloalkyl-(CH2)). [, n , ]- indicates cyclopropyl, cyclopentyl, oxetane-3-yl, oxetane-3-yl-methyl, 1,4-dialkyl-2-yl, or tetrahydropiperan-4-yl); or [Especially this type -(C=O)-] [R, CO , ] represents acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tributyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetane-3-yl-carbonyl, oxetane-3-yl-methyl-carbonyl, tetrahydropiperan-4-yl-carbonyl, methoxy-methyl-carbonyl, or 1,4-dimethyl-2-yl-carbonyl. Ø and / or a substituent attached to a carbon atom of the piperidine ring, wherein the substituent is a C1-3 alkyl (especially methyl), halogen (especially fluorine), hydroxyl or C1-3 alkoxy (especially methoxy).

[0090] 20) Another embodiment relates to a compound according to any one of Examples 1) to 4), wherein [A] of the substituent / At least one of the substituents in [A] is independently... · -C≡C- [R, T1 , ];or · -C≡CC(OH)( [R, T2 , ])( [R, T3 , ]); These groups are as defined in Example 1).

[0091] 21) Another embodiment relates to the compound according to Example 20), wherein [A] of the substituent / At least one of the substituents in [A] is · -C≡C- [R, T1 , ],in Ø [R, T1 , ]express ▪ C1-4 alkyl groups (especially methyl, ethyl, isopropyl, or isobutyl), wherein the C1-4 alkyl group is independently monosubstituted v Hydroxyl group; [In particular, such C1-4 alkyl groups represent hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl-propyl, or 1-hydroxy-1-methyl-ethyl]; v C1-3 alkoxy groups (especially methoxy groups); v -S(=O)2- [R, SOT , ],in [R, SOT , ] indicates C1-3 alkyl, C1-3 alkyl-amino or C3-5 cycloalkyl (especially such -S(=O)2- [R, SOT , ] represents methyl-sulfonyl, methyl-amino-sulfonyl, or cyclopropyl-sulfonyl); v contains one or two independent C4-6 heterocyclic groups selected from nitrogen and oxygen cyclic heteroatoms (especially azolidinyl, imidazodinyl, or pyrrolidinyl; especially azolidin-3-yl, imidazodin-3-yl, or pyrrolidin-1-yl); wherein the C4-6 heterocyclic group is monosubstituted with a side oxygen group; or disubstituted with a side oxygen group and a C1-3 alkyl group (especially methyl); (especially such C4-6 heterocyclic groups represent azolidin-2-one-3-yl, imidazodin-2-one-3-yl, 1-methyl-imidazodin-2-one-3-yl, or pyrrolidin-2-one-1-yl); ▪ Independently disubstituted C1-4 alkyl groups (especially methyl, ethyl, isopropyl, or isobutyl), wherein one substituent is a hydroxyl group and the second substituent is a trifluoromethyl group (especially 1-hydroxy-1-trifluoromethyl-ethyl); ▪ C3-6 cycloalkyl groups (especially cyclopropyl groups, which are monosubstituted with the following groups (especially at the attachment points between the C3-6 cycloalkyl group and the rest of the molecule): v Hydroxyl group; v. Depending on the case, an amino-sulfonyl group disubstituted with a methyl group; v. Phenyl groups monosubstituted with halogens (especially 4-fluoro-phenyl); v. Pyridyl (especially pyridin-2-yl); v. Pyrimidinyl groups monosubstituted with C1-3 alkyl groups (especially 6-methyl-pyrimidin-4-yl); v. Azolacillinone group (especially azolacil-2-one-3-yl); [In detail, these C3-6 cycloalkyl groups represent 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 1-(amino-sulfopropyl)-cyclopropyl, 1-(dimethyl-amino-sulfopropyl)-cyclopropyl, 1-(6-methyl-pyrimidin-4-yl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl, 1-(4-fluoro-phenyl)-cyclopropyl, 1-(pyridin-2-yl)-cyclopropyl, or 1-(azolidin-2-one-3-yl)-cyclopropyl]; ▪ Contains a C4-6 heterocyclic group independently selected from nitrogen and oxygen cyclic heteroatoms (especially aziridine, pyrrolidinyl, piperidinyl, tetrahydropiperanyl; especially aziridine-3-yl, piperidin-4-yl, pyrrolidin-3-yl, pyrrolidin-2-yl, pyrrolidin-1-yl or tetrahydropiperanyl-4-yl); wherein the C4-6 heterocyclic group is monosubstituted, disubstituted or trisubstituted (especially monosubstituted or disubstituted), wherein the substituent is independently selected from C1-3 alkyl (especially methyl), hydroxyl, syloxy, C1-3 alkyl-carbonyl (especially acetyl), C1-3 alkoxy-carbonyl (especially tert-butoxy-carbonyl), C1-3 alkyl-sulfonyl (especially methyl-sulfonyl) and C1-3 alkyl-amino-sulfonyl (especially methyl-amino-sulfonyl); In detail, these C4-6 heterocyclic groups represent N-(isopropyl-carbonyl)-3-hydroxy-azacyclobutane-3-yl, N-(tert-butoxy-carbonyl)-3-hydroxy-azacyclobutane-3-yl, N-methyl-3-hydroxy-pyrrolidin-2-one-3-yl, N-acetylated-2-methyl-pyrrolidin-2-yl, 3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl, 2-sideoxy-pyrrolidin-1-yl, N-acetylated-piperidin-4-yl, N-acetylated-4-methyl-piperidin-4-yl, N-(methyl-amino-sulfonylurea)-4-methyl-piperidin-4-yl, N-acetylated-4-hydroxy-piperidin-4-yl, N-(methyl-sulfonylurea)-piperidin-4-yl, N-(terbutoxy-carbonyl)-piperidin-4-yl, 3-hydroxy-2-sideoxy-1-methyl-pyrrolidin-2-yl or 4-hydroxy-tetrahydropiperan-4-yl); ▪ Indole (especially indole-2-yl); ▪ 3-Hydroxy-1-methyl-1,3-dihydro-indole-2-one-3-yl; or [To elaborate, this type of -C≡C-] [R, T1, ] represents 3-hydroxy-3-trifluoromethyl-but-1-yn-1-yl, 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl)-ethynyl, (7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridine -7-yl)-ethynyl, (4-hydroxy-tetrahydropiperan-4-yl)-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azacyclobutane-3-yl)-ethynyl, (1-(tert-butoxy-carbonyl)-3-hydroxy-azacyclobutane-3-yl)-ethynyl, (N-acetylated-4-hydroxy-piperidine-(3-hydroxy-N-(tert-butoxy-carbonyl)-pyrrolidin-3-yl)-ethynyl, (3-hydroxy-1-methyl-1,3-dihydro-indol-2-one-3-yl)-ethynyl or (3-hydroxy-2-toxy-1-methyl-pyrrolidin-3-yl)-ethynyl] • As defined in Example 1) -C≡CC(OH) [R, T2 , ])( [R, T3 , ]).

[0092] 22) Another embodiment relates to the compound according to Example 20), wherein [A] of the substituent / At least one of the substituents in [A] is · -C≡CC(OH)( [R, T2 , ])( [R, T3 , ]),in Ø [R, T2 , ] indicates hydrogen or a C1-3 alkyl group (especially methyl or ethyl; particularly methyl); Ø [R, T3 , ]express ▪ A 6-membered heteroaryl group (especially pyridyl, pyridyl or pyrimidinyl; especially pyridin-2-yl, pyrimidin-2-yl, pyridin-2-yl or pyrimidin-4-yl; especially pyrimidin-4-yl) containing one or two cyclic nitrogen atoms, wherein the 6-membered heteroaryl group is independently unsubstituted, monosubstituted or disubstituted; wherein the substituent(e) present is independently selected from C1-3 alkyl (especially methyl), C1-3 cycloalkyl (especially cyclopropyl), C1-3 fluoroalkyl (especially C1-fluoroalkyl; especially difluoromethyl or trifluoromethyl) and C1-3 alkoxy (especially methoxy); [In detail, these 6-membered heteroaryl groups are pyridin-2-yl, 6-methoxy-pyridin-2-yl, 6-methyl-pyridin-2-yl, pyrimidin-2-yl, 2-methoxy-pyrimidin-4-yl, 6-methoxy-pyrimidin-4-yl, pyrimidin-4-yl, 2-methyl-pyrimidin-4-yl, 6-methyl-pyrimidin-4-yl, 2,6-dimethyl-pyrimidin-4-yl, 2,6-dimethoxy-pyrimidin-4-yl, 2-methyl-6-methoxy-pyrimidin-4-yl, 2-methoxy-6-methyl-pyrimidin-4-yl, 5-methyl-pyridin-2-yl, 6-cyclopropyl-pyrimidin-4-yl, 6-difluoromethyl-pyrimidin-4-yl, 2-trifluoromethyl-pyrimidin-4-yl, or 6-trifluoromethyl-pyrimidin-4-yl] [To elaborate, this type of -C≡CC(OH)( [R, T2 , ])( [R, T3, ]) represents 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy ... 3-hydroxy-3-(2,6-dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)pent-1-yn-1-yl 3-Hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-Hydroxy-3-(6-methyl-pyridin-2-yl)-but-1-yn-1-yl, 3-Hydroxy-3-(6-methyl-pyridin-2-yl)-pent-1-yn-1-yl, 3-Hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-Hydroxy-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-1-yl, 2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-cyclopropyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-difluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl or 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl

[0093] 23) Another embodiment relates to a compound according to any one of Examples 1) to 22), wherein [B] represents a mono-, di-, or tri-substituted phenyl group, wherein the first substituent is attached at the para position relative to the attachment site of B to the remainder of the molecule, and the substituents are selected from... Ø C1-5 alkyl groups (especially methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tributyl, 1-ethyl-propyl, 2,2-dimethyl-propyl, 1,1-dimethyl-propyl; especially methyl, ethyl or isopropyl; particularly isopropyl); Ø C1-3 alkoxy-C1-4 alkyl (especially 3-methoxy-propyl); Ø C1-2-fluoroalkyl (especially trifluoromethyl or 2,2,2-trifluoroethyl); Ø C3-5 cycloalkyl groups (especially cyclopropyl or cyclobutyl), which are independently unsubstituted or monosubstituted with a C1-3 alkyl group (especially methyl) or a C1-3 fluoroalkyl group (especially trifluoromethyl) (particularly at the attachment point of the C3-5 cycloalkyl group to the rest of the molecule); and Ø C1-fluoroalkoxy (especially trifluoromethoxy); and The remaining substituents of [B] (wherein the remaining substituents are particularly relative to) [B] The attachment site with the rest of the molecule (in meta position) is selected independently of halogens (especially fluorine or chlorine; especially fluorine). [In detail, such groups] [B] represents 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 4-(1-ethyl-propyl)-phenyl, 4-(1,1-dimethyl-propyl)-phenyl, 4-(2,2-dimethyl-propyl)-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-(3-methoxy-propyl)-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl.

[0094] 24) Another embodiment relates to a compound according to any one of Examples 1) to 22), wherein [B] represents a mono-, di-, or tri-substituted phenyl group, wherein the first substituent is attached at the para position relative to the attachment site of B to the remainder of the molecule, and the substituents are selected from... • C2-4 alkyl groups (especially n-propyl, isopropyl, n-butyl, isobutyl, tributyl; particularly isopropyl); • Trifluoromethyl or 2,2,2-trifluoro-ethyl; • C3-5 cycloalkyl groups (especially cyclopropyl or cyclobutyl), which are independently unsubstituted or monosubstituted with a C1-3 alkyl group (especially methyl) or a C1-3 fluoroalkyl group (especially trifluoromethyl) (particularly at the attachment point of the C3-5 cycloalkyl group to the rest of the molecule); and • C1-fluoroalkoxy group (especially trifluoromethoxy group); and The remaining substituents of [B] (wherein the remaining substituents are particularly relative to) [B] The attachment site with the rest of the molecule (in meta position) is selected independently of halogens (especially fluorine or chlorine; especially fluorine). [In detail, such groups] [B] represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-butyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-chloro-4-isopropyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl.

[0095] 25) Another embodiment relates to a compound according to any one of Examples 1) to 22), wherein [B] represents a phenyl group that has been monosubstituted, wherein the substituent is attached at the para position relative to the attachment site of B and the rest of the molecule, wherein the substituent is selected from isopropyl (preferably), trifluoromethyl, trifluoromethoxy, trifluoromethyl, cyclopropyl, cyclobutyl, 1-methyl-cyclopropyl and 1-trifluoromethyl-cyclopropyl. [In detail, such groups] [B] represents 4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl.

[0096] 26) Another embodiment relates to a compound according to any one of Examples 1) to 25), wherein [R, 1 , ] indicates a C1-3 alkyl group (especially methyl or ethyl; particularly methyl);

[0097] 27) Another embodiment relates to a compound according to any one of Examples 1) to 26), wherein [R, 2 , ] represents C1-4 alkyl (especially methyl (preferably), ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C3-5 cycloalkyl (especially cyclopropyl or cyclobutyl), C3-5 cycloalkyl-C1-3 alkyl (especially cyclopropyl-methyl) or C1-3 fluoroalkyl (especially 2,2-difluoro-ethyl or 2-fluoroethyl).

[0098] 28) Another embodiment relates to a compound according to any one of Examples 1) to 26), wherein [R, 2 , ] represents methyl (preferably), ethyl, n-propyl, isopropyl, cyclopropyl, or cyclobutyl.

[0099] 29) Another embodiment relates to the compound according to Example 1), wherein [A] represents pyridin-3-yl, wherein the pyridin-3-yl is monosubstituted at the meta position relative to the attachment site between the pyridin-3-yl and the rest of the molecule, wherein the substituent is 5-(hydroxy-methyl)-1,2,4-diazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-diazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-diazol-3-yl, or 5-(2-hydroxy-1,1-dimethyl-ethyl)-1,2,4-diazol-3-yl; [B] represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; [R, 1 , ] represents methyl; and [R, 2 , ] indicates methyl.

[0100] 30) Another embodiment relates to the compound according to Example 1), wherein [A] represents a pyridin-3-yl group, wherein the pyridin-3-yl group is monosubstituted at the meta position relative to the attachment site between the pyridin-3-yl group and the rest of the molecule, wherein the substituent is... Ø 1,2,4-Diazol-3-yl, wherein the diazolyl group is monosubstituted, wherein the substituent is an unsubstituted, monosubstituted, or disubstituted piperidin-4-yl group, wherein one substituent is attached to the nitrogen atom of the piperidinyl ring, wherein the substituent is • Acetyl, ethyl-carbonyl, n-propyl-carbonyl, isopropyl-carbonyl, tributyl-carbonyl, hydroxymethyl-carbonyl, 2,2,2-trifluoro-ethyl-carbonyl, methoxy-methyl-carbonyl, 2-methoxy-ethyl-carbonyl, methoxy-carbonyl, ethoxy-carbonyl, 2-methoxy-ethoxy-carbonyl, cyclopropyl-carbonyl, cyclopentyl-carbonyl, oxetane-3-yl-carbonyl, oxetane-3-yl-methyl-carbonyl, tetrahydropiperan-4-yl-carbonyl, methoxy-methyl-carbonyl, or 1,4-dialkyl-2-yl-carbonyl; and / or a substituent attached to a carbon atom of the piperidine ring, wherein the substituent is a C1-3 alkyl (especially methyl), halogen (especially fluorine), hydroxyl, or C1-3 alkoxy (especially methoxy). [B] represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; [R, 1 , ] represents methyl; and [R, 2 , ] indicates methyl.

[0101] 31) Another embodiment relates to the compound according to Example 1), wherein [A] represents a pyridin-3-yl group, wherein the pyridin-3-yl group is monosubstituted at the meta position relative to the attachment site between the pyridin-3-yl group and the rest of the molecule, wherein the substituent is 3-hydroxy-3-(pyrimidin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methylpyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxypyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-methoxy-6-methylpyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethoxy-pyrimidin-4-yl)-but-1-yn-1-yl. -1-Oyn-1-yl, 3-hydroxy-3-(2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2,6-dimethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-cyclopropyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-difluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(2-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl or 3-hydroxy-3-(6-trifluoromethyl-pyrimidin-4-yl)-but-1-yn-1-yl] [B] represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl, or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; [R, 1 , ] represents methyl; and [R, 2 , ] indicates methyl.

[0102] 32) Another embodiment relates to a compound according to any one of Examples 1) to 31), which is also a compound of formula (II) (i.e.) [A] and [B] The attached asymmetric carbon atom has the absolute configuration described in formula (II). Equation (II)

[0103] 33) Another embodiment relates to the compound according to Example 1), which is selected from the group consisting of: (3-fluoro-1-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; 3-[hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methyl]-1-methyl-azacyclobutane-3-carboxylonitrile; (R)-(1-Ethyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(3-methyl-1-propyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Isopropyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Cyclopropylmethyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Cyclobutyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Isobutyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-Cyclopropyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2-fluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2,2-difluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-tert-butyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-prop-1-ynyl)-pyridin-3-yl]-methanol 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-1-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azacyclobutane-1-carboxylic acid tertiary butyl ester; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(1-methyl-1H-pyrazol-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl-pent-1-yn-3-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-tetrahydro-piperan-4-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-piperan-4-yl)-prop-2-yn-1-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-prop-2-yn-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-piperan-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazo-4-yl)-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazo-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-prop-2-yn-1-ol; 8-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-5,6,7,8-tetrahydro-quinoline-8-ol; 7-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-6,7-dihydro-5H-[1]pyridin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pent-1-yn-3-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-3-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azacyclobutane-1-yl)-2-methyl-prop-1-one; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(1H-indol-2-ylethynyl)pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-propyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-2-ol; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopentanol; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopropanol; 3-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-azacyclobutane-1-carboxylic acid tertiary butyl ester; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[2-(1-methyl-1H-pyrazol-4-yl)-ethyl]-pyridin-3-yl}-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-but-2-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl-pentan-3-ol; 4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-tetrahydro-piperan-4-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-piperan-4-yl)-prop-1-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[2-(tetrahydro-piperan-4-yl)-ethyl]-pyridin-3-yl}-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazolyl-4-yl)-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazolyl-4-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-2-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-prop-1-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinoline-8-ol; 7-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-6,7-dihydro-5H-[1]pyridin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pentan-3-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pent-3-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[2-(1H-indol-2-yl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(4-Cyclopropyl-phenyl)-(1,3-Dimethyl-azacyclobutane-3-yl)-{5-[3-(tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-5-yl]pyridin-3-yl}-methanol; (R)-(4-Cyclopropyl-phenyl)-(1,3-Dimethyl-azacyclobutane-3-yl)-{5-[3-(2-methoxy-1,1-dimethyl-ethyl)-[1,2,4]azadiazol-5-yl]pyridin-3-yl}-methanol; (R)-[5-(3-cyclobutoxymethyl-[1,2,4]azadiazol-5-yl)-pyridin-3-yl]-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yloxymethyl)-[1,2,4]azolo-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-5-yl]pyridin-3-yl}-methanol; (R)-[5-(3-cyclobutoxymethyl-[1,2,4]diazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-propyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yl)-[1,2,4]diazol-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-ylmethyl-[1,2,4]azadiazol-5-yl)pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(2,6-dimethyl-morpholin-4-ylmethyl)-[1,2,4]diazol-5-yl]pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[(1S,2S,4R)-3-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]diazol-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yloxymethyl)-[1,2,4]diazol-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-yl-[1,2,4]isodiazol-5-yl)pyridin-3-yl]-methanol; (R)-(4-Cyclopropyl-phenyl)-(1,3-Dimethyl-azacyclobutane-3-yl)-{5-[3-(4-methoxy-tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-5-yl]pyridin-3-yl}-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]azolidin-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]diazol-5-yl]pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 2-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)-2-methyl-prop-1-ol; 2-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-1-methyl-ethyl)-[1,2,4]azolo-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-cyclobutyl)-[1,2,4]azolo-5-yl]pyridin-3-yl}-methanol; 1-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)-2-methyl-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methanesulfonylmethyl-[1,2,4]azadiazol-3-yl)pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-ethyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methoxymethyl-[1,2,4]azadiazol-3-yl)pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-furan-3-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclohexanol; (R)-[5-(5-tert-butoxymethyl-[1,2,4]-diazol-3-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-ylmethyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclohexanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-cyclohexanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-cyclobutyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-oxa-spiro[2.5]oct-1-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-3-yl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-furan-2-yl)methyl]-[1,2,4]azadiazol-3-yl}-pyridin-3-yl)-methanol; (R)-2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,1,1-trifluoro-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-1-methyl-ethyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-{5-[5-((R)-cyclohexyl-hydroxy-methyl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclopropanol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclopentanol; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclobutanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-(4-fluoro-tetrahydro-piperan-4-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-((2R,4R,6S)-2,6-dimethyl-tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-yloxymethyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-methyl-1-(tetrahydro-piperan-4-yl)-ethyl]-[1,2,4]isodiazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[2-(tetrahydro-piperan-4-yl)-ethyl]-[1,2,4]azadiazol-3-yl}-pyridin-3-yl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclobutanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-2-methyl-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-tetrahydro-piperan-4-yloxymethyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-oxacyclobutane-3-yl-[1,2,4]azadiazol-3-yl)pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-1,1-dimethyl-ethyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-2-methyl-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-2-methyl-propyl)-[1,2,4]azolo-3-yl]pyridin-3-yl}-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-cyclobutanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxymethyl-cyclopropylmethyl)-[1,2,4]azolo-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-pyrazol-1-yl-ethyl)-[1,2,4]azolo-3-yl]pyridin-3-yl}-methanol; (R)-N-(2-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)ethyl)acetamide-2,2,2-d3; (R)-N-(1-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)-2-methylpropane-2-yl)acetamide-2,2,2-d3; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-2-hydroxy-acetone; (R)-1-(4-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)piperidin-1-yl)aceto-1-one-2,2,2-d3; N-[2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-ethyl]-2-hydroxy-N-methylacetamide; (R)-N-(2-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)ethyl)-N-methylacetamide-d3; (1,3-Dimethyl-azacyclobutane-3-yl)-(6-methoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(6-phenoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(6-ethoxy-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(5-methyl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-propyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-methoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-phenyl-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclobutyl-phenyl)-(1,3-Dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclobutoxy-phenyl)-(1,3-Dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-ethoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-tert-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (4-Cyclopropoxy-phenyl)-(1,3-Dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (S)-[2-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-[2-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(2-isobutoxy-pyridin-4-yl)-(4-isopropyl-phenyl)-methanol; 4-{4-[(S)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-2-yl}-2-methyl-but-2-ol; (R)-[6-(3,3-difluoro-pyrrolidin-1-yl)-tazo-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-5-tert-butyl-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-azolidin-2-one; (R)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; (S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-methyl-pyrrolidin-3-ol; 3-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone-3-ol; 2-((S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-morpholin-4-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-tetrahydro-2H-[1,3']bipyridin-5'-yl)-methanol; (R)-[5-(7-aza-bicyclo[2.2.1]hept-7-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-((S)-2-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-trifluoromethyl-pyrrolidone-3-ol; (R)-[5-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 5'-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridine-4-ol; 5'-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridine-3-ol; (R)-{5-[(2-benzylmethyloxy-ethyl)-methyl-amino]-pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; 2-[(S)-1-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-pyrrolidin-3-yl]-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(3,4,5,6-tetrahydro-2H-[1,3']bipyridin-5'-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-{5-[5-(1-cyclopropanesulfonyl-piperidin-4-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 2-({5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-methyl-amino)-ethanol; (R)-1-((S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-ethanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-azolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-phenyl-azolidin-2-one; 5-Benzyl-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-azolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-isopropyl-azolidin-2-one; 6-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-oxa-6-aza-spiro[2,4]heptane-5-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-oxa-3-aza-spiro[4.4]non-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-(tetrahydro-piperan-4-yl)-azolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5,5-dimethyl-azolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8,8-difluoro-1-oxa-3-aza-spiro[4.5]dec-2-one; 9-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7-oxa-9-aza-dispiro[3.1.4.1]undecyl-8-one; 2-Cyclopropyl-7-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-oxa-7-aza-spiro[3.4]oct-6-one; 7-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-dimethyl-5-oxa-7-aza-spiro[3.4]oct-6-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-phenyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isopropyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-isopropyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4,4-dimethyl-pyrrolidone-2-one; 5-(5-((R)-(1,3-dimethyl-azacyclobutane-3-yl)(hydroxy)(4-isopropyl-phenyl)methyl)pyridin-3-yl)hexahydro-4H-furano[2,3-c]pyrrolo-4-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.4]non-3-one; 6-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-6-aza-spiro[3.4]oct-5-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]dec-3-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(tetrahydro-piperan-4-yl)-pyrrolidone-2-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.5]dec-1-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]dec-1-one; (S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isobutyl-pyrrolidin-2-one; 4-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-trifluoromethyl-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(2-methoxy-ethyl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methoxy-ethyl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-pyrrolidone; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-((R)-3-isopropyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((2R,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-[5-((3S,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((2S,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((2R,6R)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(3-methyl-[1,2,4]azadiazol-5-yl)-pyrrolidin-1-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-thiazo-2-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-phenyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(3,3-dimethyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(2,2,6,6-tetrafluoro-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-((R)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-((S)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-trifluoromethyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[(1R,4R)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[(1S,5R)-5-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(5-benzylmethyloxypyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyridin-2-yl-ethoxy)-pyridin-3-yl]-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(2-methoxy-ethoxy)-pyridin-3-yl]-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(oxacyclobutane-3-ylmethoxy)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-isopropoxy-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(5-cyclohexyloxypyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-cyclopentyloxy)-pyridin-3-yl]-methanol; (R)-[5-(3-cyclopropyl-[1,2,4]isodiazol-5-ylmethoxy)pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[2-(3,5-dimethyl-[1,2,4]triazol-1-yl)-ethoxy]pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-but-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-methoxy-pyridin-3-yl)-methanol; (R)-[5-(2-benzylmethyloxyethoxy)pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-piperan-4-yloxy)pyridin-3-yl]-methanol; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-ethanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-1-methyl-cyclohexanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(2-phenoxy-pyrimidin-5-yl)-(4-trifluoromethoxy-phenyl)-methanol; (6-Benzylmethyloxypyridin-3-yl)-(1,3-Dimethyl-azacyclobutane-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(5-pyrazol-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(6-fluoro-5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol [;] [ ] 5-[(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-3-pyrrolidone-1-yl-pyridine-2-carboxynitrile; (1,3-Dimethyl-azacyclobutane-3-yl)-[6-(tetrahydro-piperan-4-yloxy)pyridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-[6-(oxacyclobutane-3-ylmethoxy)pyridin-3-yl]-(4-trifluoromethoxy-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-thiazo-2-yl)pyridin-3-yl]-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-thiazo-2-yl)pyridin-3-yl]-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(2-methoxy-pyrimidin-5-yl)-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyridin-4-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-[2-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-pyridin-4-yl]-(4-isopropyl-phenyl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4'-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(2-morpholin-4-yl-pyridin-4-yl)-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(2-ethyl-pyridin-4-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[2-(tetrahydro-piperan-4-ylmethoxy)-pyridin-4-yl]-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[2-(2-methoxy-ethoxy)-pyridin-4-yl]-methanol; (S)-(2-cyclopentylpyridin-4-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((R)-3-hydroxymethyl-3-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((S)-3-fluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[4-(tetrahydro-piperan-4-yl)-[1,2,3]triazol-1-yl]pyridin-3-yl}-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(5-isopropenyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (5-Cyclopropyl-pyridin-3-yl)-(1,3-Dimethyl-azacyclobutane-3-yl)-(4-Isopropyl-phenyl)-methanol; (5-Cyclopent-1-enylpyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopent-2-enol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-isopropyl-pyridin-3-yl)-methanol; (5-Cyclopentylpyridin-3-yl)-(1,3-Dimethyl-azacyclobutane-3-yl)-(4-Isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopentanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-pyridin-3-yl-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopent-2-enone; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclopent-2-enol; (3S)-3-(5-((R)-(1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol; (3R)-3-(5-((R)-(1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-ethyl-cyclopentanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-isopropyl-cyclopentanol [;] [ ] (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-azol-2-yl)pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-ethyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (R)-[5-(4,5-dihydro-furan-3-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-3-yl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-en-1-ol; N-Cyclopentyl-5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-nicotinamide; {5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-1-yl-methyl ketone; 5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-N-(tetrahydro-piperan-4-yl)-nicotinamide; (1,3-Dimethyl-azacyclobutane-3-yl)-[4-(3-methoxy-propyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(4-Cyclopropyl-phenyl)-(1,3-Dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-p-tolyl-methanol; 5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridine-1'-carboxylic acid tertiary butyl ester; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone-1-carboxylic acid tert-butyl ester; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-piperan-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(3',4',5',6'-tetrahydro-2'H-[2,1';4',3'']terpyridin-5''-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(1'-phenyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridin-5-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[1'-(toluene-4-sulfonyl)-1',2',3',4',5',6'-hexahydro-[3,4']bipyridin-5-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(5,5-dimethyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-difluoro-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-azol-2-yl)pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-yl)-azol-2-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(4-fluoro-phenoxymethyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl methyl ester of isopropyl-carbamic acid; (R)-[5-(2-benzylmethyloxy-ethyl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclohexanol; 2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopropyl)-prop-2-ol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{2-[5-(tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-3-yl]pyridin-4-yl}-methanol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyrimidin-5-yl)-methanol; and (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidin-1-yl-pyrrolidin-2-yl)-methanol. 34) Another embodiment relates to the compound according to Example 1), which is selected from the group consisting of: (R)-N-(1-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)cyclopropyl)acetamide-2,2,2-d3; (R)-N-(1-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)cyclopropyl)-N-methylacetamide-d3; (R)-N-((3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)methyl)-N-methylacetamide-d3; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-2-hydroxyacetamide; (R)-N-((3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)methyl)acetamide-2,2,2-d3; 1-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-2-methyl-prop-2-ol; 1-(3-{5-[(R)-(1-ethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-2-methyl-prop-2-ol; 2-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1-ethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)piperidine-1-carboxylic acid methyl ester; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-yl)-piperidin-1-yl]-acetone; (R)-1-(3-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)azacyclobutane-1-yl)aceto-1-one-2,2,2-d3; (R)-1-(3-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)-3-methylazacyclobutane-1-yl)aceto-1-one-2,2,2-d3; (R)-1-(3-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)-3-fluoroazacyclobutane-1-yl)ethyl-1-one-2,2,2-d3; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methyl-1-morpholin-4-yl-ethyl)-[1,2,4]isodiazol-3-yl]pyridin-3-yl}-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-methyl-piperidin-2-one; 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-pyrrolidin-1-yl]-acetone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-pyrrolidin-1-yl]-acetone; N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-methyl-ethyl]acetamide; 1-Benzyl-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-pyrrolidone; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,3-dimethyl-pyrrolidone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-isobutyl-pyrrolidone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-furan-2-ylmethyl-pyrrolidone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-phenyl-pyrrolidone; 1-Benzyl-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-pyrrolidone; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-phenyl-pyrrolidone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-pyrrolidone; (S)-5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-pyrrolidin-2-one; (R)-5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-pyrrolidone; (S)-6-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azadiazol-5-yl)azacyclobutane-2-one; (S)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-azacyclobutane-2-one; (S)-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R) or (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-piperidin-4-yl-[1,2,4]azadiazol-3-yl)pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-piperidin-4-yl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-(4-fluoro-piperidin-4-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-but-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-2,2-dimethyl-prop-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-2-methoxy-ethyl ketone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-3-methoxy-prop-1-one; Cyclopropyl-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-methyl ketone; Cyclopentyl-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-methyl ketone; [4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-(tetrahydro-piperan-4-yl)-methyl ketone; [4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-phenyl-methyl ketone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidine-1-carboxylic acid methyl ester; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidine-1-carboxylic acid ethyl ester; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-carboxylic acid 2-methoxy-ethyl ester; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-2-sulfonyl)-piperidin-4-yl]-[1,2,4]diazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-1-sulfonyl)piperidin-4-yl]-[1,2,4]diazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-[1,2,4]diazol-3-yl}-pyridin-3-yl)-methanol; 2-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidine-1-sulfonylurea]-ethanol; (R)-{5-[5-(1-cyclopentanesulfonyl-piperidin-4-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-piperan-4-sulfonyl)-piperidin-4-yl]-[1,2,4]-diazol-3-yl}-pyridin-3-yl)-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidine-1-sulfonic acid methylamide; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methylamino-cyclopropyl)-[1,2,4]azolo-3-yl]pyridin-3-yl}-methanol; [1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)cyclopropyl]-methyl-aminocarbamate; N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)cyclopropyl]-N-methyl-methanesulfonamide; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[6-(2,2-dimethyl-cyclopentyloxy)-tazo-4-yl]-(4-isopropyl-phenyl)-methanol; (R)-[6-(3,3-difluoro-cyclopentyloxy)-tazo-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yloxy}-phenyl)-ethanol; 2-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yloxy}-phenyl)-ethanol; (R)-[6-(alkyl-6-yloxy)-tazo-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 6-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yloxy}-3H-benzoxazol-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pent-1-yn-3-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[1-(4-fluoro-phenyl)-cyclopropylethynyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-pyrrolidone-1-carboxylic acid tertiary butyl ester; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidine-1-carboxylic acid tert-butyl ester; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pentan-3-ol; 2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-benzoate; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[2-(2-hydroxymethyl-phenyl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-2-ol; 3-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-pyrrolidone-1-carboxylic acid tert-butyl ester; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[2-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-pyridin-3-yl}-methanol; 4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidin-1-carboxylic acid tert-butyl ester; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyridin-2-yl-but-2-ol; 1-Cyclopropyl-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-pyridin-2-yl-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridin-3-yl)-but-2-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinoline-8-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-2-(6-methyl-pyridin-2-yl)-but-2-ol; (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidin-1-yl-pyridin-2-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-fluoro-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-methyl-piperidin-1-yl]-acetone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclohexanol; (R)-(5-cyclopentyloxymethylpyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylmethoxy}-piperidin-1-yl)-acetone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[6-(tetrahydro-piperan-4-yl)-tazo-4-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-2-phenyl-but-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{6-[(S)-(tetrahydro-furan-3-yl)oxy]-tadala-4-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{6-[(R)-(tetrahydro-furan-3-yl)oxy]-tazo-4-yl}-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-4-methyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-3-isopropyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-3,3-dimethyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-4,4-dimethyl-pyrrolidone; 5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-5-aza-spiro[2,4]heptane-6-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-4-trifluoromethyl-pyrrolidone; 4-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-pyrrolidone; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-8-oxa-2-aza-spiro[4.5]dec-3-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-1-oxa-3-aza-spiro[4.5]dec-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-4-pyridin-2-yl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-3-(2-methoxy-ethyl)-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-4-phenyl-pyrrolidone; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-2,3-dihydro-isoindol-1-one; 2-(3-{5-[(S)-(3-fluoro-1-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(S)-(3-fluoro-1-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 2-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; (R)-(1-Cyclopropyl-3-methyl-azacyclobutane-3-yl)-(4-Isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-yl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-methanol; trans-4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclohexanol; (R)-(1-Cyclopropyl-3-methyl-azacyclobutane-3-yl)-(4-Isopropyl-phenyl)-[5-(5-oxacyclobutane-3-yl-[1,2,4]oxadiazol-3-yl)pyridin-3-yl]-methanol; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyrrolidin-1-yl]-acetone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-3-hydroxy-piperidin-1-yl]-acetone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-3-methyl-piperidin-1-yl]-acetone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-4-hydroxy-piperidin-1-yl]-acetone; N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)cyclopropyl]-acetamide; Tetrahydro-piperan-4-carboxylic acid [1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-cyclopropyl]-acetamide; N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)cyclopropyl]-2-methoxy-acetamide; N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)cyclopropyl]-N-methylacetamide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,1-dimethyl-ethyl]-propionic acid; N-[2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,1-dimethyl-ethyl]-2-methoxy-acetamide; Tetrahydro-piperan-4-carboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1,1-dimethyl-ethyl]-acetylamine; N-[2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,1-dimethyl-ethyl]-isobutylamine; Cyclopropanecarboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1,1-dimethyl-ethyl]-acetylamine; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-2-methyl-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-hydroxy-piperidin-1-yl]-2-methyl-prop-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-hydroxy-piperidin-1-yl]-prop-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-methoxy-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-3,3,3-trifluoro-prop-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-2-oxecyclobutane-3-yl-ethyl ketone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-ethyl-piperidin-1-yl]-acetone; [4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]oxacyclobutane-3-yl-methyl ketone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-isopropyl-piperidin-1-yl]-2-methoxy-ethyl ketone; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-3-methyl-piperidin-1-yl]-acetone; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-5-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-methyl-pyrrolidone; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-3,3-dimethyl-pyrrolidone-2,5-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-imidazolidine-2,4-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-pyrrolidone; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-1-methyl-imidazolidine-2,4-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-3-methyl-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-azolidine-2-one; 1-Cyclopropyl-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyrrolidone-2,5-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-3-methyl-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-ylmethyl)-imidazolidine-2-one; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-1,2-diol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-pyridin-3-yl-[1,2,4]azadiazol-3-yl)pyridin-3-yl]-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)piperidin-1-yl]-acetone; (3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)acetonitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-4-hydroxy-piperidin-1-yl]-acetone; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)propionitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-3-methoxy-piperidin-1-yl]-acetone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-tetrahydro-piperan-4-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-(3-hydroxymethyl-bicyclo[1.1.1]pent-1-yl)-[1,2,4]adiazol-3-yl]pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-methyl-piperidin-2,6-dione; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-2,2-difluoroethanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(3-methoxy-phenyl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(5-isopropyl-[1,2,4]azadiazol-3-yl)pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-methyl-pyrimidin-4-yl)-[1,2,4]pyridazol-3-yl]pyridin-3-yl}-methanol; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-methyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-methyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-ethyl-pyrrolidone; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-ethyl-pyrrolidone; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-ethyl-pyrrolidone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-ethyl-pyrrolidone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-isopropyl-pyrrolidone; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-isopropyl-pyrrolidone; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-isopropyl-pyrrolidone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1-isopropyl-pyrrolidone; 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyrrolidin-1-yl]-acetone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-2-one; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-[1,2,4]azadiazol-3-yl)pyridin-3-yl]-methanol; (R)-{5-[5-(1,1-difluoro-ethyl)-[1,2,4]diazol-3-yl]pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)-tetrahydro-piperan-4-ol; (R)-[5-(3-tert-butoxymethyl-[1,2,4]-diazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(3-hydroxymethyl-[1,2,4]azadiazol-5-yl)pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)piperazine-1-yl]-acetone; 1-[3-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azadiazol-3-ylmethyl)azacyclobutane-1-yl]-acetone; 4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-ylmethyl)-tetrahydro-piperan-4-ol; [4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)piperidin-1-yl]-[1,4]diazin-2-yl-methyl ketone; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-3-yl)piperidin-1-yl]-2-methoxy-ethyl ketone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]diazol-5-yl]pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{3-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-[1,2,4]diazol-5-yl}-pyridin-3-yl)-methanol; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-yl)-piperidin-1-yl]-2-hydroxy-acetone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-[1,2,4]-diazol-3-yl-pyridin-3-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 2-(3-{5-[(R)-(4-bromo-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-naphth-2-yl-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]isodiazol-5-yl]-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]isodiazol-5-yl]-prop-2-ol; (R)-2-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-(pentafluoro-λ6-thioalkyl)phenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-benzo[b]thiophene-5-yl-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-pentafluoroethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-3-methyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(R)-(4-bromo-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-fluoro-1-methyl-ethyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]-prop-2-ol; 2-(3-{5-[(R)-[4-(1,1-difluoro-ethyl)-phenyl]-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-bicyclo[1.1.1]pent-1-yl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-(tetrahydro-piperan-4-yl)-[1,2,4]azadiazol-3-yl]pyridin-3-yl}-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methanol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1,1-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-prop-2-ol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]piperidin-1-yl}-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 2-(3-{5-[(R)-(3-chloro-4-isopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-cyclobutyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 2-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 2-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]-prop-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-piperidin-1-yl}-acetone; 2-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]-prop-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]piperidin-1-yl}-acetone; 1-{4-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]piperidin-1-yl}-acetone; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]isodiazol-5-yl]-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isobutyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropenyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]piperidin-1-yl}-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azacyclobutane-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1-cyclopropylmethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[1-(2-methoxy-ethyl)-3-methyl-azacyclobutane-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]piperidin-1-yl}-acetone; 1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[3-methyl-1-(3,3,3-trifluoro-propyl)-azacyclobutane-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]diazol-5-yl]piperidin-1-yl}-acetone; 1-[4-(3-{5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-methyl-1-propyl-azacyclobutane-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1-ethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidin-1-yl)-acetone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-but-3-yn-2-ol; Cyclopropanecarboxylic acid (3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetylamine; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-isobutylamine; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-2-methoxy-acetylamine; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-azolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidone; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-3-methyl-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-imidazolidine-2-one; 3-(1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropyl)-azolidin-2-one; 1-((R)-2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-2-methyl-pyrrolidin-1-yl)-acetone; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-hydroxy-piperidin-1-yl)-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-1-methyl-prop-2-ynyl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-2-ynyl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl)-4-methyl-piperidin-1-yl]-acetone; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidin-1-yl)-acetone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(1-methanesulfonyl-piperidin-4-ylethynyl)pyridin-3-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidine-1-sulfonic acid methylamide; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-methanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonic acid dimethylamine; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonate amide; (R)-[5-(3-cyclopropanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; (S)-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3,4-dihydro-2H-piperano[3,2-b]pyridin-4-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-1,3-dihydro-indole-2-one; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-indazol-3-yl)-but-3-yn-2-ol; 2-(1-Cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridine-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazo-5-yl)-but-3-yn-2-ol; 2-(6-Cyclopropyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetylamine; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-(S)-2-(2,6-dimethoxypyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-2-(2,6-dimethoxypyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-2-(2,6-dimethoxypyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 2-(6-Difluoromethyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(1-pyridin-2-yl-cyclopropylethynyl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[1-(6-methyl-pyrimidin-4-yl)-cyclopropylethynyl]-pyridin-3-yl}-methanol; 1-[4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)piperidin-1-yl]-acetone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-but-2-ol; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-azolidin-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-pyrrolidone-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-3-methyl-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-imidazolidine-2-one; 1-[(S)-2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-2-methyl-pyrrolidin-1-yl]-acetone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-2-ol; 2-(1-Cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridine-2-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazolyl-5-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-methyl-isoazol-5-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-imidazol-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-thiophen-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrrolo-2-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-(R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(3-ethyl-1-methyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(S)-(3-fluoro-1-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-ylethynyl}-piperidin-1-yl)-acetone; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetylamine; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidone; 4-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azacyclobutane-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxymethyl}-piperidin-1-yl)-acetone; 4-{5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-thiazolyl-5-yl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-methyl-pyridin-3-yl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-trifluoromethyl-pyridin-3-yl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1-methyl-1H-pyrazol-4-yl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1,3-dimethyl-1H-pyrazol-4-yl)-pyrrolidone-2-one; 4-(1-Difluoromethyl-1H-pyrazol-4-yl)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrrolidone; 4-(1-acetylopirin-4-yl)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidone-3-yl}-pyrrolidone; 5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-hexahydro-furano[2,3-c]pyrrole-4-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidone; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-acetone; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-[1,6]pyridin-6-yl)-acetone; 1-[4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-5-yl)-piperidin-1-yl]-acetone; and 1-[4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-4-yl)-piperidin-1-yl]-acetone.

[0104] 35) Another embodiment relates to the compound according to Example 1), which is selected from the group consisting of: (R)-2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-1,1,1-trifluoro-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 2-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; and 2-(3-{5-[(R)-(4-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol.

[0105] 36) Another embodiment relates to the compound according to Example 1), which is selected from the group consisting of: 4-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azacyclobutane-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; and 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol.

[0106] 37) Another embodiment relates to the compound according to Example 1), which is selected from the group consisting of: 1-[4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-acetone; and 1-[4-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-piperidin-1-yl]-acetone.

[0107] 38) Another aspect of the present invention relates to the compound of Example 1), which is also a compound of formula (Ip), wherein Formula (Ip) [A] indicates the presence of one to three cyclic nitrogen atoms (especially one or two cyclic nitrogen atoms; especially one or two cyclic nitrogen atoms relative to the content of the three cyclic nitrogen atoms). [A] Attachment point to the rest of the molecule [A] 6-membered heteroaryl group (between and / or para position), wherein the 6-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted or trisubstituted (especially relative to the position of para position). [A] The attachment point with the rest of the molecule, in [A] with mono- or di-substituted positions (between and / or para-substituents), wherein the substituents, if present, are independently selected from... Ø Halogens (especially fluorine); Ø Cyano group; Ø C1-4 alkyl groups (especially methyl, ethyl, propyl, or isopropyl; especially methyl, ethyl, or propyl), which are unsubstituted or monosubstituted with the following groups: • C1-3 alkoxy groups (especially methoxy groups); • Fluoro-phenoxy groups (especially 4-fluoro-phenoxy groups); • Benzyl-oxy; • A C3-6 cycloalkyl group fused to a pyridine ring (particularly at the 2 and 3 positions adjacent to the nitrogen atom of the pyridine ring), wherein the C3-6 cycloalkyl group is unsubstituted or monosubstituted with a hydroxyl group (particularly at the junction of the C3-6 cycloalkyl group and the C1-4 alkyl group); • Unsubstituted or monosubstituted pyrazolyl groups (especially pyrazol-4-yl) with C1-3 alkyl groups (especially methyl groups); • Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl), which is unsubstituted or monosubstituted with a hydroxyl group (especially 4-hydroxy-tetrahydropiperanyl-4-yl); • Indole (especially indole-2-yl); • N-(C1-3 alkyl)-amino-carbonyl-oxy; or • 1-(C1-4 alkyl-oxy-carbonyl)-3-hydroxyazacyclobutane-3-yl; In detail, such C1-4 alkyl groups, whether unsubstituted or monosubstituted as defined above, are methyl, ethyl, isopropyl, 2-(1-hydroxy-cyclopropyl)-ethyl, 2-(1-hydroxy-cyclobutyl)-ethyl, 2-(1-hydroxy-cyclopentyl)-ethyl, 3-methoxy-propyl, 4-fluoro-phenoxy-methyl, benzyl-oxy-methyl, N-(isopropyl)-amino-carbonyl-oxy-methyl, 2-(1-(terbutoxy-carbonyl) -3-hydroxyazacyclobutane-3-yl)-ethyl, 2-(1-methyl-pyrazole-4-yl)-ethyl, 2-(tetrahydropiperan-4-yl)-ethyl, 2-(4-hydroxy-tetrahydropiperan-4-yl)-ethyl, 2-(indol-2-yl)-ethyl, 2-(8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl)-ethyl or 2-(7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl)-ethyl] Ø C3-5 alkenyl, which is unsubstituted (especially isopropenyl) or monosubstituted with a hydroxyl group (especially 4-hydroxy-but-1-en-2-yl); Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl); Ø Hydroxyl-C1-6 alkyl, which may be further substituted with one or more fluorine atoms (especially 3-hydroxy-propyl, 4-hydroxy-butyl, 3-hydroxy-butyl, 3-hydroxy-3-methyl-butyl, 3-hydroxy-4-methyl-pentyl or 2,2-difluoro-3-hydroxy-propyl-1-yl); Ø C3-5 alkyl groups (especially n-propyl, n-butyl, or n-pentyl), which are derived from hydroxyl groups and [R, A1 Substitution (especially the two substituents being at the 3-position relative to the attachment site of the C3-5 alkyl group to the rest of the molecule), wherein · [R, A1 , ]express ▪ Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl); ▪ Phenyl, which is unsubstituted or monosubstituted with fluorine (especially 3-fluoro-phenyl) or C1-3 alkoxy (especially 2-methoxy-phenyl or 4-methoxy-phenyl); or ▪ Contains one or two 5- or 6-membered heteroaryl groups (especially thiazolyl, pyrazolyl, pyridinyl, or pyrimidinyl; especially thiazolyl-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl) independently selected from nitrogen or sulfur ring heteroatoms, wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, or disubstituted, and wherein the substituent(e) is, if present, independently selected from C1-3 alkyl (especially methyl) or C1-3 alkoxy (especially methoxy); In detail, as defined above, such substituted C3-5 alkyl groups are 3-hydroxy-3-(tetrahydropiperan-4-yl)-propyl, 3-hydroxy-3-phenyl-propyl, 3-hydroxy-3-phenyl-butyl, 3-hydroxy-3-(m-fluoro-phenyl)-butyl, 3-hydroxy-3-(o-methoxy-phenyl)-butyl, 3-hydroxy-3-(p-methoxy-phenyl)-butyl, 3-hydroxy-3-(1,5-dimethyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1-methyl-pyrazol-3-yl)-butyl, 3-hydroxy-3-(1,5-dimethyl- Pyrazol-3-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazolyl-4-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-butyl, 3-hydroxy-3-(pyrimidin-2-yl)-butyl, 3-hydroxy-3-(6-methoxy-pyrimidin-4-yl)-butyl, 3-hydroxy-3-(1,3-dimethyl-pyrazol-4-yl)-propyl, 3-hydroxy-3-(2-methyl-thiazolyl-4-yl)-propyl, 3-hydroxy-3-(pyridin-2-yl)-pentyl or 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pentyl Ø Unsubstituted, C3-6 cycloalkyl groups monosubstituted or disubstituted with C1-3 alkyl (especially methyl, ethyl, isopropyl), hydroxyl or hydroxy-C1-3 alkyl (especially 1-hydroxy-1-methyl-ethyl), wherein, where appropriate, one ring carbon atom of the C3-6 cycloalkyl group is substituted with an oxygen atom; [In detail, as defined above, such C3-6 cycloalkyl groups, whether unsubstituted, monosubstituted, or disubstituted, are cyclopropyl, cyclopentyl, 3-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 3-hydroxy-3-ethyl-cyclopentyl, 3-hydroxy-3-isopropyl-cyclopentyl, 2-(2-hydroxy-isopropyl)-cyclopropyl, 4-hydroxy-4-methyl-cyclohexyl, tetrahydrofuran-3-yl, tetrahydrofuran-2-yl, tetrahydropiperan-4-yl, 5-methyl-tetrahydrofuran-2-yl, or 5,5-dimethyl-tetrahydrofuran-2-yl] Ø Unsubstituted, C4-6 cycloalkenyl groups (especially cyclopentenyl; particularly cyclopent-1-en-1-yl) monosubstituted or disubstituted with C1-3 alkyl, side-oxygen (i.e., =O) or hydroxyl groups, wherein, where appropriate, one of the ring carbon atoms of the C4-6 cycloalkenyl group is replaced by an oxygen atom; [In detail, as defined above, such C4-6 cycloalkenyl groups, whether unsubstituted, monosubstituted, or disubstituted, are 3-sideoxy-cyclopent-1-en-1-yl, 3-hydroxy-3-methyl-cyclopent-1-en-1-yl, 2,3-dihydro-furan-3-yl, or 5-methyl-furan-2-yl.] Ø -O- [R, O , ],in · [R, O , ]express ▪ C1-4 alkyl groups (especially methyl, ethyl, isopropyl, dibutyl, or isobutyl); ▪ Hydroxy-C1-5 alkyl (especially 2-hydroxy-ethyl, 3-hydroxy-propyl, 2-hydroxy-2-methyl-propyl, or 3-hydroxy-3-methyl-butyl); ▪ C1-3 alkoxy-C2-3 alkyl (especially 2-methoxy-ethyl); ▪ Unsubstituted, C3-6 cycloalkyl groups (especially cyclopentyl or cyclohexyl) monosubstituted or disubstituted with C1-3 alkyl (especially methyl), hydroxyl or C1-3 alkoxy (especially methoxy); ▪ Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl); ▪ Tetrahydropiperanyl-C1-3 alkyl (especially tetrahydropiperanyl-4-yl-methyl); ▪ Oxycyclic butyl-C1-3 alkyl (especially oxycyclic butane-3-yl-methyl); ▪ Phenyl; ▪ Benzyl; ▪ Benzyl-oxy-C1-3 alkyl (especially 2-(benzyl-oxy)-ethyl); ▪ Pyridyl-C1-3 alkyl (especially 2-(pyridin-2-yl)-ethyl); ▪ (3-Cyclopropyl-1,2,4-Diazol-5-yl)-methyl; or ▪ 2-(3,5-Dimethyl-1,2,4-triazol-1-yl)-ethyl; [To elaborate, this type of -O-] [R, O ] represents methoxy, ethoxy, isopropoxy, isobutoxy, dibutoxy, phenoxy, benzyloxy, 2-(benzyloxy)-ethoxy, 2-methoxy-ethoxy, oxadiazon-3-yl-methoxy, 3-hydroxy-propoxy, cyclohexyl-oxy, 4-hydroxy-cyclohexyl-oxy, 4-methyl-4-hydroxy-cyclohexyl-oxy, 2-hydroxy-2-methyl-propoxy, 2-hydroxy-ethoxy, 3-hydroxy-3-methyl-butoxy, tetrahydropiperan-4-yl-oxy, tetrahydropiperan-4-yl-methoxy, 3-methoxy-cyclopentyl-oxy, (3-cyclopropyl-1,2,4-diazol-5-yl)-methoxy, or 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-ethoxy. Ø -C≡C- [R, T1 , ],in Ø [R, T1 , ]express ▪ Hydroxyl-C1-4 alkyl (especially hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl-propyl or 1-hydroxy-1-methyl-ethyl); ▪ C1-3 alkoxy-C1-3 alkyl (especially methoxy-methyl); ▪ C3-6 cycloalkyl groups monosubstituted with hydroxyl groups (especially at the attachment point between the C3-6 cycloalkyl group and the rest of the molecule; particularly 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, or 1-hydroxy-cyclopentyl); ▪ A C3-6 cycloalkyl group (particularly cyclopentyl or cyclohexyl) fused with a pyridine ring (especially at the 2 and 3 positions of the pyridine ring), wherein the C3-6 cycloalkyl group is monosubstituted with a hydroxyl group (particularly at the 1 position of the C3-6 cycloalkyl ring) (particularly 8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl or 7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl); ▪ Pyrazolyl (especially pyrazol-4-yl, which is monosubstituted with a methyl group (especially 1-methyl-pyrazol-4-yl); ▪ Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl), which is unsubstituted or monosubstituted with a hydroxyl group (especially 4-hydroxy-tetrahydropiperanyl-4-yl); ▪ Indole (especially indole-2-yl); or ▪ Hydroxy-azacyclobutane (especially 3-hydroxy-azacyclobutane-3-yl) with a C1-4 alkoxy-carbonyl substitution at N (especially isopropyl-carbonyl or terbutoxy-carbonyl); [To elaborate, this type of -C≡C-] [R, T1 ] represents 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, 3-methoxy-prop-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl (7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl)-ethynyl, (1-methyl-pyrazol-4-yl)-ethynyl, (tetrahydropiperan-4-yl)-ethynyl, (4-hydroxy-tetrahydropiperan-4-yl)-ethynyl, indole-2-yl-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azacyclobutane-3-yl)-ethynyl or (1-(tert-butoxy-carbonyl)-3-hydroxy-azacyclobutane-3-yl)-ethynyl] Ø -C≡CC(OH)( [R, T2 , ])( [R, T3 , ]),in Ø [R, T2 , ] indicates hydrogen or C1-3 alkyl (especially methyl or ethyl); Ø [R, T3 , ]express ▪ Unsubstituted or monosubstituted phenyl groups, wherein the substituent(s), if present, is independently selected from C1-3 alkoxy groups (especially methoxy groups) or halogens (especially fluorine groups); [In detail, such unsubstituted or monosubstituted phenyl groups are 3-fluorophenyl, 4-methoxyphenyl, or 2-methoxyphenyl.] ▪ Contains one or two 5- to 6-membered heteroaryl groups (especially thiazolyl, pyrazolyl, pyridinyl, or pyrimidinyl; especially thiazolyl-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl) independently selected from nitrogen or sulfur ring heteroatoms, wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, or disubstituted, and wherein the substituent(e) is, if present, independently selected from C1-3 alkyl (especially methyl) and C1-3 alkoxy (especially methoxy); or [In detail, these 5 to 6-membered heteroaryl groups are 1-methyl-pyrazole-3-yl, 1,3-dimethyl-pyrazole-4-yl, 1,5-dimethyl-pyrazole-3-yl, 2-methyl-thiazolyl-4-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, or 1,5-dimethyl-pyrazole-3-yl] ▪ Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl); [To elaborate, this type of -C≡CC(OH)( [R, T2 , ])( [R, T3 , ]) is 3-hydroxy-3-(tetrahydropiperan-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazo-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(1,3-dimethyl-pyrazole-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1,5-dimethyl-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyrimidin-2-yl) 3-hydroxy-3-(1-methylpyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(3-fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methylpyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl Ø -N [R, N1 , R, N2, ],in ˙ [R, N1 , ] indicates C1-3 alkyl groups (especially methyl groups); ˙ [R, N2 , ] indicates hydroxy-C1-3 alkyl (especially 2-hydroxy-ethyl) or 2-(benzylmethyl-oxy)-C1-3 alkyl (especially 2-(benzylmethyl-oxy)-ethyl); or [R, N1 , ]and [R, N2 Together with the nitrogen atom attached to it, it forms a 4- to 6-membered (especially 5- to 6-membered) heterocycle, wherein the members required for the integrity of the heterocycle are each independently selected from -CH2-, -O-, -(C=O)-, -CH [R, X , ]- and -C( [R, Y , ])2-; wherein the heterocycle does not contain more than one member of the group consisting of -O- and -(C=O)- independently selected; wherein the heterocycle does not contain more than two members of the group consisting of -CH [R, X , ]- members of a group; and wherein the heterocycle does not contain more than two choices -C( [R, Y , ])2- The members of the group; among which [R, X , ] independently represent fluorine, methyl, isopropyl, isobutyl, tributyl, hydroxy, trifluoromethyl, hydroxy-methyl, 1-hydroxy-ethyl, 1-hydroxy-1-methyl-ethyl, cyclopropyl, 2-methoxy-ethyl, 4-methyl-thiazolyl-2-yl, phenyl, benzyl, tetrahydropiperan-4-yl, 1,2,4-diazolyl, 3-methyl-1,2,4-diazol-5-yl, pyridin-2-yl, or 1-methoxy-methyl; and wherein [R, Y , ] independently represent fluorine, hydroxyl, cyclopropyl, methyl, hydroxy-methyl or trifluoromethyl [especially such -N] [R, N1 , R, N2 , ] represents pyrrolidyl; 2-pyrrolidone; acezolidinone (especially 1,3-acezolidin-2-one-3-yl); piperidinyl; or morpholinyl, which, depending on the case, are independently selected by one or two independent groups. [R, X , ]and [R, YSubstituents of the group consisting of , ]; [In detail, this type of -N] [R, N1 , R, N2 ] represents pyrrolidin-1-yl, 3-fluoro-pyrrolidin-1-yl, 3,3-difluoro-pyrrolidin-1-yl, 3,4-difluoro-pyrrolidin-1-yl, 3-isopropyl-pyrrolidin-1-yl, 3,3-dimethyl-pyrrolidin-1-yl, 3-hydroxy-pyrrolidin-1-yl, 2-methyl-pyrrolidin-1-yl, 3-hydroxy-3-methyl-pyrrolidin-1-yl, 3-(hydroxy-methyl)-pyrrolidin-1-yl, 2-(hydroxy-methyl)-pyrrolidin-1-yl, 3-hydroxy-3-cyclopropyl-pyrrolidin-1-yl, 3-hydroxy-3-trifluoromethyl-pyrrolidin-1-yl, 3-trifluoromethyl 3-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl, 3-(1-hydroxy-ethyl)-pyrrolidin-1-yl, 3-(hydroxy-methyl)-3-methyl-pyrrolidin-1-yl, 1,3-acezolin-2-one-3-yl, 5-(tert-butyl)-1,3-acezolin-2-one-3-yl, 5-phenyl-1,3-acezolin-2-one-3-yl, 5-benzyl-1,3-acezolin-2-one-3-yl, 5-isopropyl-1,3-acezolin-2-one-3-yl, 5-(tetrahydropiperan-4-yl)-1,3-acezolin-2-one-3-yl, 5,5-dimethyl-1,3-acezolin Pyridine-2-one-3-yl, Morpholin-4-yl, Piperidin-1-yl, 4-Hydroxy-piperidin-1-yl, 3-Hydroxy-piperidin-1-yl, 3-(Tetrahydropiperan-4-yl)-pyrrolidin-2-one-1-yl, N-Methyl-N-(2-(benzyl-oxy)-ethyl)-amino, N-Methyl-N-(2-hydroxy-ethyl)-amino, Pyrrolidin-2-one-1-yl, 4-Phenyrrolidin-2-one-1-yl, 4-Isopropyl-pyrrolidin-2-one-1-yl, 3-Isopropyl-pyrrolidin-2-one-1-yl, 4,4-Dimethyl-pyrrolidin-2-one-1-yl, 3-(piperidin-4-yl)-pyrrolidin-2-one-1-yl 4-Isobutyl-pyrrolidin-2-one-1-yl, 4-cyclopropyl-pyrrolidin-2-one-1-yl, 4-trifluoromethyl-pyrrolidin-2-one-1-yl, 3-(2-methoxy-ethyl)-pyrrolidin-2-one-1-yl, 4-(2-methoxy-ethyl)-pyrrolidin-2-one-1-yl, 2,2,6,6-tetrafluoro-morpholin-4-yl, 2,6-dimethyl-morpholin-4-yl, 2-(methoxy-methyl)-morpholin-4-yl, 3-(3-methyl-1,2,4-diazol-5-yl)-pyrrolidin-1-yl, 3-(4-methyl-thiazolyl)-pyrrolidin-1-yl or 3-(phenyl)-pyrrolidin-1-yl Ø -(C=O)-N( [R, N3 , ])( [R, N4 , ]),in ˙ [R, N3 , ] represents hydrogen; and [R, N4 , ] indicates C3-6 cycloalkyl (especially cyclopentyl) or tetrahydropiperanyl (especially tetrahydropiperan-4-yl); or ˙ [R, N3 , ]and [R, N4 , ] together with the nitrogen attached to it, form a pyrrolidin group; In detail, this type of -(C=O)-N( [R, N3 , ])( [R, N4 , ]) is N-cyclopentyl-amino-carbonyl, N-(tetrahydropiperan-4-yl)-amino-carbonyl or pyrrolidinyl-carbonyl] Ø Piperidin-4-yl or pyrrolidin-3-yl, independently monosubstituted at a nitrogen ring atom, wherein the substituent is selected from C1-4 alkoxy-carbonyl (especially tert-butoxy-carbonyl), pyridyl (especially pyridin-2-yl), phenyl, and (4-methylphenyl)-sulfonyl; [In detail, these piperidine-4-yl or pyrrolidine-3-yl groups are N-(tert-butoxy-carbonyl)-piperidine-4-yl, N-(tert-butoxy-carbonyl)-pyrrolidine-3-yl, N-(pyridin-2-yl)-piperidine-4-yl, N-(phenyl)-piperidine-4-yl, or N-((4-methylphenyl)-sulfonylurea)-piperidine-4-yl] Ø Contains one to three (especially two or three; especially three) 5-membered heteroaryl groups independently selected from nitrogen, oxygen and sulfur cyclic heteroatoms (especially pyrazolyl, triazolyl, acezolyl, thiazolyl, acediazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, acezol-2-yl, thiazol-2-yl, 1,2,4-acediazol-5-yl or 1,2,4-acediazol-3-yl); wherein the 5-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted or trisubstituted (especially monosubstituted; especially relative to the 5-membered heteroaryl group and the [A] is attached at position 3 (monosubstituted), where the substituent (etc.) is independently selected if present. Ø Unsubstituted or monosubstituted C1-4 alkyl groups with hydroxyl or C1-4 alkoxy groups (especially methoxy and tert-butoxy groups); [In detail, such C1-4 alkyl groups, whether unsubstituted or monosubstituted as defined above, are methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, or tert-butoxy-methyl; preferably, such C1-4 alkyl groups are 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1,1-dimethyl-ethyl.] Ø Amino-C1-4 alkyl (especially 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), wherein the amino group is monosubstituted or disubstituted (especially monosubstituted) with a C1-3 alkyl (especially methyl), a C1-3 alkyl-carbonyl (including deuterated C1-3 alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3) or a hydroxy-C1-3 alkyl-carbonyl (especially hydroxy-methyl-carbonyl); [In detail, these amino-C1-4 alkyl groups are N-acetylated-2-amino-ethyl, N-(acetylated-2,2,2-d3)-2-amino-ethyl, N-acetylated-2-amino-2,2-dimethyl-ethyl, N-(acetylated-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetylated-2-amino-ethyl, or N-methyl-N-(acetylated-2,2,2-d3)-2-amino-ethyl] Ø C3-6 cycloalkyl- [L, 2 , ]-,in ▪ - [L, 2 , ]- indicates a single bond (i.e., the C3-6 cycloalkyl group is directly attached to the rest of the molecule), oxygen, C1-3 alkyl group (especially -CH2-, -CH2-CH2- or -C(CH3)2-), hydroxy-C1-2 alkyl group (especially -CH(OH)-) or oxy-C1-2 alkyl group (especially -O-CH2-) (where the C3-6 cycloalkyl group is attached to the oxygen atom of the oxy-C1-2 alkyl group); ▪ C3-6 cycloalkyl unsubstituted, fluorinated, C1-3 alkyl (especially methyl), C1-3 alkoxy (especially methoxy), hydroxyl, hydroxy-C1-3 alkyl or C1-3 alkoxy-C1-3 alkyl monosubstituted or disubstituted; wherein, if applicable, one ring carbon atom of the C3-6 cycloalkyl is substituted with an oxygen atom; In detail, this type of C3-6 cycloalkyl- [L, 2 ]- represents oxadiazon-3-yl, cyclobutoxy-methyl, 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 1-hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1-hydroxy-cyclohexyl)-methyl, (1-hydroxy-cyclobutyl)-methyl, 1-hydroxy-1-cyclohexylmethyl, 1-methoxy-cyclobutyl, 1-methoxy-cyclopentyl, 1-(1-(methoxy-methyl)-cyclopropyl)-methyl, tetrahydrofuran-2-yl-methyl Tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropiperan-3-yl, tetrahydropiperan-4-yl, 4-methyl-tetrahydropiperan-4-yl, 2,6-dimethyl-tetrahydropiperan-4-yl, 4-methoxy-tetrahydropiperan-4-yl, 4-fluoro-tetrahydropiperan-4-yl, tetrahydropiperan-4-yl-methyl, 2-(tetrahydropiperan-4-yl)-ethyl, 1-(tetrahydropiperan-4-yl)-1-methyl-ethyl, tetrahydropiperan-4-yl-oxy-methyl or (4-methyl-tetrahydropiperan-4-yl)-oxy-methyl Ø Piperidin-4-yl group substituted with a C1-3 alkyl-carbonyl group (especially acetyl), a (hydroxy-C1-3 alkyl)-carbonyl group (especially hydroxymethyl-carbonyl), or a C3-5 cycloalkyl-sulfonyl group at N; [In detail, this type of piperidine-4-yl is N-acetylopyridine-4-yl, N-(hydroxymethyl-carbonyl)-piperidine-4-yl, or N-(cyclopropyl-sulfonyl)-piperidine-4-yl] Ø Morpholinyl- [L, 3 , ]- (especially (morpholin-4-yl)- [L, 3 , ]-),in- [L, 3 , ]- indicates a single bond (i.e., the morpholino group is directly attached to the rest of the molecule) or a C1-2 alkyl group; wherein the morpholino group is unsubstituted or disubstituted with a methyl group; [In detail, this type of morpholino-] [L, 3 , ]- represents morpholin-4-yl, morpholin-4-yl-methyl, or (2,6-dimethyl-morpholin-4-yl)-methyl] Ø Pyrazolyl-C1-3 alkyl (especially 2-(pyrazol-1-yl)-ethyl); Ø C1-3 alkyl-sulfonyl-C1-3 alkyl (especially methyl-sulfonyl-methyl); Ø 2,2,2-Trifluoro-1-hydroxy-1-methyl-ethyl; Ø 3-Hydroxymethyl-bicyclo[1.1.1]pent-1-yl; Ø 7-oxa-bicyclo[2.2.1]hept-2-yl; and Ø 6-oxa-spiro[2.5]octyl-1-yl; Ø 5-Side-oxy-4-oxa-6-azaspiro[2.4]hept-6-yl, 2,2-dimethyl-6-side-oxy-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-cyclopropyl-6-side-oxy-5-oxa-7-azaspiro[3.4]oct-7-yl, 2-side-oxy-1-oxa-3-azaspiro[4.4]non-3-yl, 8,8-difluoro-2-side-oxy-1-oxa-3-azaspiro[4.5]dec-3-yl or 8-side-oxy-7-oxa-9-azabispiro[3.1.4.1]undecane-9-yl; Ø 7-aza-bicyclo[2.2.1]hept-7-yl, 2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl, 6-oxa-3-aza-bicyclo[3.1.1]hept-3-yl or 8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl; Ø 5-Sideoxy-6-azaspiro[3.4]oct-6-yl, 3-Sideoxy-2-azaspiro[4.4]non-2-yl, 1-Sideoxy-2-azaspiro[4.5]dec-2-yl, 1-Sideoxy-8-oxa-2-azaspiro[4.5]dec-2-yl, 3-Sideoxy-8-oxa-2-azaspiro[4.5]dec-2-yl or 4-Sideoxy-hexahydro-5H-furano[2,3-c]pyrrole-5-yl; Ø 3-(7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl)propyl); and Ø 2-(6,7-dihydro-5H-[1]pyridin-7-ol)-ethyl or 2-(8-hydroxy-5,6,7,8-tetrahydro-quinoline-8-yl)-ethyl; [B] represents phenyl, which is unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially relative to phenyl). [B] The attachment site to the rest of the molecule, at the para position via monosubstitution), wherein the substituent (etc.) is independently selected if present. Ø C1-5 alkyl groups (especially methyl, ethyl, n-propyl, isopropyl, or tert-butyl; particularly isopropyl); Ø C1-3 alkoxy groups (especially methoxy, ethoxy, or isopropoxy groups); Ø C1-3 alkoxy-C1-4 alkyl (especially 3-methoxy-propyl); Ø C1-3 fluoroalkyl groups (especially trifluoromethyl); Ø C3-5 cycloalkyl (especially cyclopropyl or cyclobutyl), which is independently unsubstituted or monosubstituted with a C1-3 alkyl (especially methyl) or a C1-3 fluoroalkyl (especially trifluoromethyl) (particularly at the point of attachment of the C3-5 cycloalkyl to the rest of the molecule); Ø C3-5 cycloalkoxy groups (especially cyclopropoxy or cyclobutoxy groups); and Ø C1-3 fluoroalkoxy groups (especially trifluoromethoxy groups); [To elaborate, this type of] [B] is phenyl, 4-methyl-phenyl, 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-tert-butyl-phenyl, 4-cyclopropyl-phenyl, 4-methoxy-phenyl, 4-ethoxy-phenyl, 4-isopropoxy-phenyl, 4-trifluoromethyl-phenyl, 4-(1-methyl-cyclopropyl)-phenyl, 4-cyclobutyl-phenyl, 4-cyclopropoxy-phenyl, 4-cyclobutoxy-phenyl, 4-(trifluoromethoxy)-phenyl, 4-(3-methoxy-propyl)-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl] [R, 1 , ] indicates a C1-3 alkyl group (especially methyl), a cyano group, or a halogen (especially fluorine); [R, 2 , ] represents C1-4 alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl), C3-5 cycloalkyl (especially cyclopropyl or cyclobutyl), C3-5 cycloalkyl-C1-3 alkyl (especially cyclopropyl-methyl) or C1-3 fluoroalkyl (especially 2,2-difluoroethyl or 2-fluoroethyl).

[0108] 39) Another embodiment relates to the compound of formula (IP) according to Example 38), wherein the features of any one of Examples 2) to 32) are applicable with necessary modifications.

[0109] 40) One embodiment of the present invention relates to the compound according to Example 38), wherein [A] represents pyridinyl, pyrimidinyl, pyridyl or taryl (especially pyridin-3-yl, pyridin-4-yl, pyrimidin-5-yl, pyridin-2-yl or taryl-4-yl; especially pyridin-3-yl), wherein [A] Independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially relative to) [A] The attachment point with the rest of the molecule, in [A] is mono- or di-substituted at the mid-position and / or para-position; especially relative to the position of [A] [A] The attachment point with the rest of the molecule, in [A] (monosubstituted between), wherein the substituent (etc.) is defined as in Example 38 if present.

[0110] 41) Another embodiment of the present invention relates to the compound according to Example 38), wherein [A] represents pyridin-3-yl or pyridin-4-yl, where [A] Independently unsubstituted, monosubstituted, disubstituted, or trisubstituted (especially relative to) [A] The attachment point with the rest of the molecule, in [A] is mono- or di-substituted at the mid-position and / or para-position; especially relative to the position of [A] [A] The attachment point with the rest of the molecule, in [A] (monosubstituted between), wherein the substituent (etc.) is defined as in Example 38 if present.

[0111] 42) Another embodiment of the present invention relates to the compound according to Example 38), wherein [A] is Ø Not replaced; Ø Monosubstituted (especially relative to) [A] The attachment point with the rest of the molecule, in [A] between positions), where the substituents are as defined in Example 38). Ø Disubstituted, wherein the first substituent (especially relative to) [A] The attachment point with the rest of the molecule, in [A] The substituents between the two groups are selected from those defined in Example 38 (especially excluding halogens (especially fluorine) or cyano); and the second substituent group (especially relative to) [A] The attachment point with the rest of the molecule, in [A] is selected from halogens (especially fluorine) and cyano groups. In one of the sub-examples of Example 4, [A] is pyridin-3-yl]

[0112] 43) Another embodiment of the present invention relates to a compound according to any one of Examples 40) to 42), wherein [A] relative to [A] The attachment point with the rest of the molecule, in [A] is monosubstituted between positions, where The substituents of [A] are Ø Contains one to three (especially two or three; especially three) five-membered heteroaryl groups independently selected from nitrogen, oxygen and sulfur cyclic heteroatoms (especially pyrazolyl, triazolyl, acezolyl, thiazolyl, acediazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, acezol-2-yl, thiazol-2-yl, 1,2,4-acediazol-5-yl or 1,2,4-acediazol-3-yl; preferably 1,2,4-acediazol-5-yl or 1,2,4-acediazol-3-yl); wherein the five-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted or trisubstituted (especially monosubstituted; especially relative to the five-membered heteroaryl group and the [A] is attached at position 3 (monosubstituted), where the substituent (etc.) is independently selected if present. Ø Unsubstituted or monosubstituted C1-4 alkyl groups with hydroxyl or C1-4 alkoxy groups (especially methoxy and tert-butoxy groups); [In detail, such C1-4 alkyl groups, whether unsubstituted or monosubstituted as defined above, are methyl, 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, 2-hydroxy-1,1-dimethyl-ethyl, methoxy-methyl, 2-methoxy-ethyl, 1-methoxy-1-methyl-ethyl, 2-methoxy-2-methyl-propyl, 2-methoxy-1,1-dimethyl-ethyl, or tert-butoxy-methyl; preferably, such C1-4 alkyl groups are 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1,1-dimethyl-ethyl.] Ø Amino-C1-4 alkyl (especially 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), wherein the amino group is monosubstituted or disubstituted (especially monosubstituted) with a C1-3 alkyl (especially methyl), a C1-3 alkyl-carbonyl (including deuterated C1-3 alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3) or a hydroxy-C1-3 alkyl-carbonyl (especially hydroxy-methyl-carbonyl); [In detail, these amino-C1-4 alkyl groups are N-acetylated-2-amino-ethyl, N-(acetylated-2,2,2-d3)-2-amino-ethyl, N-acetylated-2-amino-2,2-dimethyl-ethyl, N-(acetylated-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetylated-2-amino-ethyl, or N-methyl-N-(acetylated-2,2,2-d3)-2-amino-ethyl] Ø C3-6 cycloalkyl- [L, 2 , ]-,in ▪ - [L, 2 , ]- indicates a single bond (i.e., the C3-6 cycloalkyl group is directly attached to the rest of the molecule), oxygen, C1-3 alkyl group (especially -CH2-, -CH2-CH2- or -C(CH3)2-), hydroxy-C1-2 alkyl group (especially -CH(OH)-) or oxy-C1-2 alkyl group (especially -O-CH2-) (where the C3-6 cycloalkyl group is attached to the oxygen atom of the oxy-C1-2 alkyl group); and ▪ C3-6 cycloalkyl unsubstituted, fluorinated, C1-3 alkyl (especially methyl), C1-3 alkoxy (especially methoxy), hydroxyl, hydroxy-C1-3 alkyl or C1-3 alkoxy-C1-3 alkyl monosubstituted or disubstituted; wherein, if applicable, one ring carbon atom of the C3-6 cycloalkyl is substituted with an oxygen atom; In detail, this type of C3-6 cycloalkyl- [L, 2 ]- represents oxadiazon-3-yl, cyclobutoxy-methyl, 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, 3-hydroxy-cyclobutyl, 1-hydroxy-cyclopentyl, 3-hydroxy-3-methyl-cyclopentyl, 1-hydroxy-cyclohexyl, 4-hydroxy-cyclohexyl, (1-hydroxy-cyclohexyl)-methyl, (1-hydroxy-cyclobutyl)-methyl, 1-hydroxy-1-cyclohexylmethyl, 1-methoxy-cyclobutyl, 1-methoxy-cyclopentyl, 1-(1-(methoxy-methyl)-cyclopropyl)-methyl, tetrahydrofuran-2-yl-methyl Tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropiperan-3-yl, tetrahydropiperan-4-yl, 4-methyl-tetrahydropiperan-4-yl, 2,6-dimethyl-tetrahydropiperan-4-yl, 4-methoxy-tetrahydropiperan-4-yl, 4-fluoro-tetrahydropiperan-4-yl, tetrahydropiperan-4-yl-methyl, 2-(tetrahydropiperan-4-yl)-ethyl, 1-(tetrahydropiperan-4-yl)-1-methyl-ethyl, tetrahydropiperan-4-yl-oxy-methyl or (4-methyl-tetrahydropiperan-4-yl)-oxy-methyl Ø Piperidin-4-yl group substituted with a C1-3 alkyl-carbonyl group (especially acetyl), a (hydroxy-C1-3 alkyl)-carbonyl group (especially hydroxymethyl-carbonyl), or a C3-5 cycloalkyl-sulfonyl group at N; [In detail, this type of piperidine-4-yl is N-acetylopyridine-4-yl, N-(hydroxymethyl-carbonyl)-piperidine-4-yl, or N-(cyclopropyl-sulfonyl)-piperidine-4-yl] Ø Morpholinyl- [L, 3, ]- (especially (morpholin-4-yl)- [L, 3 , ]-),in- [L, 3 , ]- indicates a single bond (i.e., the morpholino group is directly attached to the rest of the molecule) or a C1-2 alkyl group; wherein the morpholino group is unsubstituted or disubstituted with a methyl group; [In detail, this type of morpholino-] [L, 3 , ]- represents morpholin-4-yl, morpholin-4-yl-methyl, or (2,6-dimethyl-morpholin-4-yl)-methyl] Ø Pyrazolyl-C1-3 alkyl (especially 2-(pyrazol-1-yl)-ethyl); Ø C1-3 alkyl-sulfonyl-C1-3 alkyl (especially methyl-sulfonyl-methyl); Ø 2,2,2-Trifluoro-1-hydroxy-1-methyl-ethyl; Ø 3-Hydroxymethyl-bicyclo[1.1.1]pent-1-yl; Ø 7-oxa-bicyclo[2.2.1]hept-2-yl; and Ø 6-oxa-spiro[2.5]octyl-1-yl.

[0113] 44) Another embodiment of the present invention relates to a compound according to any one of Examples 40) to 42), wherein [A] is relative to [A] The attachment point with the rest of the molecule, in [A] is monosubstituted between positions, where The substituents of [A] are Ø Contains one to three (especially two or three; especially three) 5-membered heteroaryl groups independently selected from nitrogen, oxygen and sulfur cyclic heteroatoms (especially pyrazolyl, triazolyl, acezolyl, thiazolyl, acediazolyl; especially pyrazol-1-yl, 1,2,3-triazol-1-yl, acezol-2-yl, thiazol-2-yl, 1,2,4-acediazol-5-yl or 1,2,4-acediazol-3-yl; preferably 1,2,4-acediazol-5-yl or 1,2,4-acediazol-3-yl); wherein the 5-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted or trisubstituted (especially monosubstituted; especially relative to the 5-membered heteroaryl group and the [A] is attached at position 3 (monosubstituted), where the substituent (etc.) is independently selected if present. Ø Amino-C1-4 alkyl (especially 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), wherein the amino group is monosubstituted or disubstituted (especially monosubstituted) with a C1-3 alkyl (especially methyl), a C1-3 alkyl-carbonyl (including deuterated C1-3 alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3) or a hydroxy-C1-3 alkyl-carbonyl (especially hydroxy-methyl-carbonyl); [In detail, these amino-C1-4 alkyl groups are N-acetylated-2-amino-ethyl, N-(acetylated-2,2,2-d3)-2-amino-ethyl, N-acetylated-2-amino-2,2-dimethyl-ethyl, N-(acetylated-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetylated-2-amino-ethyl, or N-methyl-N-(acetylated-2,2,2-d3)-2-amino-ethyl] Ø Piperidin-4-yl group substituted at N with a C1-3 alkyl-carbonyl (especially acetyl), (hydroxy-C1-3 alkyl)-carbonyl (especially hydroxymethyl-carbonyl) or C3-5 cycloalkyl-sulfonyl group. [In detail, this type of piperidine-4-yl is N-acetylopyridine-4-yl, N-(hydroxymethyl-carbonyl)-piperidine-4-yl, or N-(cyclopropyl-sulfonyl)-piperidine-4-yl]

[0114] 45) Another embodiment of the invention relates to a compound according to any one of Examples 40) to 42), wherein [A] is relative to [A] The attachment point with the rest of the molecule, in [A] is monosubstituted at the position, wherein the substituent is Ø A monosubstituted 1,2,4-diazol-3-yl group, wherein the substituents are independently selected from... Ø Amino-C1-4 alkyl (especially 2-amino-ethyl or 2-amino-2,2-dimethyl-ethyl), wherein the amino group ▪ Monosubstituted with a C1-3 alkyl-carbonyl group (including deuterated C1-3 alkyl-carbonyl groups) (especially acetyl or acetyl-2,2,2-d3); ▪ Disubstituted, wherein the first substituent is a C1-3 alkyl (especially methyl) and the second substituent is a C1-3 alkyl-carbonyl (especially acetyl) or a C1-3 alkyl-carbonyl (including deuterated C1-3 alkyl-carbonyl) (especially acetyl or acetyl-2,2,2-d3); or ▪ Disubstituted, wherein the first substituent is a C1-3 alkyl (especially methyl) and the second substituent is a hydroxy-C1-3 alkyl-carbonyl (especially hydroxy-methyl-carbonyl); [In detail, these amino-C1-4 alkyl groups are N-acetylated-2-amino-ethyl, N-(acetylated-2,2,2-d3)-2-amino-ethyl, N-acetylated-2-amino-2,2-dimethyl-ethyl, N-(acetylated-2,2,2-d3)-2-amino-2,2-dimethyl-ethyl, N-methyl-N-(hydroxy-methyl-carbonyl)-2-amino-ethyl, N-methyl-N-acetylated-2-amino-ethyl, or N-methyl-N-(acetylated-2,2,2-d3)-2-amino-ethyl] Ø Piperidin-4-yl group substituted at N with a C1-3 alkyl-carbonyl (especially acetyl), (hydroxy-C1-3 alkyl)-carbonyl (especially hydroxymethyl-carbonyl) or C3-5 cycloalkyl-sulfonyl group. [In detail, this type of piperidine-4-yl is N-acetylopyridine-4-yl, N-(hydroxymethyl-carbonyl)-piperidine-4-yl, or N-(cyclopropyl-sulfonyl)-piperidine-4-yl]

[0115] 46) Another embodiment of the invention relates to a compound according to any one of Examples 40) or 42), wherein [A] indicates relative to [A] The attachment site to the rest of the molecule is a meta-substituted pyridinyl group (especially pyridin-3-yl), wherein the substituent is a monosubstituted diazolyl group (especially 1,2,4-diazol-3-yl), wherein the substituent is an unsubstituted or C1-4 alkyl group monosubstituted with a hydroxyl or C1-4 alkoxy group (especially such C1-4 alkyl group is 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl or 2-hydroxy-1,1-dimethyl-ethyl).

[0116] 47) Another embodiment of the invention relates to a compound according to any one of Examples 40) to 42), wherein [A] relative to [A] The attachment point with the rest of the molecule, in [A] is monosubstituted between positions, where The substituents of [A] are Ø -C≡C- [R, T1 , ],in Ø [R, T1 , ]express ▪ Hydroxyl-C1-4 alkyl (especially hydroxy-methyl, 1-hydroxy-ethyl, 2-hydroxy-ethyl, 1-hydroxy-2-methyl-propyl or 1-hydroxy-1-methyl-ethyl); ▪ C1-3 alkoxy-C1-3 alkyl (especially methoxy-methyl); ▪ C3-6 cycloalkyl groups monosubstituted with hydroxyl groups (especially at the attachment point between the C3-6 cycloalkyl group and the rest of the molecule; particularly 1-hydroxy-cyclopropyl, 1-hydroxy-cyclobutyl, or 1-hydroxy-cyclopentyl); ▪ A C3-6 cycloalkyl group (particularly cyclopentyl or cyclohexyl) fused with a pyridine ring (especially at the 2 and 3 positions of the pyridine ring), wherein the C3-6 cycloalkyl group is monosubstituted with a hydroxyl group (particularly at the 1 position of the C3-6 cycloalkyl ring) (particularly 8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl or 7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl); ▪ Mono-substituted pyrazolyl groups (especially pyrazol-4-yl) (especially 1-methyl-pyrazol-4-yl); ▪ Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl), which is unsubstituted or monosubstituted with a hydroxyl group (especially 4-hydroxy-tetrahydropiperanyl-4-yl); ▪ Indole (especially indole-2-yl); or ▪ Hydroxy-azacyclobutane (especially 3-hydroxy-azacyclobutane-3-yl) with a C1-4 alkoxy-carbonyl group substituted at N (especially isopropyl-carbonyl or terbutoxy-carbonyl); [To elaborate, this type of -C≡C-] [R, T1 ] represents 3-hydroxy-prop-1-yn-1-yl, 4-hydroxy-but-1-yn-1-yl, 3-hydroxy-but-1-yn-1-yl, 3-hydroxy-3-methyl-but-1-yn-1-yl, 3-hydroxy-4-methyl-pent-1-yn-1-yl, 3-methoxy-prop-1-yn-1-yl, (1-hydroxy-cyclopropyl)-ethynyl, (1-hydroxy-cyclobutyl)-ethynyl, (1-hydroxy-cyclopentyl)-ethynyl, (8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl (7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl)-ethynyl, (1-methyl-pyrazol-4-yl)-ethynyl, (tetrahydropiperan-4-yl)-ethynyl, (4-hydroxy-tetrahydropiperan-4-yl)-ethynyl, indole-2-yl-ethynyl, (1-(isopropyl-carbonyl)-3-hydroxy-azacyclobutane-3-yl)-ethynyl or (1-(tert-butoxy-carbonyl)-3-hydroxy-azacyclobutane-3-yl)-ethynyl] Ø -C≡CC(OH)( [R, T2 , ])( [R, T3 , ]),in Ø [R, T2 , ] indicates hydrogen or C1-3 alkyl (especially methyl or ethyl); Ø [R, T3 , ]express ▪ Unsubstituted or monosubstituted phenyl groups, wherein the substituent, if present, is selected from C1-3 alkoxy groups (especially methoxy groups) or halogens (especially fluorine groups); [In detail, such groups are 3-fluoro-phenyl, 4-methoxy-phenyl, or 2-methoxy-phenyl] ▪ Contains one or two 5- to 6-membered heteroaryl groups (especially thiazolyl, pyrazolyl, pyridinyl, or pyrimidinyl; especially thiazolyl-4-yl, pyrazol-3-yl, pyrazol-4-yl, pyridin-2-yl, pyrimidin-2-yl, or pyrimidin-4-yl) independently selected from nitrogen or sulfur ring heteroatoms, wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, or disubstituted, and wherein the substituent(e) is, if present, independently selected from C1-3 alkyl (especially methyl) and C1-3 alkoxy (especially methoxy); or [In detail, these 5 to 6-membered heteroaryl groups are 1-methyl-pyrazole-3-yl, 1,3-dimethyl-pyrazole-4-yl, 1,5-dimethyl-pyrazole-3-yl, 2-methyl-thiazolyl-4-yl, pyridin-2-yl, 6-methoxy-pyridin-2-yl, pyrimidin-2-yl, pyrimidin-4-yl, or 1,5-dimethyl-pyrazole-3-yl] ▪ Tetrahydropiperanyl (especially tetrahydropiperanyl-4-yl); [To elaborate, this type of -C≡CC(OH)( [R, T2 , ])( [R, T3, ]) is 3-hydroxy-3-(tetrahydropiperan-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-prop-1-yn-1-yl, 3-hydroxy-3-(2-methyl-thiazo-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-(1,3-dimethyl-pyrazole-4-yl)-prop-1-yn-1-yl, 3-hydroxy-3-phenyl-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1,5-dimethyl-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(1-methyl-pyrazole-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyrimidin-2-yl) 3-hydroxy-3-(1-methylpyrazol-3-yl)-but-1-yn-1-yl, 3-hydroxy-3-(3-fluoro-phenyl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methylpyrimidin-4-yl)-but-1-yn-1-yl, 3-hydroxy-3-(pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-but-1-yn-1-yl, 3-hydroxy-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-1-yl, 3-hydroxy-3-(4-methoxy-phenyl)-but-1-yn-1-yl or 3-hydroxy-3-(2-methoxy-phenyl)-but-1-yn-1-yl

[0117] 48) Another embodiment of the invention relates to a compound according to any one of Examples 38) to 42), wherein [A] relative to [A] The attachment point with the rest of the molecule, in [A] is monosubstituted between positions, where The substituents of [A] are as defined in Examples 42) or 46).

[0118] 49) Another embodiment of the present invention relates to a compound according to any one of Examples 38) to 48), wherein [B] indicates a phenyl group that is monosubstituted at the para position relative to the attachment point between B and the rest of the molecule, wherein the substituent is selected from C1-5 alkyl groups (especially ethyl, n-propyl, isopropyl or tert-butyl; especially isopropyl). [To elaborate, this type of] [B] is 4-ethyl-phenyl, 4-propyl-phenyl, 4-isopropyl-phenyl, 4-tert-butyl-phenyl; especially 4-isopropyl-phenyl.

[0119] 50) Another embodiment of the invention relates to a compound according to any one of Examples 38) to 49), wherein [R, 1 , ] indicates C1-3 alkyl (especially methyl).

[0120] 51) Another embodiment of the present invention relates to a compound according to any one of Examples 38) to 50), wherein [R, 2 , ] indicates C1-4 alkyl (especially methyl, ethyl, n-propyl, isopropyl, tert-butyl or isobutyl).

[0121] 52) Another embodiment of the present invention relates to the compound according to Example 38), wherein [A] indicates relative to [A] The attachment site to the rest of the molecule, at the meta position, is a monosubstituted pyridinyl group (especially pyridin-3-yl), wherein the substituent is a monosubstituted diazolyl group (especially 1,2,4-diazol-3-yl), wherein the substituent is an unsubstituted or monosubstituted C1-4 alkyl group (unsubstituted or monosubstituted C1-4 alkoxy groups are especially 1-hydroxy-1-methyl-ethyl, 2-hydroxy-2-methyl-propyl, or 2-hydroxy-1,1-dimethyl-ethyl); [B] indicates a phenyl group that is monosubstituted at the para position relative to the attachment point between B and the rest of the molecule, wherein the substituent is a C1-5 alkyl group (especially isopropyl). [R, 1 , ] indicates C1-3 alkyl (especially methyl); and [R, 2 , ] indicates C1-4 alkyl (especially methyl).

[0122] 53) Another embodiment relates to a compound according to any one of Examples 38) to 52), which is also a compound of formula (IIp) (i.e.) [A] and [B] The attached asymmetric carbon atom has the absolute configuration described in formula (IIp). Formula (IIp) Implementation

[0123] It should be understood that, for [A] is pyridin-3-yl, pyrimidin-5-yl, pyridin-2-yl, or pyridin-4-yl (especially pyridin-3-yl), as described in formula (IIp). [A] and [B] The attached asymmetric carbon atom has an absolute configuration (R). [A] indicates pyridin-4-yl, as described in formula (II). [A] and [B] The attached asymmetric carbon atom has an absolute configuration (S).

[0124] Based on the reliance on the different embodiments 1) to 37) disclosed above, the following embodiments are therefore possible and contemplated, and are specifically disclosed herein in the following individualized form: 2+1、3+1、4+1、11+1、11+2+1、11+3+1、11+4+1、12+11+1、12+11+2+1、12+11+3+1、12+11+4+1、13+11+1、13+11+2+1、13+11+3+1、13+11+4+1、14+11+1、14+11+2+1、14+11+3+1、14+11+4+1、15+11+1、15+11+2+1、15+11+3+1、15+11+4+1、16+1、16+2+1、16+3+1、16+4+1、17+16+1、17+16+2+1、17+16+3+1、17+16+4+1、18+16+1、18+16+2+1、18+16+3+1、18+16+4+1、19+16+1、19+16+2+1、19+16+3+1、19+16+4+1、20+1、20+2+1、20+3+1、20+4+1、21+20+1、21+20+2+1、21+20+3+1、21+20+4+1、22+20+1、22+20+2+1、22+20+3+1、22+20+4+1、23+1、23+2+1、23+3+1、23+4+1、23+5、23+6、23+7、23+8、23+9、23+10、23+11+1、23+11+2+1、23+11+3+1、23+11+4+1、23+12+11+1、23+12+11+2+1、23+12+11+3+1、23+12+11+4+1、23+13+11+1、23+13+11+2+1、23+13+11+3+1、23+13+11+4+1、23+14+11+1、23+14+11+2+1、23+14+11+3+1、23+14+11+4+1、23+15+11+1、23+15+11+2+1、23+15+11+3+1、23+15+11+4+1、23+16+1、23+16+2+1、23+16+3+1、23+16+4+1、23+17+16+1、23+17+16+2+1、23+17+16+3+1、23+17+16+4+1、23+18+16+1、23+18+16+2+1、23+18+16+3+1、23+18+16+4+1、23+19+16+1、23+19+16+2+1、23+19+16+3+1、23+19+16+4+1、23+20+1、23+20+2+1、23+20+3+1、23+20+4+1、23+21+20+1、23+21+20+2+1、23+21+20+3+1、23+21+20+4+1、23+22+20+1、23+22+20+2+1、23+22+20+3+1、23+22+20+4+1、26+1、26+2+1、26+3+1、26+4+1、26+5、26+6、26+7、26+8、26+9、26+10、26+11+1、26+11+2+1、26+11+3+1、26+11+4+1、26+12+11+1、26+12+11+2+1、26+12+11+3+1、26+12+11+4+1、26+13+11+1、26+13+11+2+1、26+13+11+3+1、26+13+11+4+1、26+14+11+1、26+14+11+2+1、26+14+11+3+1、26+14+11+4+1、26+15+11+1、26+15+11+2+1、26+15+11+3+1、26+15+11+4+1、26+16+1、26+16+2+1、26+16+3+1、26+16+4+1、26+17+16+1、26+17+16+2+1、26+17+16+3+1、26+17+16+4+1、26+18+16+1、26+18+16+2+1、26+18+16+3+1、26+18+16+4+1、26+19+16+1、26+19+16+2+1、26+19+16+3+1、26+19+16+4+1、26+20+1、26+20+2+1、26+20+3+1、26+20+4+1、26+21+20+1、26+21+20+2+1、26+21+20+3+1、26+21+20+4+1、26+22+20+1、26+22+20+2+1、26+22+20+3+1、26+22+20+4+1、26+23+1、26+23+2+1、26+23+3+1、26+23+4+1、26+23+5、26+23+6、26+23+7、26+23+8、26+23+9、26+23+10、26+23+11+1、26+23+11+2+1、26+23+11+3+1、26+23+11+4+1、26+23+12+11+1、26+23+12+11+2+1、26+23+12+11+3+1、26+23+12+11+4+1、26+23+13+11+1、26+23+13+11+2+1、26+23+13+11+3+1、26+23+13+11+4+1、26+23+14+11+1、26+23+14+11+2+1、26+23+14+11+3+1、26+23+14+11+4+1、26+23+15+11+1、26+23+15+11+2+1、26+23+15+11+3+1、26+23+15+11+4+1、26+23+16+1、26+23+16+2+1、26+23+16+3+1、26+23+16+4+1、26+23+17+16+1、26+23+17+16+2+1、26+23+17+16+3+1、26+23+17+16+4+1、26+23+18+16+1、26+23+18+16+2+1、26+23+18+16+3+1、26+23+18+16+4+1、26+23+19+16+1、26+23+19+16+2+1、26+23+19+16+3+1、26+23+19+16+4+1、26+23+20+1、26+23+20+2+1、26+23+20+3+1、26+23+20+4+1、26+23+21+20+1、26+23+21+20+2+1、26+23+21+20+3+1、26+23+21+20+4+1、26+23+22+20+1、26+23+22+20+2+1、26+23+22+20+3+1、26+23+22+20+4+1、26+24、26+25、28+1、28+2+1、28+3+1、28+4+1、28+5、28+6、28+7、28+8、28+9、28+10、28+11+1、28+11+2+1、28+11+3+1、28+11+4+1、28+12+11+1、28+12+11+2+1、28+12+11+3+1、28+12+11+4+1、28+13+11+1、28+13+11+2+1、28+13+11+3+1、28+13+11+4+1、28+14+11+1、28+14+11+2+1、28+14+11+3+1、28+14+11+4+1、28+15+11+1、28+15+11+2+1、28+15+11+3+1、28+15+11+4+1、28+16+1、28+16+2+1、28+16+3+1、28+16+4+1、28+17+16+1、28+17+16+2+1、28+17+16+3+1、28+17+16+4+1、28+18+16+1、28+18+16+2+1、28+18+16+3+1、28+18+16+4+1、28+19+16+1、28+19+16+2+1、28+19+16+3+1、28+19+16+4+1、28+20+1、28+20+2+1、28+20+3+1、28+20+4+1、28+21+20+1、28+21+20+2+1、28+21+20+3+1、28+21+20+4+1、28+22+20+1、28+22+20+2+1、28+22+20+3+1、28+22+20+4+1、28+23+1、28+23+2+1、28+23+3+1、28+23+4+1、28+23+5、28+23+6、28+23+7、28+23+8、28+23+9、28+23+10、28+23+11+1、28+23+11+2+1、28+23+11+3+1、28+23+11+4+1、28+23+12+11+1、28+23+12+11+2+1、28+23+12+11+3+1、28+23+12+11+4+1、28+23+13+11+1、28+23+13+11+2+1、28+23+13+11+3+1、28+23+13+11+4+1、28+23+14+11+1、28+23+14+11+2+1、28+23+14+11+3+1、28+23+14+11+4+1、28+23+15+11+1、28+23+15+11+2+1、28+23+15+11+3+1、28+23+15+11+4+1、28+23+16+1、28+23+16+2+1、28+23+16+3+1、28+23+16+4+1、28+23+17+16+1、28+23+17+16+2+1、28+23+17+16+3+1、28+23+17+16+4+1、28+23+18+16+1、28+23+18+16+2+1、28+23+18+16+3+1、28+23+18+16+4+1、28+23+19+16+1、28+23+19+16+2+1、28+23+19+16+3+1、28+23+19+16+4+1、28+23+20+1、28+23+20+2+1、28+23+20+3+1、28+23+20+4+1、28+23+21+20+1、28+23+21+20+2+1、28+23+21+20+3+1、28+23+21+20+4+1、28+23+22+20+1、28+23+22+20+2+1、28+23+22+20+3+1、28+23+22+20+4+1、28+24、28+25、28+26+1、28+26+2+1、28+26+3+1、28+26+4+1、28+26+5、28+26+6、28+26+7、28+26+8、28+26+9、28+26+10、28+26+11+1、28+26+11+2+1、28+26+11+3+1、28+26+11+4+1、28+26+12+11+1、28+26+12+11+2+1、28+26+12+11+3+1、28+26+12+11+4+1、28+26+13+11+1、28+26+13+11+2+1、28+26+13+11+3+1、28+26+13+11+4+1、28+26+14+11+1、28+26+14+11+2+1、28+26+14+11+3+1、28+26+14+11+4+1、28+26+15+11+1、28+26+15+11+2+1、28+26+15+11+3+1、28+26+15+11+4+1、28+26+16+1、28+26+16+2+1、28+26+16+3+1、28+26+16+4+1、28+26+17+16+1、28+26+17+16+2+1、28+26+17+16+3+1、28+26+17+16+4+1、28+26+18+16+1、28+26+18+16+2+1、28+26+18+16+3+1、28+26+18+16+4+1、28+26+19+16+1、28+26+19+16+2+1、28+26+19+16+3+1、28+26+19+16+4+1、28+26+20+1、28+26+20+2+1、28+26+20+3+1、28+26+20+4+1、28+26+21+20+1、28+26+21+20+2+1、28+26+21+20+3+1、28+26+21+20+4+1、28+26+22+20+1、28+26+22+20+2+1、28+26+22+20+3+1、28+26+22+20+4+1、28+26+23+1、28+26+23+2+1、28+26+23+3+1、28+26+23+4+1、28+26+23+5、28+26+23+6、28+26+23+7、28+26+23+8、28+26+23+9、28+26+23+10、28+26+23+11+1、28+26+23+11+2+1、28+26+23+11+3+1、28+26+23+11+4+1、28+26+23+12+11+1、28+26+23+12+11+2+1、28+26+23+12+11+3+1、28+26+23+12+11+4+1、28+26+23+13+11+1、28+26+23+13+11+2+1, 28+26+23+13+11+3+1, 28+26+23+13+11+4+1, 28+26+23+14+11+1, 28+26+23+14+11+2+1, 28+26+23+14+11+3+1, 28+26+23+14+11+4+1, 28+26+23+15+11+1, 28+26+23+15+11+2+1, 28+26+23+1 5+11+3+1, 28+26+23+15+11+4+1, 28+26+23+16+1, 28+26+23+16+2+1, 28+26+23+16+3+1, 28+26+23+16+4+1, 28+26+23+17+16+1, 28+26+23+17+16+2+1, 28+26+23+17+16+3+1, 28+26+23+17+16+4+1, 28+26+23+18+1 6+1, 28+26+23+18+16+2+1, 28+26+23+18+16+3+1, 28+26+23+18+16+4+1, 28+26+23+19+16+1, 28+26+23+19+16+2+1, 28+26+23+19+16+3+1, 28+26+23+19+16+4+1, 28+26+23+20+1, 28+26+23+20+2+1, 28+26+23+20+ 3+1, 28+26+23+20+4+1, 28+26+23+21+20+1, 28+26+23+21+20+2+1, 28+26+23+21+20+3+1, 28+26+23+21+20+4+1, 28+26+23+22+20+1, 28+26+23+22+20+2+1, 28+26+23+22+20+3+1, 28+26+23+22+20+4+1 or 28+26+24, 28+26+25.

[0125] This invention relates to compounds of formula (I) as defined in Embodiment 1), or such compounds further limited by the features of any of Embodiments 2) to 53) with regard to their respective dependencies; pharmaceutically acceptable salts thereof; and the use of such compounds as medicines, particularly for the treatment of diseases or conditions involving CCR6 receptors as described below.

[0126] This invention also includes isotopically labeled, particularly 2H (deuterium) labeled compounds of formula (I), which are identical to compounds of formula (I) except that one or more atoms are each replaced with atoms having the same number of atoms but with atomic masses different from those commonly found in nature. Isotopically labeled, particularly 2H (deuterium) labeled compounds of formula (I) and their salts are within the scope of this invention. Replacing hydrogen with the heavier isotope 2H (deuterium) can produce greater metabolic stability, resulting in, for example, an increased in vivo half-life or a reduced dose requirement, or a reduced inhibition of cytochrome P450 enzymes, thereby, for example, improving the safety profile. In one embodiment of this invention, the compound of formula (I) is unlabeled, or is labeled with only one or more deuterium atoms. In a sub-embodiment, the compound of formula (I) is completely unlabeled. Isotopically labeled compounds of formula (I) can be prepared similarly to the methods described below, but using appropriate isotopic variants of suitable reagents or starting materials.

[0127] When the plural form is used for compounds, salts, pharmaceutical compositions, diseases or their analogues, it is also intended to mean a single compound, salt, pharmaceutical composition, disease or its analogue.

[0128] Where appropriate and convenient, any reference to compounds of formula (I) according to Examples 1) to 53) should be understood to also refer to salts of such compounds (and especially pharmaceutically acceptable salts).

[0129] The term "medically acceptable salt" refers to a salt that retains the desired biological activity of the subject compound and exhibits minimal undesirable toxicological effects.

[0130] Depending on the presence of basic and / or acidic groups in the subject compound, such salts include addition salts of inorganic or organic acids and / or inorganic or organic bases. For reference, see, for example, "Handbook of Pharmaceutical Salts. Properties, Selection and Use," P. Heinrich Stahl, Camille G. Wermuth (eds.), Wiley-VCH, 2008; and "Pharmaceutical Salts and Co-crystals," Johan Wouters and Luc Quéré (eds.), RSC Publishing, 2012.

[0131] The definitions provided herein are intended to apply uniformly to compounds of formula (I) as defined in any of Examples 1) through 53), and, with necessary modifications, are provided throughout the specification and claims unless expressly stated otherwise. It should be fully understood that the definition or preferred definition of a term is defined independently (and in combination with) and substitutes for any definition or preferred definition of any or all other terms as defined herein.

[0132] Compounds of formula (I) may encompass compounds having one or more asymmetric centers, such as one or more asymmetric carbon atoms, that can exist in (R)- and (S)-configurations. Compounds of formula (I) may further encompass compounds having one or more double bonds that allow for Z- and E-configurations; and / or compounds having substituents in the ring...

Claims

1. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein A represents a 6-membered heteroaryl group containing one or two cyclic nitrogen atoms, wherein the 6-membered heteroaryl group is unsubstituted; monosubstituted or disubstituted at the interposition of A with respect to the attachment point between A and the remainder of the molecule, wherein the first substituent is at the interposition of A with respect to the attachment point between A and the remainder of the molecule, and the second substituent is at the para position of A with respect to the attachment point between A and the remainder of the molecule; wherein the second substituent is selected from fluorine and cyano; and the first substituent is selected from hydroxy-C1-6 alkyl groups substituted with one to three fluorine atoms as appropriate; unsubstituted or monosubstituted C1-5 alkyl groups; C1-3 alkyl groups. Oxide; C3-6 cycloalkyl group fused with a pyridine ring, wherein the C3-6 cycloalkyl group is unsubstituted or monosubstituted with a hydroxyl group; -O-RO1, wherein RO1 represents a C3-6 cycloalkyl or pyrrolidinyl group that is independently unsubstituted or monosubstituted with a C1-3 alkyl or C1-4 alkyl-carbonyl group; phenyl-L1-, wherein the phenyl group is unsubstituted or monosubstituted with a fluorine, C1-4 alkoxy-carbonyl or hydroxy-C1-4 alkyl group; wherein -L1- represents a single bond, oxygen or the group -CH2-O-; C4-6 heterocyclic group containing one or two independently selected cyclic heteroatoms from nitrogen and oxygen, wherein the C4-6 heterocyclic group is unsubstituted, monosubstituted with an oxy group, hydroxyl group, C1-3 alkyl group, C1-4 alkyl-carbonyl group or C1-4 alkoxy-carbonyl group. Monosubstituted or disubstituted; a 5-membered heteroaryl group containing one or two cyclic nitrogen atoms, wherein the 5-membered heteroaryl group is unsubstituted or monosubstituted with a C1-3 alkyl group; indolyl; pyrrolopyridyl; N-(C1-3 alkyl)-amino-carbonyl-oxy; or 1-hydroxy-1-C3-5 cycloalkyl-1-(pyridyl)-methyl; a C3-5 alkyl group substituted with hydroxyl and RA1, wherein the substituents are all located at the 3-position relative to the attachment point of the C3-5 alkyl group to the rest of the molecule; wherein RA1 represents tetrahydropiperanyl; an unsubstituted or monosubstituted phenyl group substituted with fluorine or C1-3 alkoxy; a 5- or 6-membered heteroaryl group containing one or two independently selected cyclic heteroatoms of nitrogen or sulfur, wherein the 5- or 6-membered heteroaryl group is independently unsubstituted or monosubstituted. Or disubstituted, wherein the substituent(s), if present, is independently selected from C1-3 alkyl, C3-5 cycloalkyl, or C1-3 alkoxy; or indazole; unsubstituted or hydroxyl-monosubstituted C3-5 alkenyl; unsubstituted, C4-6 cycloalkenyl monosubstituted or disubstituted with C1-3 alkyl, oxy, or hydroxyl, wherein, where appropriate, one ring carbon atom of the C4-6 cycloalkenyl is substituted with an oxygen atom; unsubstituted, C3-6 cycloalkyl monosubstituted or disubstituted with C1-3 alkyl, hydroxyl, or hydroxy-C1-3 alkyl, wherein, where appropriate, one ring carbon atom of the C3-6 cycloalkyl is substituted with an oxygen atom; -O-RO2, wherein RO2 represents C1-4 alkyl; C2-5 alkyl monosubstituted with hydroxyl or C1-3 alkoxy;-L2-CY2, wherein -L2- independently represents a single bond, -CH2- or -CH2-CH2-; and CY2 independently represents an unsubstituted or monosubstituted phenyl group with a hydroxy-C1-3 alkyl group; benzyl-oxy; containing one to three 5- or 6-membered heteroaryl groups independently selected from nitrogen, oxygen or sulfur cyclic heteroatoms, wherein the 5- or 6-membered heteroaryl groups are independently unsubstituted, monosubstituted or disubstituted; wherein the substituents, if present, are independently selected from C1-3 alkyl or C1-3 cycloalkyl; C3-6 cycloalkyl, wherein, where appropriate, one carbon ring atom is substituted by a heteroatom selected from oxygen and nitrogen; wherein the C3-6 cycloalkyl is unsubstituted, monosubstituted or disubstituted, wherein the substituents are selected from C1-3 alkyl, hydroxyl, fluorine , side-oxygen, C1-3 alkyl-carbonyl and C1-3 alkoxy; benzoxazolone; or alkyl; -C≡C-RT1, wherein RT1 represents a C1-4 alkyl, wherein the C1-4 alkyl is independently monosubstituted by: hydroxyl; C1-3 alkoxy; -S(=O)2-RSOT, wherein RSOT represents a C1-3 alkyl, C1-3 alkyl-amino or C3-5 cycloalkyl; -NRNT1RNT2, wherein RNT1 represents hydrogen and RNT2 represents a C1-3 alkyl-carbonyl, C1-3 alkoxy-C1-3 alkyl-carbonyl or C3-5 cycloalkyl-carbonyl; containing one or two C4-6 heterocyclic groups independently selected from nitrogen and oxygen cyclic heteroatoms; wherein the C4-6 heterocyclic group is monosubstituted by a side-oxygen. Or disubstituted with a side oxygen group and a C1-3 alkyl group; or N-(C1-3 alkyl-carbonyl)-piperidinyl-C1-3 alkyl; disubstituted C1-4 alkyl group, wherein one substituent is hydroxyl and the second substituent is trifluoromethyl; C3-6 cycloalkyl group monosubstituted with: hydroxyl; amino-sulfonyl group disubstituted with methyl as appropriate; phenyl group monosubstituted with halogen; pyridinyl group; pyrimidinyl group monosubstituted with C1-3 alkyl group; or azolidinone group; C3-6 cycloalkyl group fused with a pyridine ring, wherein the C3-6 cycloalkyl group is monosubstituted with a hydroxyl group; wherein, wherein, wherein, one ring carbon atom of the C3-6 cycloalkyl group is replaced by an oxygen atom; containing a C4-6 heterocyclic group independently selected from nitrogen and oxygen ring heteroatoms; wherein the C4- 6. The heterocyclic group is monosubstituted, disubstituted, or trisubstituted, wherein the substituent(s) are independently selected from C1-3 alkyl, hydroxyl, syloxy, C1-3 alkyl-carbonyl, C1-3 alkoxy-carbonyl, C1-3 alkyl-sulfonyl, and C1-3 alkyl-amino-sulfonyl; pyrazolyl substituted with methyl at N; indolyl; 3-hydroxy-1-methyl-1,3-dihydro-indol-2-one-3-yl; or 4-hydroxy-3,4-dihydro-2H-piperano[3,2-b]pyridin-4-yl; -C≡CC(OH)(RT2)(RT3), wherein RT2 represents hydrogen or C1-3 alkyl; RT3 represents an unsubstituted or monosubstituted phenyl group, wherein the substituent(s) are selected from C1-3 alkoxy and halogens, if present.Contains one or two 5- or 6-membered heteroaryl groups independently selected from nitrogen, oxygen, or sulfur cyclic heteroatoms; wherein the 5- or 6-membered heteroaryl groups are independently unsubstituted, monosubstituted, or disubstituted, and wherein the substituent(s) are, if present, independently selected from C1-3 alkyl, C1-3 cycloalkyl, C1-3 fluoroalkyl, and C1-3 alkoxy; Contains one C4-7 heterocyclic group selected from nitrogen and oxygen cyclic heteroatoms; wherein the C4-7 heterocyclic group is unsubstituted, monosubstituted, or disubstituted, and wherein the substituent(s) are, if present, independently selected from C1-3 alkyl or C1-3 alkyl-carbonyl; or indazole; -NRN3RN4, wherein RN3 represents C1-3 alkyl; and RN4 represents hydroxy-C1-3 alkyl or 2-(benzylmethyl-oxy)-C1-3 alkyl. The group; or RN3 and RN4 together with the nitrogen attached thereto form a 4 to 6-membered heterocycle, wherein the members required for the integrity of the heterocycle are each independently selected from -CH2-, -O-, -(C=O)-, -CHRX- and -C(RY)2-; wherein the heterocycle does not contain more than one member independently selected from the group consisting of -O- and -(C=O)-; wherein the heterocycle does not contain more than two members selected from the group consisting of -CHRX-; and wherein the heterocycle does not contain more than two members selected from the group consisting of -C(RY)2-; wherein RX independently represents fluorine, methyl, isopropyl, isobutyl, tributyl, hydroxy, trifluoromethyl, hydroxy-methyl, 1-hydroxy-ethyl, 1-hydroxy-1-methyl-ethyl, cyclopropyl, 2-methoxy- Ethyl, 2-methyl-thiazolyl-5-yl, 4-methyl-thiazolyl-2-yl, phenyl, benzyl, tetrahydropiperan-4-yl, N-acetylopidin-4-yl, 1,2,4-diazolyl, 3-methyl-1,2,4-diazolyl-5-yl, 2-methyl-2H-[1,2,3]triazol-4-yl, 1-methyl-1H-pyrazole-4-yl, 1-difluoromethyl-1H-pyrazole-4-yl, 1,3-dimethyl-1H-pyrazole-4-yl, pyridin-2-yl, 6-methyl-pyridin-3-yl, 6-isopropyl-pyridin-2-yl, 6-trifluoromethyl-pyridin-3-yl, 2-isopropyl-pyrimidin-4-yl or 1-methoxy-methyl; wherein RY independently represents fluorine, hydroxyl, cyclopropyl, methyl, hydroxyl alkyl-methyl or trifluoromethyl; -(C=O)-N(RN5)(RN6), wherein RN5 represents hydrogen; and RN6 represents a C3-6 cycloalkyl or tetrahydropiperanyl; or RN5 and RN6 together with the nitrogen atom to which they are attached form a pyrrolidyl group; a piperidin-4-yl or pyrrolidin-3-yl group monosubstituted at a nitrogen ring atom, wherein the substituent is independently selected from C1-4 alkoxy-carbonyl, pyridyl, phenyl, and 4-methylphenyl-sulfonyl; containing one to three 5- or 6-membered heteroaryl groups independently selected from nitrogen, oxygen, and sulfur ring heteroatoms; wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted, or trisubstituted, wherein the substituent(e) if present is independently selected from C1-4 alkyl groups that are unsubstituted; monosubstituted with the following: hydroxyl;C1-4 alkoxy; or -N(RN7)(RN8), wherein RN7 represents hydrogen or C1-3 alkyl; and RN8 independently represents C3-5 cycloalkyl-carbonyl, C1-3 alkyl, C1-3 alkyl-carbonyl including deuterated C1-3 alkyl-carbonyl, C1-3 alkoxy-C1-3 alkyl-carbonyl, tetrahydropiperanyl-carbonyl, or hydroxy-C1-3 alkyl-carbonyl; disubstituted, wherein one substituent is hydroxyl and the other substituent is trifluoromethyl; or both substituents are hydroxyl; or disubstituted. Or trisubstituted, wherein two substituents are fluorine, and if present, one substituent is a hydroxyl group; -L3-CY3, wherein -L3- independently represents a mono-bond, -CH2-, -CH2-CH2-, -C(CH3)2-, -CH(OH)-, or -O-CH2-, wherein when -L3- is -O-CH2-, the CY3 is attached to the oxygen atom of the -O-CH2-; and CY3 independently represents a C3-6 cycloalkyl or C4-6 heterocyclic group, wherein the C4-6 heterocyclic group contains one or two mono-bonds. The CY3 is independently selected from nitrogen and oxygen cyclic heteroatoms; wherein the CY3 is independently unsubstituted, monosubstituted, disubstituted, or trisubstituted, wherein the substituents are independently selected from halogens; oxy groups; hydroxyl groups; C1-3 alkyl groups monosubstituted with C1-3 alkoxy groups as appropriate; C1-3 alkoxy groups; -(C=O)-RCO, wherein RCO represents a C1-3 alkyl group monosubstituted with hydroxyl or C1-3 alkoxy groups as appropriate; C1-3 fluoroalkyl groups; C1-3 alkoxy groups, wherein the C1-3 alkoxy groups are monosubstituted with C1-3 alkoxy groups as appropriate. Monosubstituted; C3-6 cycloalkyl-(CH2)n-, wherein one or two carbon ring atoms are replaced by one or two oxygen ring atoms, depending on the case; wherein n represents an integer 0, 1, or 2; or phenyl; -N(RN9)(RN10), wherein RN9 represents hydrogen or C1-3 alkyl; and RN10 represents C1-3 alkyl, C1-3 alkyl-carbonyl, C1-3 alkyl-sulfonyl, C1-3 alkoxy-carbonyl, C1-3 alkoxy-C1-3 alkyl-carbonyl, or tetrahydropiperanyl-carbonyl; -S(=O)2 -RSO, wherein RSO represents a C1-3 alkyl group monosubstituted with a hydroxyl, C1-3 alkoxy, or amino group as appropriate; or a C3-5 cycloalkyl group, wherein one carbon ring atom is substituted with an oxygen ring atom as appropriate; a 5-membered heteroaryl group containing a cyclic heteroatom selected from nitrogen, oxygen, and sulfur; wherein the 5-membered heteroaryl group is unsubstituted; and phenyl-(CH2)p-, wherein p represents an integer 0, 1, or 2; a phenyl or 6-membered heteroaryl group containing one or two cyclic nitrogen atoms; wherein the phenyl or 6-membered heteroaryl group is independently unsubstituted or monosubstituted with a C1-3 alkyl or C1-3 alkoxy group; pyrazolyl-C1-3 alkyl; C1-3 alkyl-sulfonyl-C1-3 alkyl; 3-hydroxymethyl-bicyclo[; 1.1.1] Pentyl-1-yl; 7-oxa-bicyclo[2.2.1] Heptyl-2-yl; and 6-oxa-spiro[2.5] Octyl-1-yl; 5-side-oxy-4-oxa-6-azaspiro[2.4] Heptyl-6-yl, 5-azaspiro[2.4] Heptane-6-one-5-yl, 2,2-dimethyl-6-side-oxy-5-oxa-7-azaspiro[3.4] Octyl-7-yl, 2-cyclopropyl-6-side-oxy-5-oxa-7-azaspiro[3.4] Octyl-7-yl, 2-side-oxy-1-oxa-3-azaspiro[4.4] Nonyl-3-yl, 8,8-difluoro-2-side-oxy-1-oxa-3-azaspiro[4.5] Decyl-3 - or 8-side-oxy-7-oxa-9-azabispiro[3.1.4.1]undecane-9-yl; 7-azabicyclo[2.2.1]hept-7-yl, 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, 6-oxa-3-azabicyclo[3.1.1]hept-3-yl or 8-oxa-3-azabicyclo[3.2.1]oct-3-yl; 5-side-oxy-6-azaspiro[3.4]oct-6-yl, 3-side-oxy-2-azaspiro[4.4]non-2-yl, 1-oxa-3-azaspiro[4.5]dec-2-one-3-yl, 1-side-oxy-2-azaspiro[4.5]dec-2-yl, 1- Side-oxy-8-oxa-2-azaspiro[4.5]dec-2-yl, 3-side-oxy-8-oxa-2-azaspiro[4.5]dec-2-yl or 4-side-oxy-hexahydro-5H-furano[2,3-c]pyrrole-5-yl; 3-(7-hydroxy-6,7-dihydro-5H-cyclopentano[b]pyridin-7-yl)propyl or 3-(8-hydroxy-5,6,7,8-tetrahydroquinoline-8-yl)propyl); 6-acetyl-5,6,7,8-tetrahydro-1,6-acetyl-2-yl; 2-(6,7-dihydro-5H-[1]pyridin-7-ol)-ethyl; 2-(8-hydroxy-5,6,7,8-tetrahydro-quinoline-8-yl) -Ethyl; 2,3-dihydro-isoindol-1-one-2-yl; and 6-acetyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-2-yl; B represents a phenyl group, which is unsubstituted, monosubstituted, disubstituted or trisubstituted, wherein if a first substituent is present, it is in the para position relative to the attachment point of B to the rest of the molecule, wherein the first substituent is selected from halogens; C1-5 alkyl; C2-4 alkenyl; C1-3 alkoxy; C1-3 alkoxy-C1-4 alkyl; C1-4 fluoroalkyl; C3-5 cycloalkyl that is independently unsubstituted or monosubstituted with C1-3 alkyl or C1-3 fluoroalkyl; -SF5; bicyclo[1.1].[1] Pentyl-1-yl; C3-5 cycloalkoxy; and C1-3 fluoroalkoxy; and if the remaining substituents of B are present, they are in the meta position relative to the attachment site of B to the rest of the molecule, wherein the remaining substituents are independently selected from halogens and C1-3 alkyl; or B represents benzothiophene or naphthyl; R1 represents C1-3 alkyl, cyano, or halogen; and R2 represents C1-4 alkyl, C3-5 cycloalkyl, C3-5 cycloalkyl-C1-3 alkyl, hydroxy-C1-3 alkyl, C1-3 alkoxy-C1-3 alkyl, or C1-3 fluoroalkyl, and at least one pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein A represents pyridin-3-yl, wherein A is monosubstituted at a position between A and the rest of the molecule relative to the attachment site of A, wherein the substituent is the first substituent as defined in claim 1.

3. The pharmaceutical composition of claim 2, wherein the substituent of A is a 5- or 6-membered heteroaryl group as defined in claim 1, wherein the substituent(e) of the 5- or 6-membered heteroaryl group, if present, is independently selected from, as appropriate, substituted C1-4 alkyl groups as defined in claim 1.

4. The pharmaceutical composition of claim 3, wherein the substituent of A is a 5- or 6-membered heteroaryl group containing one to three independently selected cyclic heteroatoms of nitrogen, oxygen and sulfur; wherein the 5- or 6-membered heteroaryl group is independently unsubstituted, monosubstituted, disubstituted or trisubstituted, wherein the substituent(e) is, if present, independently selected from C1-4 alkyl groups that are unsubstituted; monosubstituted with: hydroxyl; or C1-4 alkoxy; disubstituted with one substituent being hydroxyl and the other substituent being trifluoromethyl; or both substituents being hydroxyl; or disubstituted or trisubstituted with two substituents being fluorine and, if present, one substituent being hydroxyl.

5. The pharmaceutical composition of claim 3, wherein the substituent of A is 1,2,4-diazol-5-yl or 1,2,4-diazol-3-yl, wherein the diazolyl group is monosubstituted, wherein the substituent is independently selected from C1-4 alkyl groups monosubstituted with hydroxyl or C1-4 alkoxy groups.

6. The pharmaceutical composition of claim 3, wherein A represents pyridin-3-yl, wherein the pyridin-3-yl is monosubstituted at the meta position relative to the attachment site of the pyridin-3-yl to the remainder of the molecule, wherein the substituent represents 5-(hydroxy-methyl)-1,2,4-diazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-diazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-diazol-3-yl or 5-(2-hydroxy-1,1-dimethyl-ethyl)-1,2,4-diazol-3-yl.

7. A pharmaceutical composition of any one of claims 1 to 6, wherein B represents a monosubstituted, disubstituted, or trisubstituted phenyl group, wherein the first substituent is attached at the para position relative to the attachment site of B with the remainder of the molecule, wherein the substituent is selected from C1-5 alkyl; C1-3 alkoxy-C1-4 alkyl; C1-2-fluoroalkyl; C3-5 cycloalkyl, which is unsubstituted or monosubstituted with C1-3 alkyl or C1-3 fluoroalkyl; and C1-fluoroalkoxy; and the remaining substituents of B, if present, are independently selected from halogens.

8. A pharmaceutical composition of any one of claims 1 to 6, wherein B represents a phenyl group that is monosubstituted, wherein the substituent is attached at the para position relative to the attachment site of B to the remainder of the molecule, wherein the substituent is selected from isopropyl, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclobutyl, 1-methyl-cyclopropyl or 1-trifluoromethyl-cyclopropyl.

9. A pharmaceutical composition of any one of claims 1 to 6, wherein B represents a phenyl group that is monosubstituted, wherein the substituent is attached at the para position relative to the attachment site of B to the remainder of the molecule, wherein the substituent represents an isopropyl group.

10. The pharmaceutical composition of any one of claims 1 to 6, wherein R1 represents methyl.

11. The pharmaceutical composition of any one of claims 1 to 6, wherein R2 represents a C1-4 alkyl, C3-5 cycloalkyl, C3-5 cycloalkyl-C1-3 alkyl, or C1-3 fluoroalkyl.

12. The pharmaceutical composition of any one of claims 1 to 6, wherein R2 represents methyl.

13. The pharmaceutical composition of claim 1, wherein A represents pyridin-3-yl, wherein the pyridin-3-yl is monosubstituted at the meta position relative to the attachment site of the pyridin-3-yl to the remainder of the molecule, wherein the substituent represents 5-(hydroxy-methyl)-1,2,4-diazol-3-yl, 5-(1-hydroxy-1-methyl-ethyl)-1,2,4-diazol-3-yl, 5-(2-hydroxy-2-methyl-propyl)-1,2,4-diazol-3-yl or 5-(2-hydroxy-1,1-dimethyl- (Ethyl)-1,2,4-diazol-3-yl; B represents 4-propyl-phenyl, 4-isopropyl-phenyl, 4-isobutyl-phenyl, 4-tert-butyl-phenyl, 3-fluoro-4-isopropyl-phenyl, 3,5-difluoro-4-isopropyl-phenyl, 4-cyclopropyl-phenyl, 4-trifluoromethyl-phenyl, 4-trifluoromethoxy-phenyl, 4-(2,2,2-trifluoro-ethyl)-phenyl, 4-cyclobutyl-phenyl or 4-(1-trifluoromethyl-cyclopropyl)-phenyl; R1 represents methyl; and R2 represents methyl.

14. A pharmaceutical composition of any one of claims 1 to 6 or 13, wherein the compound is of formula (II).

15. The pharmaceutical composition of claim 1, wherein the compound or a pharmaceutically acceptable salt or stereoisomer thereof is: (3-fluoro-1-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; 3-[hydroxy-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methyl]-1-methyl-azacyclobutane-3-carboxylonitrile; (R)-(1-ethyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(3-methyl-1-propyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol. (R)-(1-isopropyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclopropylmethyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclobutyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-cyclobutyl-3-methyl-azacyclobutane-3-yl)-( (R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2-fluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2-fluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-[1-(2,2-difluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (R)-(1-tert-butyl-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; -Methyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-prop-1-ynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-1-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-3-yn-2-ol;(R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopentanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]- 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azacyclobutane-1-carboxylic acid tert-butyl ester; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-butane-3-yn-1-ol; )-(4-isopropyl-phenyl)-[5-(1-methyl-1H-pyrazol-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-but-3-yn-2-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-tetrahydro-piperan-4-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-piperan-4-yl)-prop-2-yn-1-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-prop-2-yn-1-ol;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-piperan-4-ylethynyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazo-4-yl)-prop-2-yn-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-1H-pyrazol ... 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazo-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl ... 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-prop-2-yn-1-ol;8-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-5,6,7,8-tetrahydro-quinoline-8-ol; 7-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-6,7-dihydro-5H-[1]pyridin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pent-1-yn-3-ol; 1-{5-[(R)-(1,3-dimethyl- Azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pent-1-yn-3-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-azacyclobutane-1-yl)-2-methyl-prop-1-one; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(1H-indol-2-ylethynyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5 -(3-methoxy-propyl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-methyl-but-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl]-prop-1-ol; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopentanol; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclopropanol; 3-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-3-hydroxy-azacyclobutane-1-carboxylic acid tertiary butyl ester;1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-cyclobutanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[2-(1-methyl-1H-pyrazol-4-yl)-ethyl]-pyridin-3-yl}-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)- 4-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-phenyl-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-phenyl-but-2-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-methyl-pentan-3-ol; 4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl) -Tetrahydro-piperan-4-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(tetrahydro-piperan-4-yl)-prop-1-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[2-(tetrahydro-piperan-4-yl)-ethyl]-pyridin-3-yl}-1-(1,3-dimethyl-1H-pyrazol-4-yl)-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[2-(tetrahydro-piperan-4-yl)-ethyl]-pyridin-3-yl}-1-(tetrahydro-piperan-4-yl)-ethyl]-pyridin-3-yl}-1-(tetrahydro-piperan-4-yl)-prop-1-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(2-methyl-thiazo-4-yl)-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-fluoro-phenyl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(4-methoxy-phenyl)-but-2-ol;4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-phenyl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazolyl-4-yl)-but-2-ol; 4- {5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyrimidin-2-yl-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-2-ol; 4-{5 -[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methylpyrimidin-4-yl)-but-2-ol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-(1,5-dimethyl-1H-pyrazol-3-yl)-prop-1-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinoline-8 - Alcohol; 7-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-6,7-dihydro-5H-[1]pyridin-7-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-pyridin-2-yl-pent-3-ol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methoxy-pyridin-2-yl)-pent-3-ol;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[2-(1H-indol-2-yl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(tetrahydro-piperan-4-yl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(2-methoxy-1,1-dimethyl-ethyl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-methanol; (R)-[5-(3 (R)-(1,2,4]-(1,2,4]-(3-cyclobutoxymethyl-[1,2,4]-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-propyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yloxymethyl)-[1,2,4]-(3-cyclobutoxymethyl)-[1,2,4]-(3-cyclobutoxymethyl)-[4-propyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yl)-[1,2,4]-(3-cyclobutoxymethyl)-[4-cyclobutane-5-yl]-pyridin-3-yl}-methanol; (R)-[5-(3-cyclobutoxymethyl)-[4-cyclobutane-3-yl)-[4-cyclobutane-phenyl)-{5-[3-(tetrahydro-piperan-4-yl)-[1,2,4]-(3-cyclobutoxymethyl)-[4-cyclobutane-5-yl]-pyridin-3-yl}-methanol; -[1,2,4]-diazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-propyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-ylmethyl-[1,2,4]-diazol-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3- -(2,6-dimethyl-morpholino-4-ylmethyl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-tetrahydro-piperan-4-yl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[(1S,2S,4R)-3-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-methanol;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(tetrahydro-piperan-4-yloxymethyl)-[1,2,4]azolidin-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-morpholin-4-yl-[1,2,4]azolidin-5-yl)-pyridin-3-yl]-pyridin-3-yl [Pyridin-3-yl]-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(4-methoxy-tetrahydro-piperan-4-yl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-methanol; (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[; 1.1.1]pent-1-yl)-[1,2,4]diazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[3-(3-hydroxymethyl-bicyclo[ 1.1.1]Pent-1-yl)-[1,2,4]pyridazol-5-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 2-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]pyridazol-3-yl)-2-methyl-prop-1-ol; 2-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]pyridazol-3-yl)-prop-2-ol; ... (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-1-methyl-ethyl)-[1,2,4]azolidin-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methoxy-cyclobutyl)-[1,2,4]azolidin-5-yl]-pyridin-3-yl}-methanol; 1-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azolidin-3-yl)-2-methyl-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methanesulfonylmethyl-[1,2,4]azolidin-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-ethyl)-[1,2,4]azolidin-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methoxymethyl-[1,2,4]azolidin-3-yl)-pyridin-3-yl]-methanol; (R)-( 1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-furan-3-yl)-[1,2,4] acediazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-yl)-[1,2,4] acediazol-3-yl]-pyridin-3-yl}-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4] acediazol-5-yl)-cyclohexanol;(R)-[5-(5-tert-butoxymethyl-[1,2,4]azolidin-3-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-ylmethyl)-[1,2,4]azolidin-3-yl]-pyridin-3-yl}-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azolidin-5-yl)-cyclohexanol; 1-(3-{5-[(R)-[5-[(R] ... (R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-cyclohexanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-cyclobutyl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-oxa-spiro[2.5]oct-1-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-oxa-spiro[2.5]oct-1-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-3-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-furan-2-yl)methyl]-[1,2,4]-diazol-3-yl}-pyridin-3-yl)-methanol; (R)-2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1,1,1-trifluoro-propane-2-ol) ;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxy-1-methyl-ethyl)-[1,2,4]azolidin-3-yl]-pyridin-3-yl}-methanol; (R)-{5-[5-((R)-cyclohexyl-hydroxy-methyl)-[1,2,4]azolidin-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azolidin-5-yl)-cyclopropanol;2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-cyclopentanol; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)- Cyclobutanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-(4-fluoro-tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-((2R,4R,6S)-2,6-dimethyl-tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-fluoro-tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-methyl-1-(tetrahydro-piperan-4-yl)-ethyl]-[1,2,4]azacyclobutane-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[2-(tetrahydro-piperan-4-yl)-ethyl]-[1,2,4]azacyclobutane-3-yl}-pyridin-3-yl)-methanol; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[2-(tetrahydro-piperan-4-yl)-ethyl]-[1,2,4]azacyclobutane-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-cyclobutanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(7-oxa-bicyclo[2.2.1]hept-2-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-tetrahydro-piperan-4-yloxymethyl)-[1,2,4] acediazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-oxacyclobutane-3-yl-[1,2,4] acediazol-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy] -1,1-Dimethyl-ethyl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-2-methyl-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-methoxy-2-methyl-propyl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; 1-(3 -{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-cyclobutanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methoxymethyl-cyclopropylmethyl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(2-pyrazol-1-yl-ethyl]-pyridin-3-yl]-methanol (R)-N-(2-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-azacyclobutane-5-yl)ethyl)acetamide-2,2,2-d3; (R)-N-(1-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-azacyclobutane-5-yl)-2-methylpropane-2-yl)acetamide-2,2,2-d3; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-2-hydroxy-acetone;(R)-1-(4-(3-(5-((1,3-dimethylaziridine-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)piperidin-1-yl)ethyl-1-one-2,2,2-d3;N-[2-(3-{5-[(R)-(1,3-dimethylaziridine-3-yl)-hydroxy-(4-isopropylphenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-ethyl]-2-hydroxy-N-methylacetamide;(R)-N-(2-(3-(5-((1,3-dimethylaziridine-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin- 3-yl)-1,2,4-diazol-5-yl)ethyl)-N-methylacetamide-d3; (1,3-dimethyl-azacyclobutane-3-yl)-(5-methyl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-propyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-methoxy-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (1 (3-Dimethyl-azacyclobutane-3-yl)-phenyl-(5-pyrrolidin-1-yl-pyridine-3-yl)-methanol; (4-cyclobutyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridine-3-yl)-methanol; (4-cyclobutoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridine-3-yl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-ethoxy-phenyl)-(5-pyrrolidin-1-yl-pyridine-3-yl)-methanol; (4-tert-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridine-3-yl)-methanol (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropoxy-phenyl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-methanol; (4-cyclopropoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-methanol;(S)-[2-(3,3-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-[2-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(2-isobutoxy-pyridin-4-yl)-(4-isopropyl-phenyl)-methanol; 4-{4-[(S)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)- (R)-[6-(3,3-difluoro-pyrrolidin-1-yl)-pyrrolidin-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-5-tert-butyl-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidin-3-yl}-azolidin-2-one; (R)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidin-3-yl}-pyrrolidin-3-ol; ( S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone-3-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((S)-3-hydroxymethyl-pyrrolidone-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-pyrrolidone-1-yl-pyridin-3-yl)-methanol; (S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone-3-ol; (R)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl] ... 3-Cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-ol; 2-((S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-morpholin-4-yl-pyridin-3-yl)-methanol;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-tetrahydro-2H-[1,3']bipyridin-5'-yl)-methanol; (R)-[5-(7-aza-bicyclo[2.2.1]hept-7-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-((S)-2-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl- (R)-[5-(3,3-difluoro-pyrrolidin-1-yl)-pyrrolidin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 5'-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridine-4-ol; 5'-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridine-3-ol; 5'-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3,4,5,6-tetrahydro-2H-[1,3']bipyridine-3-ol; (R) -{5-[(2-benzylmethyloxy-ethyl)-methyl-amino]-pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-methyl-cyclopropyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; 2-[(S)-1-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-}-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-}-(5-{(R)-(5-{(R)-(5-{(R)-(5-{(R)-(5-{(R)-{(1,3-dimethyl-azacyclobutane-3-}-{(R)-(5-{(R)-(5-{(R)-(5-{(R)-{(4 ... (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(3,4,5,6-tetrahydro-2H-[1,3']bipyridine-5'-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol;(R)-{5-[5-(1-cyclopropanesulfonyl-piperidin-4-yl)-[1,2,4]diazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 2-({5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-methyl-amino)-ethanol; (R)-1-((S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-ethanol; 3-{5-[(R)-(1,2,4]diazol-3-yl]-pyridin-3-yl}-pyrrolidin-3-yl)-ethanol; 2-({5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-3-yl)-ethanol; 3-{5-[(R)-(1,2,4]diazol-3-yl]-pyridin-3-yl]-pyrrolidin-3-yl)-ethanol; 3-{5-[(R)-(1,2,4]diazol-3-yl]-pyrrolidin-3-yl]-methanol; 2-(5-[(R)-(1,2,4]diazol-3-yl]-pyridin-3-yl]-methyl-amino)-ethanol; 3-{5-[(R)-(1,2,4]dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl 3-Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-azolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-phenyl-azolidin-2-one; 5-benzylmethyl-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-azolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl} -5-Isopropyl-azolidin-2-one; 6-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-oxa-6-aza-spiro[2.4]heptane-5-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-oxa-3-aza-spiro[4.4]non-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-(tetrahydro-piperan-4-yl)-azolidin -2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5,5-dimethyl-azolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8,8-difluoro-1-oxa-3-aza-spiro[4.5]dec-2-one; 9-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7-oxa-9-aza-dispiro[3.1.4.1]undec-8-one;2-Cyclopropyl-7-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-5-oxa-7-aza-spiro[3.4]oct-6-one; 7-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-dimethyl-5-oxa-7-aza-spiro[3.4]oct-6-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-phenyl-pyrrolidin-2-one; 1- {5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isopropyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3 ...phenyl]-pyridin-3-yl [Phenyl)-methyl]-pyridin-3-yl}-4,4-dimethyl-pyrrolidin-2-one; 5-(5-((R)-(1,3-dimethyl-azacyclobutane-3-yl)(hydroxy)(4-isopropyl-phenyl)methyl)pyridin-3-yl)hexahydro-4H-furano[2,3-c]pyrrolo-4-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4,4]non-3-one; 6-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-6-aza -spiro[3.4]oct-5-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]dec-3-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(tetrahydro-piperan-4-yl)-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-aza-spiro[4.5]dec-1-one;2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-8-oxa-2-aza-spiro[4.5]dec-1-one; (S)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isobutyl-pyrrolidin-2-one; 4-cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-isobutyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-trifluoromethyl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3- (2-Methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidin-3-yl}-4-(2-Methoxy-ethyl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidin-3-yl}-pyrrolidin-2-one; (1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidin-3-yl}-pyrrolidin-2-one; (1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidin-3-yl}-pyrrolidin-2-one; (1,3-dimethyl-azacyclobutane-3-yl)-pyrrolidin-2-one; (R)-(4-isopropyl-phenyl)-[5-((R)-3-isopropyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((2R,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[; 3.1.1]Hept-3-yl)-pyridin-3-yl]-methanol; (R)-[5-((3R,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-[5-((3S,4S)-3,4-difluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl) -Methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((2S,6S)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((2R,6R)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((2R,6R)-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(3-methyl-[1,2,4]-diazol-5-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-thiazolyl-2-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(4-methyl-thiazolyl-2-yl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(3,3-dimethyl-azacyclobutane-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2][1]Hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(2,2,6,6-tetrafluoro-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-((R)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-((S)-2-methoxymethyl-morpholin-4-yl)-pyridin-3-yl]-methanol -3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-trifluoromethyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[(1R,4R)-5-(2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[(1S,5R)-5-(8-oxa-3-aza-bicyclo[... 3.2.1] Oct-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1] hept-5-yl)-pyridin-3-yl]-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-[5-(6-oxa-3-aza-bicyclo[ 3.1.1]Hept-3-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-[(1S,4S)-5-(2-oxa-5-aza-bicyclo[2.2.1]Hept-5-yl)-pyridin-3-yl]-methanol; (R)-(5-benzylmethyloxy-pyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyridin-2-yl-ethoxy)-pyridin-3-yl]-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyridin-2-yl-ethoxy)-pyridin-3-yl]-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(2-pyridin-2-yl-ethoxy)-pyridin-3-yl]-methanol; (5-(2-methoxy-ethoxy)-pyridin-3-yl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(oxacyclobutane-3-ylmethoxy)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-isopropoxy-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(5-cyclohexyloxy-pyridin-3-yl)-(1,3-dimethyl-azacyclobutane)-(5-isopropoxy-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(5-cyclohexyloxy-pyridin-3-yl)-(1,3-dimethyl-azacyclobutane)-(5-isopropoxy-pyridin-3-yl)-(5-cyclohexyloxy-pyridin-3-yl)-(1,3-dimethyl-azacyclobutane)-(5-isopropoxy-pyridin-3-yl)-(5-isopropyl-phenyl)-(5-cyclohexyloxy-pyridin-3-yl ... -3-yl)-(4-isopropyl-phenyl)-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-methoxy-cyclopentyloxy)-pyridin-3-yl]-methanol; (R)-[5-(3-cyclopropyl-[1,2,4]-diazol-5-ylmethoxy)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 3-yl)-{5-[2-(3,5-dimethyl-[1,2,4]triazol-1-yl)-ethoxy]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-2-methyl-but-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-methoxy-pyridin-3-yl)-methanol; (R)-[5-(2-benzylmethyloxy-ethoxy)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-piperan-4-yloxy)-pyridin-3-yl]-methanol; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-ethanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclo Hexanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-1-methyl-cyclohexanol; (1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrazol-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(6-fluoro-5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethoxy-phenyl)-methanol; 5-[(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-3-pyrrolidone-1-yl-pyridine-2-carboxynitrile; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-thiazolyl-2-yl)-pyridine-3-yl]-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl) (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyrrolidin-4-yl)-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(2-pyrrolidin-1-yl-pyrrolidin-4-yl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-[2-((R)-2-hydroxymethyl-pyrrolidin-1-yl)-pyrrolidin-4-yl]-(4-isopropyl-phenyl) -Methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(3,4,5,6-tetrahydro-2H-[1,2']bipyridin-4'-yl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(2-morpholin-4-yl-pyridin-4-yl)-methanol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(2-ethyl (S)-(1,3-dimethyl-azonobutan-3-yl)-(4-isopropyl-phenyl)-[2-(tetrahydro-piperan-4-ylmethoxy)-pyridin-4-yl]-methanol; (S)-(1,3-dimethyl-azonobutan-3-yl)-(4-isopropyl-phenyl)-[2-(2-methoxy-ethoxy)-pyridin-4-yl]-methanol;(S)-(2-cyclopentyl-pyridin-4-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridin-3-yl)-(4-trifluoromethyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((R)-3-hydroxymethyl-3-methyl-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-((S)-3-fluoro-pyrrolidin-1-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[4-(tetrahydro-piperan-4-yl)-[1,2,3]triazol-1-yl]-pyridin-3-yl}-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(5-isopropenyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (5-cyclopropyl-pyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (5-cyclopent-1-enyl-pyridin-3-yl) 3-{5-[(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopentan-2-enol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-isopropyl-pyridin-3-yl)-methanol; (5-cyclopentyl-pyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 3-{5-[(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopentan-2-enol; Alcohols; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-pyridin-3-yl-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopentanone; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclopentan-2-enol; (3S)-3-(5-((R)-(1,3-dimethyl-azacyclobutane-3-yl)(hydroxy)(4-isopropyl-phenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol;(3R)-3-(5-((R)-(1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1-methylcyclopentan-1-ol; 3-{5-[(R)-(1,3-dimethylazacyclobutane-3-yl)-hydroxy-(4-isopropylphenyl)-methyl]-pyridin-3-yl}-1-ethyl-cyclopentanol; 3-{5-[(R)-(1,3-dimethylazacyclobutane-3-yl)-hydroxy-(4-isopropylphenyl)-methyl]-pyridin-3-yl}-1-isopropyl-cyclopentanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(4-methyl-azolo-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-ethyl-pyridin-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-methyl-pyridin-3-yl)-methanol; (R)-[5-(4,5-dihydro-furan-3-yl)-pyridin-3-yl]-( 1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-3-yl)-pyridin-3-yl]-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-en-1-ol; N-cyclopentyl-5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4- [5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidin-1-yl-methyl ketone; 5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-N-(tetrahydro-piperan-4-yl)-nicotinamide; (1,3-dimethyl-azacyclobutane-3-yl)-[4-(3-methoxy-propyl)-phenyl]-(5-pyrrolidin-1-yl-pyridin-3-yl ...(5-(3-methoxy-propyl)-phenyl)-(5-pyrrolidin-1-yl-pyrrolidin-3-yl)-(5-(3-methoxy-propyl)-phenyl)-(5-(3-methoxy-propyl)-phenyl)-(5-(3-methoxy-propyl)-phenyl)-(5-(3-methoxy-propyl)-phenyl)-(5-( (R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridine-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(5-pyrrolidin-1-yl-pyridine-3-yl)-p-tolyl-methanol; 5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridine-1'-carboxylic acid tertiary butyl ester;3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrrolidone-1-carboxylic acid tert-butyl ester; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-piperan-4-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(3',4',5',6'-tetrahydro-2'H-[2,1';4',3'']terpyridin-5''-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-(tetrahydro-piperan-4-yl)-pyridin-3''-yl)-methanol (R)-(1'-phenyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridin-5-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[1'-(toluene-4-sulfonyluyl)-1',2',3',4',5',6'-hexahydro-[3,4']bipyridin-5-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(tetrahydro-furan-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-) 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5,5-dimethyl-tetrahydro-furan-2-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2,2-difluoro-prop-1-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-azol-2-yl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-azol-2-yl)-pyridin-3-yl]-methanol; Cyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-yl)-azol-2-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(4-fluoro-phenoxymethyl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; isopropyl-carbamate 5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl methyl ester; (R)-[5-(2-benzylmethyloxy-ethyl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol;4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-methyl-cyclohexanol; 2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclopropyl)-prop-2-ol; (S)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{2-[5-(tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-4-yl}-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{2-[5-(tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-4-yl}-methanol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-4-yl}-methanol (R)-N-(1-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)cyclopropyl)acetamide-2,2,2-d3; (R)-N-(1-(3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)cyclopropyl)-N-methylacetamide-d3; (R)-N-((3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)) (4-Isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)methyl)-N-methylacetamide-d3; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropylphenyl)-methyl]-pyridin-3-yl}-[1,2,4]azol-5-ylmethyl)-2-hydroxyacetamide; (R)-N-((3-(5-((1,3-dimethylazacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)methyl)acetamide-2,2,2-d3; 1-(3-{5-[(R)-hydroxy-(1-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)methyl)acetamide-2,2,2-d3; propyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-2-methyl-prop-2-ol; 1-(3-{5-[(R)-(1-ethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-2-methyl-prop-2-ol; 2-(3-{5-[(R)-hydroxy-(1-isopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol;2-(3-{5-[(R)-(1-ethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-yl)-piperidin-1-carboxylic acid methyl ester; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl} -[1,2,4](1,2,4)-diazol-3-yl)-piperidin-1-yl]-ethyl ketone;(R)-1-(3-(3-(5-((1,3-dimethylaziridine-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)aziridine-1-yl)ethyl-1-one-2,2,2-d3;(R)-1-(3-(3-(5-((1,3-dimethylaziridine-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)-3-methylaziridine-1-yl)ethyl-1-one-2,2,2-d3;(R) -1-(3-(3-(5-((1,3-dimethyl-azacyclobutane-3-yl)(hydroxy)(4-isopropylphenyl)methyl)pyridin-3-yl)-1,2,4-diazol-5-yl)-3-fluoroazacyclobutane-1-yl)ethyl-1-one-2,2,2-d3;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropylphenyl)-{5-[5-(1-methyl-1-morpholin-4-yl-ethyl)-[1,2,4]diazol-3-yl]-pyridin-3-yl}-methanol;4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropylphenyl) 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azacyclobutane-5-yl)-pyrrolidin-1-yl]-acetone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azacyclobutane-5-yl)-pyrrolidin-1-yl]-acetone;N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1-methyl-ethyl]-acetylamine; 1-benzyl-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-pyrrolidone; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-pyrrolidone 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-5-diazole-1-isobutyl-pyridin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-5-diazole-1-furan-2-ylmethyl-pyridin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-5-diazole-1-furan-2-ylmethyl-pyridin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy- 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-1-phenyl-pyrrolidone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-pyrrolidone; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-1-phenyl-pyrrolidone; 4-(3-{5-[(R)- (1,3-Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-pyrrolidone; (S)-5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-pyrrolidone; (R)-5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-pyrrolidone;(S)-6-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-2-one; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol (S)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-azacyclobutane-2-one; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1,4-dimethyl-pyrrolidin-2-one; (R)-(1,3-dimethyl-aziridine-3-yl)-(4-isopropyl-phenyl)-[5-(5-piperidin-4-yl-[1,2,4]aziridine-3-yl)-pyridine-3-yl]-methanol; (R)-(1,3-dimethyl-aziridine-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-piperidin-4-yl)-[1,2,4]aziridine-3-yl]-pyridine-3-yl}-methanol; (R)-(1,3-dimethyl-aziridine-3-yl)-(4-isopropyl-phenyl)-{5-[5-(4-methyl-piperidin-4-yl)-[1,2,4]aziridine-3-yl]-pyridine-3-yl}-methanol; (R)-(1,3-dimethyl-aziridine-3-yl)-{5-[5-( 4-Fluoro-piperidin-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-but-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-2,2-dimethyl-prop-1-one;1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-2-methoxy-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-3-methoxy-prop-1-one; cyclopropyl-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-3-methoxy-prop-1-one] pyridin-3-yl}-[1,2,4]pyridazol-5-yl)-piperidin-1-yl]-methyl ketone; cyclopentyl-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]pyridazol-5-yl)-piperidin-1-yl]-methyl ketone; [4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)piperidin-1-yl]-(tetrahydro-piperan-4-yl)-methyl ketone; ... Butane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-phenyl-methyl ketone; methyl 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-carboxylate; ethyl 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-carboxylate; ethyl 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-carboxylate; 3-Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-piperidin-1-carboxylic acid 2-methoxy-ethyl ester; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methanesulfonyl- (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-2-sulfonyl)-piperidin-4-yl]-[1,2,4]azacyclobutane-3-yl}-pyridin-3-yl)-methanol;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(propane-1-sulfamethoxy)-piperidin-4-yl]-[1,2,4]-diazol-3-yl}-pyridin-3-yl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(2-methoxy-ethanesulfamethoxy)-piperidin-4-yl]-[1,2,4]-diazol-3-yl}-pyridin-3-yl)-methanol; 2-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)- (R)-{5-[5-(1-cyclopentanesulfonyl-piperidin-4-yl)-[1,2,4]diazol-5-yl)-piperidin-1-sulfonylurea]-ethanol; (R)-{5-[5-(1-cyclopentanesulfonyl-piperidin-4-yl)-[1,2,4]diazol-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{5-[1-(tetrahydro-piperan-4-sulfonylurea)-piperidin-4-yl]-[1,2,4]diazol-3-yl}-pyridin-3-yl)-methanol; 4-(3-{5-[(R)-( 1,3-Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidine-1-sulfonic acid methylamide; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(1-methylamino-cyclopropyl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; [1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-cyclopropyl] ethyl methyl-aminocarbamate; N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-cyclopropyl]-N-methyl-methanesulfonamide; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[6-(2,2-dimethyl-cyclopentyloxy)-tazo-4-yl]-(4-isopropyl-phenyl)-methanol; (R)-[6-(3,3-difluoro-cyclopentyloxy)-tazo-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol;2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yloxy}-phenyl)-ethanol; 2-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yloxy}-phenyl)-ethanol; (R)-[6-(ta-6-yloxy)-ta-4-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 6-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)- (R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pent-1-yn-3-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R ...3H-benzopyrimidin-4-yl}-3H-benzopyrimidin-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3- (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1,5-dimethyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-(1,3- (S)-4-{5-[1-(4-fluoro-phenyl)-cyclopropylethynyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrazol-3-yl)-but-3-yn-2-ol;3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-pyrrolidone-1-carboxylic acid tributyl ester; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidine-1-carboxylic acid tributyl ester; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pentan-3-ol; 2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-3-(6-methyl-pyrimidin-4-yl)-pentan-3-ol; Methyl benzoate ((R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-benzoate; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[2-(2-hydroxymethyl-phenyl)-ethyl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-2-ol; 3-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-2-ol]- 4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-{5-[2-(1H-pyrrolo[2,3-b]pyridin-2-yl)-ethyl]-pyridin-3-yl}-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidin-1-carboxylic acid tertiary butyl ester; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-pyridin- 2-yl-but-2-ol; 1-cyclopropyl-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-pyridin-2-yl-prop-1-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridin-3-yl)-but-2-ol; 8-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-5,6,7,8-tetrahydro-quinoline-8-ol;4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-2-(6-methoxy-pyridin-2-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-2-(6-methyl-pyridin-2-yl)-but-2-ol; (1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(6-pyrrolidin-1-yl-pyridin-2-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)- 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxy}-cyclohexanone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy- (4-Isopropyl-phenyl)-methyl]-pyridin-3-yl}-cyclohexanol; (R)-(5-cyclopentyloxymethyl-pyridin-3-yl)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylmethoxy}-piperidin-1-yl)-acetone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[6-(tetrahydro-piperan-4-yl)-tazo-4-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl]-[6-(tetrahydro-piperan-4-yl)-tazo-4-yl]-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{6-[(S)-(tetrahydro-furan-3-yl)oxy]-azacyclobutane-4-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{6-[(R)-(tetrahydro-furan-3-yl)oxy]-azacyclobutane-4-yl}-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-azacyclobutane-3-yl}-4-methyl-pyrrolidone;1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-3-isopropyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-3,3-dimethyl-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-4,4-dimethyl-pyrrolidone; 5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-4,4-dimethyl-pyrrolidone; 3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yl}-5-aza-spiro[2,4]heptane-6-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yl}-4-trifluoromethyl-pyrrolidin-2-one; 4-cyclopropyl-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yl}-pyrrolidin-2-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yl}-pyrrolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yl}-1-oxa-3-aza-spiro[4.5]dec-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yl}-4-pyridin-2-yl-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-ta-3-yl}-3-( 2-Methoxy-ethyl)-pyrrolidone-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-4-phenyl-pyrrolidone-2-one; 2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-2,3-dihydro-isoindol-1-one; 2-(3-{5-[(S)-(3-fluoro-1-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrrolidone-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol;2-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(S)-(3-fluoro-1-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(S)-(1-cyclopropyl-3-fluoro-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 4][5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4][5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4][5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4][5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4][5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5- ... (tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-methanol; trans-4-(3-{5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-cyclohexanol; (R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-oxacyclobutane-3-yl-[1,2,4]-diazol-3-yl)-pyridin-3-yl]-methanol; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-[1,2,4]-diazol-3-yl)-pyridin-3-yl]-methanol; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azolidin-5-yl)-pyrrolidin-1-yl]-acetone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azolidin-5-yl)-piperidin-1-yl]-acetone;1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-3-methyl-piperidin-1-yl]-acetone; 1-[3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-piperidin-1-yl]-acetone; [1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azacyclobutane-5-ylmethyl)-cyclopropyl]-acetylamine; tetrahydro-piperan-4-carboxylic acid [1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azacyclobutane-5-ylmethyl)-cyclopropyl]-acetylamine; N-[1-(3-{ 5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-cyclopropyl]-2-methoxy-acetamide; N-[1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-cyclopropyl]-N-methyl-acetamide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin- [3-yl}-[1,2,4]-diazol-5-yl)-1,1-dimethyl-ethyl]-propionamide; N-[2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1,1-dimethyl-ethyl]-2-methoxy-acetamide; Tetrahydro-piperan-4-carboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1,1-dimethyl-ethyl]-acetamide;N-[2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azolidinyl-5-yl)-1,1-dimethyl-ethyl]-isobutylamine; cyclopropanecarboxylic acid [2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azolidinyl-5-yl)-1,1-dimethyl-ethyl]-acetamide; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)]-acetamide]-[1,2,4]azolidinyl-5-yl)-1,1-dimethyl-ethyl]-acetamide; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-4-hydroxy-piperidin-1-yl]-2-methyl-prop-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-4-hydroxy-piperidin-1-yl]-prop-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-4-methoxy-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-3,3,3-trifluoro-prop-1-one; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl ...propane]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]-acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]acetone]ace [4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azacyclobutane-5-yl)-4-ethyl-piperidin-1-yl]-ethyl ketone; [4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azacyclobutane-5-yl)-piperidin-1-yl]-oxetane-3-yl ketone;1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-4-isopropyl-piperidin-1-yl]-2-methoxy-ethyl ketone; 1-[cis-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-3-methyl-piperidin-1-yl]-ethyl ketone; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl] 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-5-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-5-methyl-piperidin-2-one; 5-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-piperidin-2-one; 4 ... 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-ylmethyl)-3,3-dimethyl-pyrrolidone; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-ylmethyl)-imidazolidine-2,4-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-ylmethyl)-imidazolidine-2,4-dione; 1-(3-{5-[(R)-(1,3-[1,3-[1,3-[1,2,4]azin-5-ylmethyl]-imidazolidine-2,4-dione; 1-(3-{5-[(R)-( ... Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyrrolidone; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-1-methyl-imidazolidine-2,4-dione;1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-3-methyl-imidazolidine-2,4-dione; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyridin-2-one; 1-cyclopropyl-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin- 3-yl}-[1,2,4]-diazol-5-ylmethyl)-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyrrolidine-2,5-dione; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-3-methyl-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-3-methyl-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-3-methyl-imidazolidine-2-one; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azinazole-5-ylmethyl)-imidazolidine-2-one; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azinazole-5-yl)-prop-1,2-diol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-pyridin-3-yl-[1,2,4]azinazole-3-yl)-pyridin-3-yl]-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-[5-(5-pyridin-3-yl-[1,2,4]azinazole-3-yl)-pyridin-3-yl]-methanol; (3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-piperidin-1-yl]-acetonitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-acetonitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-4-hydroxy-piperidin-1-yl]-acetonitrile;3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-propionitrile; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-3-methoxy-piperidin-1-yl]-acetone; 1-[(R)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-3-methoxy-piperidin-1-yl]-acetone; 3-Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-tetrahydro-piperan-4-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-(3-hydroxymethyl-bicyclo[; 1.1.1]Pent-1-yl)-[1,2,4]pyridazol-3-yl]-pyridin-3-yl}-(4-isopropyl-phenyl)-methanol; 4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]pyridazol-5-yl)-1-methyl-piperidin-2,6-dione; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]pyridazol-5-yl)-2,2-difluoroethanol;(R)- (1,3-Dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(3-methoxy-phenyl)-[1,2,4]azolidin-3-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-[5-(5-isopropyl-[1,2,4]azolidin-3-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[5-(6-methylpyrimidin-4-yl)-[1,2,4]azolidin-3-yl]-pyridin-3-yl}-methanol; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1-methyl-pyrrolidone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1-methyl-pyrrolidone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1-methyl-pyrrolidone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1-methyl-pyrrolidone; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-1-ethyl-pyrrolidone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-1-isopropyl-pyrrolidone;(R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-1-isopropyl-pyrrolidone; 1-[(S)-3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyrrolidone-1-yl]-acetone; (S)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-ylmethyl)-pyrrolidone-1-yl]-acetone; (R)-4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azin-5-yl)-piperidin-2-one; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(5-methyl-[1,2,4]azin-3-yl)-pyridin-3-yl]-methanol; (R)-{5-[5-(1,1-difluoro-ethyl)-[1,2,4]azinazole [-3-yl]-pyridin-3-yl}-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; 4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]azadiazol-3-yl)-tetrahydro-piperan-4-ol; (R)-[5-(3-tert-butoxymethyl-[1,2,4]azadiazol-5-yl)-pyridin-3-yl]-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl) -[5-(3-hydroxymethyl-[1,2,4]-diazol-5-yl)-pyridin-3-yl]-(4-isopropyl-phenyl)-methanol; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-yl)-piperazin-1-yl]-acetone; 1-[3-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-ylmethyl)-azacyclobutane-1-yl]-acetone;4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-ylmethyl)-tetrahydro-piperan-4-ol; [4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-yl)-piperidin-1-yl]-[1,4]di-2-yl-methyl ketone; 1-[4-(5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-yl)-piperidin-1-yl]-[1,4]di-2-yl-methyl ketone; [3-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl]-2-methoxy-ethyl ketone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-{5-[3-(1-methanesulfonyl-piperidin-4-yl)-[1,2,4]-diazol-5-yl]-pyridin-3-yl}-methanol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-{3-[1-(2-methoxy-ethanesulfonyl)-piperidin-4-yl]-[1,2,4]-diazol-5-yl}-pyridin-3-yl)-methanol; 1-[4-(5-{5-[(R)- (1,3-Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-3-yl)-piperidin-1-yl]-2-hydroxy-acetone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-(5-[1,2,4]-diazol-3-yl-pyridin-3-yl)-methanol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 2-(3-{5 -[(R)-(4-bromo-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-naphthyl-2-yl-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-prop-2-ol;2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl]-prop-2-ol]-prop-2-ol]-prop-2-ol; 2-(3-(5-((1,3-dimethylaziridine-3-yl)-[1,2,4]pyridin-5-yl)prop-2-ol; (R)-2-(3-(5-((1,3-dimethylaziridine-3-yl)(hydroxy)(4-(pentafluoro-λ6-thioalkyl)phenyl)methyl)pyridin-3-yl)-1,2,4-aziridine-5-yl)prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethylaziridine-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]pyridin-3-yl}-[1,2,4]aziridine-5-yl)prop-2-ol; 2-(3-{5-[(R)-(4-tert-butyl-phenyl)-(1 2-(3-{5-[(R)-benzo[b]thiophene-5-yl-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-pentafluoroethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-pentafluoroethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-3-methyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol;1-[4-(3-{5-[(R)-(4-bromo-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-piperidin-1-yl]-acetone; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-fluoro-1-methyl-ethyl)-phenyl]-hydroxy] 2-(3-{5-[(R)-[4-(1,1-difluoro-ethyl)-phenyl]-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]azacyclobutane-5-yl)-propane-2-ol; 2-(3-{5-[(R)-(4-bicyclo[; 1.1.1]Pent-1-yl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-{5-[5-(tetrahydro-piperan-4-yl)-[1,2,4]-diazol-3-yl]-pyridin-3-yl}-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methanol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1,1-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5- 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(3-fluoro-4-isopropyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-piperidin-1-yl}-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethyl-cyclopropyl)-methyl] ...]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethyl-cyclopropyl)-methyl]-pyrid [Methoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropoxy-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 2-(3-{5-[(R)-(3-chloro-4-isopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-cyclobutyl-phenyl]- 1-[4-(3-{5-[(R)-(4-cyclobutyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone;2-(3-{5-[(R)-(3,5-difluoro-4-isopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 2-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl]-prop-2-ol]-prop-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl]-prop-2-ol]-prop-2-ol; 1-[4-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-prop-2-yl] ... 1-{4-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(1-ethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]azin-5-yl]-piperidin-1-yl}-acetone; 2-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]azin-5-yl]-prop-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]azin-5-yl]-prop-2-ol; 1-{4-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-[4-ethyl-propyl)-[4-ethyl-propyl] ... -(2,2-dimethyl-propyl)-phenyl]-hydroxy-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-piperidin-1-yl}-acetone; 1-{4-[3-(5-{(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-piperidin-1-yl}-acetone; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3 -{5-[(R)-(4-cyclopropyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-(3-{5-[(R)-(4-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol;2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; 2-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-prop-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isobutyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl) -propan-2-ol; 2-(3-{5-[(R)-(4-cyclobutoxy-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)propan-2-ol; 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropenyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)propan-2-ol; 1-{4-[3-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-[1,2 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-propyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazole-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazole-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azacyclobutane-3-yl ...]-[1,2,4]-diazole-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-yl]-[5-[(R)-[1-(2,2-difluoro-ethyl)-3-[5-[(R)-[1-(2,2-difluoro-ethyl)-3-[5-[(R)-[1-(2,2-difluoro-ethyl)-3-[5-[(R)-[1-(2,2-difluoro-ethyl)-3-[5-[(R)-[1-(2,2-difluoro-ethyl)-3-[5-[(R)-[1-(2,2-difluoro [3-{5-[(R)-(1-(2-hydroxy-ethyl)-3-methyl-azacyclobutane-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-pyridin-5-yl]-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1-cyclopropylmethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-pyridin-5-yl]-piperidin-1-yl]-acetone;1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[1-(2-methoxy-ethyl)-3-methyl-azacyclobutane-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-piperidin-1-yl}-acetone; 1-{4-[3-(5-{(R)-hydroxy-(4-isopropyl-phenyl)-[3-methyl-1-(3,3,3-trifluoro-propyl)-azacyclobutane-3-yl]-methyl}-pyridin-3-yl)-[1,2,4]-diazol-5-yl]-piperidin-1-yl}-acetone; 1-[4-(3-{5-[(R)-hydroxy-(4-isopropyl-phenyl)-(3-methyl- 1-Propyl-azacyclobutane-3-yl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1-ethyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-piperidin-1-yl]-acetone; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidin-1-yl)-acetone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-piperidin-1-yl)-acetone; -azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-but-3-yn-2-ol; cyclopropanecarboxylic acid (3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-yn-yl)-acetylamine; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-yn-yl)-isobutylamine; N-(3-{5-[(R)-( 1,3-Dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-2-methoxy-acetylamine; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidone; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidone;1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-3-methyl-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-prop-2-ynyl)-imidazolidine-2-one; 3-(1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropyl)-azolidinidine-2- Ketones; 1-((R)-2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-2-methyl-pyrrolidin-1-yl)-ketones; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-hydroxy-piperidin-1-yl)-ketones; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-1-methyl-prop-2-ynyl)-piperidin -1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop-2-ynyl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-2-ynyl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-prop-2-ynyl)-piperidin-1-yl]-acetone; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1-hydroxy-prop- 2-Alynyl)-4-methyl-piperidin-1-yl]-acetone; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidin-1-yl)-acetone; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(1-methanesulfonyl-piperidin-4-ylethynyl)-pyridin-3-yl]-methanol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-4-methyl-piperidin-1-sulfonic acid methylamine;(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-[5-(3-methanesulfonyl-3-methyl-but-1-ynyl)-pyridin-3-yl]-methanol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonate dimethylamine; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-cyclopropanesulfonate dimethylamine; (R)-[5-(3-cyclopropanesulfonyl-3-methyl-but-1-ynyl]-pyridin-3-ylethynyl}-cyclopropanesulfonate dimethylamine; (R)-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methanol; (S)-3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-pyrrolidin-2-one; 3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-ylethynyl}-3-hydroxy-1-methyl-1,3-dihydro-indole-2-one; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-3-yn-2-ol ...2H-phenyl-2-yl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-2H-phenyl-2-yl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-3 2-(1-methyl-1H-indazol-3-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol;4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridine-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazolyl-5-yl)-but-3-yn-2-ol; 2-(6-cyclopropyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl} (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl] (R)-4-{5-[(R)-(1,3-dimethyl-aziridine-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S ...]-pyridin-3-yl}-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-aziridine-3-yl]-pyridin-3-yl]-2-(2-methoxy-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-aziridine-3-yl]-2-[5-[(R)-[1,3-di (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-2-(2,6-dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2,6-dimethyl-pyrimidin-4-yl)-but-3-yn-2-ol;(R)-2-(2,6-dimethoxy-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methoxy-6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S ... (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methoxy-2-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)- (R)-(1,3-dimethyl-azetane-3-yl)-2-(6-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 2-(6-difluoromethyl-pyrimidin-4-yl)-4-{5-[(R)-(1,3-dimethyl-azetane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyrimidin-3-yl}-but-3-yn-2-ol; (R)-(1,3-dimethyl-azetane-3-yl)-(4-isopropyl-phenyl)-[5-(1-pyridin-2-yl-cyclopropylethynyl)-pyridin-3-yl]-methanol; (R)-(1,3-dimethyl-azetane-3-yl)-(4-isopropyl-phenyl)-{5-[1-(6-methyl-pyrimidin-4-yl)-cyclo[4-isopropyl-phenyl]-[5-[1-(6-methyl-pyrimidin-4-yl)-[4-isopropyl-phenyl]-[5-[1-(6-methyl-pyrimidin-4-yl)-[4-isopropyl-phenyl]-[5-[1-(6-methyl-pyrimidin-4-yl)-[5-[1-[6-methyl-pyrimidin-4-yl] ... [Propylethynyl]-pyridin-3-yl}-methanol; 1-[4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-piperidin-1-yl]-acetone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1,1-trifluoro-2-methyl-but-2-ol; 3-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-azolidin-2-one;1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-pyrrolidone-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-3-methyl-imidazolidine-2-one; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-1,1-dimethyl-propyl)-imidazolidine-2-one; 1-[(S)-2-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-ethyl)-2-methyl-pyrrolidin-1-yl]-acetone; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1H-indazol-3-yl)-but-2-ol; 2-(1-cyclopropyl-1H-pyrazol-3-yl)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-but-2- Alcohols; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-pyrimidin-4-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-pyridin-2-yl)-but-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-methyl-thiazolyl-5-yl)-but-2-ol; 4-{5-[( R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(3-methyl-isoazol-5-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-imidazol-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(5-methyl-thiophen-2-yl)-but-3-yn-2-ol;4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(1-methyl-1H-pyrrolo-2-yl)-but-3-yn-2-ol; (R)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2-trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(2 -trifluoromethyl-pyrimidin-4-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(1-methyl-cyclopropyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy- (4-Trifluoromethyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-ethyl-phenyl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(4-tert-butyl-phenyl)-(1,3-dimethyl-azacyclobutane-3-yl ...3-ethyl-1-methyl-azacyclobutane-3-yl)-hydroxy-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(3-ethyl-1-methyl-azacyclobutane-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(6-ethyl-1-methyl-azacyclobutane-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(6-ethyl-1-methyl-azacyclobutane-3-yl)-2-(6-methyl-pyridin-2-yl Cyclobutane-3-yl)-hydroxy-(4-trifluoromethoxy-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-(5-{(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-[4-(2,2,2-trifluoro-ethyl)-phenyl]-methyl}-pyridin-3-yl)-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(S)-(3-fluoro-1-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol;1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-ylethynyl}-piperidin-1-yl)-acetone; N-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-1,1-dimethyl-prop-2-ynyl)-acetamide; 1-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tadala-3-yl}-1,1-dimethyl-prop-2-ynyl)-pyrrolidin-2-one; 4-{5-[(R)-hydroxy 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-hydroxy-[1-(2-hydroxy-ethyl)-3-methyl-azacyclobutane-3-yl]-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 4-{5-[(R)-[1-(2,2-difluoro-ethyl)-3-methyl-azacyclobutane-3-yl]-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yn-2-ol; 1-(4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yloxymethyl}-piperidin-1-yl)-acetone; 4-{5-[(R)-(1-cyclopropyl-3-methyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyridin-2-yl)-but-3-yl]- 2-Alkyne alcohol; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-isopropyl-pyrimidin-4-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(2-methyl-thiazo-5-yl)-pyrrolidin-2-one; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-methyl-pyridin-3-yl)-pyrrolidin-2-one;1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-trifluoromethyl-pyridin-3-yl)-pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1-methyl-1H- 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(1,3-dimethyl-1H-pyrazol-4-yl)-pyridin-2-yl; 4-(1-difluoromethyl-1H-pyrazol-4-yl)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyridin-2-yl; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyridin-2-yl; 4-(1-methyl]-pyridin-3-yl}-4-(2-methyl-2H-[1,2,3]triazol-4-yl)-pyrrolidone; 4-(1-acetylopirin-4-yl)-1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-pyrrolidone; 5-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-hexahydro-furano[2,3-c]pyrrolidone; 1-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-tazo-3-yl}-hexahydro-furano[2,3-c]pyrrolidone; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-4-(6-isopropyl-pyridin-2-yl)-pyrrolidone; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-pyrido[4,3-d]pyrimidin-6-yl)-acetone; 1-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-7,8-dihydro-5H-[1,6]pyridin-6-yl)-acetone;1-[4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-5-yl)-piperidin-1-yl]-acetone; or 1-[4-(2-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-pyrimidin-4-yl)-piperidin-1-yl]-acetone; or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 1, wherein the compound or a pharmaceutically acceptable salt or stereoisomer thereof is: 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; 1-[4-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]-diazol-5-yl)-prop-2-ol; (R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-piperidin-1-yl]-acetone; or (S)-4-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-2-(6-methyl-pyrimidin-4-yl)-but-3-yn-2-ol; or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 1, wherein the compound or a pharmaceutically acceptable salt or stereoisomer thereof is: 2-(3-{5-[(R)-(1,3-dimethyl-azacyclobutane-3-yl)-hydroxy-(4-isopropyl-phenyl)-methyl]-pyridin-3-yl}-[1,2,4]diazol-5-yl)-prop-2-ol; or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition of any one of claims 1 to 6, 13 and 15 to 17, used as a medicament for treating inflammatory / autoimmune diseases / conditions or cancer.

19. Use of a pharmaceutical composition as claimed in any one of claims 1 to 17 for the preparation of a medicament for treating inflammatory / autoimmune diseases / conditions or cancer.

20. Use of a pharmaceutical composition as claimed in any one of claims 1 to 17 for preparing a medicament for treating inflammatory / autoimmune diseases / conditions selected from psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, inflammatory skin diseases, rosacea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, dry eye disease, multiple sclerosis, systemic lupus erythematosus, Hugh Grant's disease, autoimmune hepatitis, and primary sclerosing cholangitis.

21. Use of a pharmaceutical composition as claimed in any one of claims 1 to 17 for the preparation of a medicament for treating cancer selected from lymphoma, brain cancer, breast cancer, colorectal cancer, liver cancer, renal cell carcinoma, lung cancer, and stomach cancer.